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abstract During the last decade the pharmaceutical industry (PI) operations 
became far more complex due to several structural and 
organizational changes, new legislation and pharmacoeconomic 
constraints.  The role of Medical Affairs (MA) has been increasingly 
important and the interactions between PI and healthcare 
professionals (HCP) are currently much more based on science, 
than in marketing or commercial arguments. This thesis provides an 
in-depth description of the MA function, maps key areas of activity, 
challenges processes and opportunities, based on the feedback 
collected from PI professionals, HCP, regulatory authorities, payers 
and patient´s associations, while suggesting metrics to evaluate the 
activity and impact of such actions. To collect insights from these 
sources two questionnaires were sent to 400 pharmaceutical 
industry professionals and to 197 customers, addressing the most 
relevant topics of the MA contribution to strategic and operational 
activities, while identifying areas where there was greater perceived 
value of their activity. There were 169 responders to the first survey 
(colleagues), while 40 answers to the second one (customers). The 
importance of the MA on the overall results of the company was very 
high rated and, its contribution to strategic activities was seen as 
essential for the support of product launch, improvement of 
therapeutic adherence and partnerships with Patient’s Associations. 
Higher scores were also given to operational activities such as 
medical awareness/education and symposia preparation, internal 
training and advisory board management. A great deal of medical 
effort was also spent in content creation, preparation and review of 
materials, in medicine related responses, presentations, 
reimbursement dossiers, safety risk management, internal cross 
functional meetings, as well as, in dealing with customers. Digital 
and multichannel medical labor was still rated low, while the 
contribution for mobile applications and similar devices gained some 
interest. The number of medicines considered reasonable for a 
Medical Affairs professional to be responsible for, was two through 
three. Customer facing activity was found to be reasonable up to ten 
customers per medical full time equivalent (FTE). MA efficiency was 
considered to be better exercised if office based rather than home 
based, while clinical research was considered to be more efficient if 
performed by company resources than by clinical research 
organizations (CRO). 
x 
For these colleagues, the most important driver for clinical research 
in our country was said to be interest/perceived value while, long 
approval timelines, lack of resources and low curriculum vitae impact 
were identified as major roadblocks. The customer’s experience with 
clinical trials was greater than with investigator initiated research 
(IIR) or other non-interventional studies. When recruiting a Medical 
Affairs person, the characteristics perceived as most relevant were: a 
problem solving attitude, flexibility, pro-activeness and competency. 
The most important factors impacting Medical Affairs retention were: 
opportunities for personal development, recognition and work 
conditions. The contribution of the Medical Affairs to the reputation 
and credibility of the pharmaceutical industry was very highly rated. 
Looking at the future, most colleagues forsee a greater involvement 
of MA in pharmaceutical opperations. The impact of the 
implementation of the European Federation of Pharmaceutical 
Industries and Associations (EFPIA) disclosure code of ethics and 
transparency governing the relations between pharma industry and 
HCP was considered to be high, while the pharmaceutical image 
was assessed as good. In the future, the majority of customers 
foresee greater Medical Affairs involvement, while patients as well as 
citizens, will have a greater participation on the decision making 
process of their own health. At the end, set of MA metrics on volume 
and impact is also suggested.
xi 
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resumo Durante a última década, a gestão das operações na indústria 
farmacêutica (PI) tornou-se  mais complexa devido a várias 
mudanças estruturais e organizacionais das empresas, a nova 
legislação e às restrições orçamentais a nível nacional e 
internacional. O papel dos Assuntos Médicos/Medical Affairs (MA) 
tem vindo a ser cada vez mais importante e as interações entre 
empresas farmacêuticas e os profissionais de saúde (HCP), muito 
mais baseadas em ciência, do que em argumentos comerciais ou de 
marketing. Esta tese fornece uma descrição detalhada da função 
MA, mapeia as principais áreas de actividade, problemas, desafios e 
oportunidades, com base na informação recolhida junto de 
profissionais da indústria farmacêutica, HCP, autoridades 
regulamentares, pagadores e associações de doentes, ao mesmo 
tempo sugerindo métricas, para avaliar a actividade e o impacto de 
tais ações. Para recolha de dados elaborámos dois questionários 
que, foram enviados por email a 400 profissionais da indústria 
farmacêutica e a 197 clientes, abordando os tópicos mais relevantes 
da contribuição de MA para as atividades estratégicas e 
operacionais, identificando as áreas onde existe um maior valor 
percebido dessa acção. Foram recebidas 169 respostas ao primeiro 
inquérito (colegas) enquanto que 40 respostas ao segundo inquérito 
(clientes). Os resultados obtidos permitem concluir que a 
contribuição dos MA para os resultados globais da empresa e para 
as estratégias definidas foi muito alta, sendo essencial para o apoio 
ao lançamento dos medicamentos, melhoria da adesão terapêutica 
e colaboração com as associações de doentes. Foram igualmente 
salientadas as atividades operacionais, como as relacionadas com 
materiais educacionais e de actualização, preparação de simpósios, 
treino interno e de consultoria. Um grande esforço médico é 
igualmente investido na criação de conteúdos, preparação e revisão 
de materiais, bem como, nas respostas relacionadas com os 
medicamentos, planos de gestão de risco, contribuição para dossiês 
de reembolso, em reuniões internas de alinhamento e na interacção 
com clientes. O contributo médico para as actividades digitais e 
multicanal foi ainda classificado como pouco relevante, enquanto 
que, as aplicações móveis registaram interesse. O número de 
medicamentos considerado razoável para um profissional de MA ter 
sob sua responsabilidade foi de dois a três, enquanto que o número 
de clientes a acompanhar deveria rondar os dez. A eficiência destes 
profissionais foi considerada melhor se exercida a partir do escritório 
do que do domicílio, enquanto que, a investigação clínica foi 
considerada mais eficiente se realizada pelos recursos da empresa 
vs recursos contratados (CRO).  
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Para estes colegas, alguns dos factores determinantes para a 
investigação clínica no nosso país foram: o interesse na 
investigação e valor percebido dessa participação, enquanto que, os 
longos tempos de aprovação, a falta de recursos e o baixo impacto 
no curriculum vitae, constituíram alguns dos principais obstáculos. A 
experiência dos clientes com os ensaios clínicos é maior do que 
com os estudos de iniciativa do investigador (IIR), ou outros estudos 
não-intervencionais (NIS). Ao recrutar um profissional para Assuntos 
Médicos/Medical Affairs, as características percebidas como mais 
relevantes foram: uma atitude visando a solução de problemas, 
flexibilidade, pró-atividade e competência. Os factores mais 
relevantes referidos como impactantes na retenção destes 
profissionais foram: as oportunidades de desenvolvimento pessoal, 
o reconhecimento e as condições de trabalho. A contribuição dos
Assuntos Médicos/Medical Affairs para a reputação e credibilidade 
da indústria farmacêutica foi altamente reconhecida, prevendo no 
futuro um ainda maior envolvimento médico nas empresas. O 
impacto da implementação do Código de Ética e Transparência da 
Federação Europeia da Indústria Farmacêutica e Associações 
(EFPIA), que rege as relações entre a indústria farmacêutica com os 
profissionais de saúde, foi considerado elevado; enquanto que a sua 
imagem foi avaliada como boa. No futuro, prevê-se um envolvimento 
maior dos Assuntos Médicos/Medical Affairs nas operações da 
indústria farmacêutica, dos doentes e dos cidadãos, no processo de 
decisão sobre a sua saúde. No final sugerem-se um conjunto de 
métricas sobre a actividade de MA em termos de volume e de 
impacto.
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Foreword 
I moved to the Pharmaceutical Industry (PI) after a relatively long medical career in Hospitals, 
Primary Care Health Centers and at the General-Directorate of Health. At the time, I thought I 
had the knowledge and attributes to perform competently the Medical Director function.  
I recognize now that I knew little about the Medical Affairs (MA) job characteristics, the 
regulatory environment, the complexity of the actions and the reach of such a role. Time, day-to-
day management, personal experience and the support of some colleagues, allowed me to 
progressively consolidate this knowledge and eventually, to become an expert on this field. 
My purpose was to investigate the importance of this role and associated responsibilities, seen 
from the perspective of the colleagues working at the Pharmaceutical Industry, as well as the 
customers we serve. Questionnaires were addressed to these two target populations, inquiring 
on major activities and areas where MA can contribute efficiently to bring the best treatment 
options and services to Health Care Professionals (HCPs) and patients, while ensuring 
compliance and maintaining a trustful relationship.  
Therefore, the structure of this thesis comprises: 
• An Introduction to the Medical Affairs function.
• Results of a questionnaire sent to Professionals working for the
Pharmaceutical Industry.
• Results of a questionnaire sent to Customers.
• Discussion and conclusions of the analyses performed to both of them.
• A set of metrics useful to evaluate the MA activity and impact.
After devoting more than 20 years to MA, I’m absolutely convinced that what we do is 
fundamental to the Pharma Industry's activity and to the population as a whole. Calling the 
reader’s attention to the characteristics of this function, how it is valued by the market, the 
environmental challenges, the opportunities and how to provide an increasingly efficient service 
to our customers, might also be useful for those already working in pharma, as well as, to 
newcomers to Medical Affairs. 
Lisbon, June 5th 2018 
José Augusto Aleixo Dias 
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CHAPTER I – PHARMACEUTICAL INDUSTRY TRENDS 
“A lot of new discoveries are often at the interface between different fields.” 
Paul-Peter Tak 
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CHAPTER I – PHARMACEUTICAL INDUSTRY TRENDS 
1.1- The Pharmaceutical Industry and Medical Affairs 
The Pharmaceutical Industry (PI) is a strategic sector for the health and the country 
economy, translating in innovation, qualified work and health gains. The economic 
pressure related to the European recession in recent years seriously affected the health 
sector, leading to substantial reductions in investments (-27.2%) and manpower1. The 
number of pharma companies in Portugal dropped from 130 (2010) to 122 (2013) and 121 
(2016)2, while the number of professionals experienced an 18.5% cut overall and 21.1% in 
multinational companies. Cuts were primarily focused on sales force and some other 
supporting functions, whereas in Medical one sees stabilization or even an increased 
demand. These environmental changes together with the recognition of the value of 
Medical Affairs (MA) in communicating the clinical value of medicines and devices, 
understanding customer’s needs, capturing insights, identifying opportunities, while 
ensuring compliance and transparency, raised more focus and interest in this function.  
Pharmaceutical companies dispute the most well prepared and qualified professionals. 
This role requires, among other skills: strong understanding of scientific issues and clinical 
research, fluency in foreign languages, ethics, transparency, knowledge about country 
codes and standard operating procedures (SOP), adherence to safety standards and 
reporting, agility in establishing and maintaining relationships while responding to 
customer needs. Investigators, key opinion leaders (KOL) and prescribers, they all recognize 
the Medical function as of paramount importance, contributing to improve patient access, 
disease awareness and patient outcomes. 
Working predominantly in the field close to the customer, is a natural strategic evolution of 
the traditional MA role, demonstrating value, business alignment, integration, governance 
and transparency, which are essential pillars in building customer partnerships and trust. 
Customers such as patients, regulators, health administrators and other healthcare 
professionals (HCP), expect pharmaceutical companies to deliver not only medicines but a 
continuum of care, ranging from disease awareness, prevention, diagnosis and treatment 
of marked health value.  
1.2- Challenging the decision making process at pharma 
The majority of the companies still exercise a top-down approach but, increasingly, they 
listen from stakeholders and local affiliates which are the best strategies to implement. The 
majority of the decision making is derived from the executive level (40.0%); technology 
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decision making is driven primarily by executive management (34%), business, sales and 
marketing (28.0%) and IT (24.0%)3. Medical should contribute to strategic decisions both 
at product and management level. The Medical Affairs’ view and scientific advice should 
be independent from commercial, although in line with the market characteristics and 
company interests.  
In recent years the medical segment has been progressively recognized by pharma, 
through the added value they incorporate in the decision making process. Their 
knowledge about the therapeutic areas involved, the product characteristics, the potential 
alternatives available in the market, the patient profiles, the medical thinking while 
prescribing, the economic and legislative environment and the safety and compliance 
patterns, justify this recognition. 
1.3- Innovative Medicines are crucial to the quality of care provided 
The National Health Service (NHS) is universal and has predominantly free access, 
supported by a high number of qualified healthcare professionals; it provides access to 
innovation and shows fairly good results versus investments. Pharmacologic innovation 
was responsible for 75.0% of the life gains in life expectancy achieved during the first 
decade of this century. Access to innovative medicines is critical for the impact on results, 
namely in what regards disease prevention, early diagnosis and treatment4. However, only 
a limited number of medicines are approved for reimbursement each year in Portugal (Fig. 
1), despite some recent positive changes.  
More than 50% 
of the drugs 
approved by EMA 
are reimbursed 
France 
Germany 
Italy 
Spain 
UK 
Belgium 
Denmark 
Greece 
Luxembourg 
Between 40% and 
50% of the drugs 
approved by EMA 
are reimbursed 
Bulgaria 
Czech 
Republic 
Slovakia 
Slovenia 
Less than 40% 
of the drugs 
approved by EMA 
are reimbursed 
Austria 
Croatia 
Cyprus 
Estonia 
Finland 
Hungary 
Ireland 
Latvia 
Lithuania 
Norway 
Poland 
Portugal 
Romania 
Figure 1 – Reimbursement of innovative drugs approved by European Medicines Agency (EMA) - 
(adapted from Wikman, J – 2016) 
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Time to price approval (667 days) is one of the longest in Europe, well above the European 
average (435 days) and 5.6 times longer than the shortest time (Denmark: 120 days) as 
shown in (Fig. 2)5.  
Medical Affairs can contribute to a much quicker approval process by gathering scientific 
evidence from Epidemiologic studies, Clinical Trials, Real World Data, Pharmacoeconomic 
studies and competitive data that will be included in the submission dossiers, providing 
the best evidence possible of the added value of the medicine being submitted. 
Authorities have to do also their part being more efficient in managing this process. 
Figure 2 – Time to pricing for innovative drugs in EU countries (adapted from Wikman, J – 2016) 
1.4- Clinical Research is key to understand in depth the disease characteristics and 
treatment options 
Traditionally, research and development (R&D) in pharma has been a secret activity 
conducted within the walls of R&D. In recent years, the external collaboration with 
universities, other pharma companies, consultants, health providers and payers, have 
expanded it. By breaking internal silos and enhancing collaboration with external partners, 
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pharmaceutical companies can extend their knowledge and data networks. Due to the 
disinvestment in R&D in Europe and in Portugal in recent years6, it is difficult to show an 
attractive study recruitment record (Fig. 3).  
Figure 3 –Clinical studies in EU (adapted from EFPIA – 2012) 
There was a decline of studies submitted to INFARMED from 160 in 2006 to 88 in 2011, 
showing some marginal improvement since then, with 137 submissions in 20177. The 
European Commission (EC) classifies the Pharmaceutical Industry as a strategic sector for 
the European economy8, while politicians and some HCPs at the country level are 
apparently embedded with the same spirit9; however we need to act decisively to attract 
these investments and scientific knowledge and showcase10. The new regulation of the 
European Parliament11 also reinforces this strategy. 
1.5- Moving from R&D to commercialization 
Bringing a new pharmaceutical product to market is usually a long process and a challenge 
for either big or small biotech companies, who need to make early decisions regarding 
their investigational compounds. There is no real equivalent to Medical Affairs in 
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biotechnology, yet it plays an ever-increasing and important role in that industry as well12. 
The traditional pharma model includes two main pillars: an R&D organization in charge of 
developing new products and, a commercial organization in charge of marketing and 
selling those products. The bridge between development and commercialization is 
provided by Medical Affairs during the various phases: pre-launch (drug development, 
clinical research, KOL mapping, competitors characteristics, reimbursement dossiers), 
launch (awareness, competitive advantage, prescribers feedback), as well as during post-
launch (public acceptance, dosage management, compliance/adherence, 
pharmacovigilance, willingness to pay, etc). 
1.6- Customers expect pharmaceutical companies to deliver not only medicines but a 
continuum of care – Medical Affairs drive this effort 
The current pharmaceutical model is still based, in some companies, around the efficacy, 
safety and cost of medicines, but one can see a shift towards a more valued-based and 
patient-centric approach, increased external partnerships and the outsourcing of non-
strategic activities (Fig. 4)13.  
What changes to the commercial business 
model is your company taking? 
December 
2013 
March 
2015 
Change 
Increased focus on market access strategies 54% 50% -4% 
Shift to a more patient-centric approach 37% 41% 4% 
Redefining the role of the sales force 46% 37% -9% 
Utilizing multichannel engagement strategy N/A 34% N/A 
Increased focus on Key Opinion Leaders 41% 29% -12% 
Developing external therapeutic partnerships 18% 25% 7% 
Increased use of digital channels 27% 23% -4% 
Increased focus on marketing 28% 22% -6% 
Increased focus on Medical Science Liaisons N/A 19% N/A 
Outsourcing of non-strategic activities 10% 14% 4% 
No changes at this time N/A 6% N/A 
Figure 4 – Changes in the pharmaceutical business model: 2013 – 2015 (adapted from IMS Health, 2015) 
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Pharma needs to be close to the customers, understand their needs, capturing insights, 
communicating and responding timely and appropriately. Medical Affairs are the best 
resources to manage expectations and to respond to this challenge.  
The increasing collaboration with Patients’ Associations are mostly done through Medical 
Affairs and are decisively contributing to improve disease awareness, early diagnosis, 
treatment compliance, transparency and trust. 
1.7- Consolidating a more patient-centric approach 
Pharmaceutical companies need to understand the customers’ point of view, their most 
critical needs and challenges, so that they can provide adequate and pragmatic support to 
Patients’ Associations. Effective communication channels, clarity of the message, available 
and adequate contents and capability to respond in due time, are critical for the success 
of these partnerships. As shown in the previous figure, a more customer-centric approach 
has been experienced in recent years, but it still needs improvement. For Medical Affairs, 
having the patient at the center of the system means having the patient in mind in 
everything we do. It translates in allowing Patients’ Associations and Caregivers to 
contribute in almost every stage of the development process, starting from the study 
design, protocol conception of studies - namely in what concerns determining more 
judicious endpoints, data analysis, and outcomes. In addition to the HCPs, and payers, 
these groups play an important role and should be considered as such. Support homecare 
initiatives, provide digital education and tools tailored to patient’s needs, and contribute to 
secure the supply chain14 is very important. But, it also means helping these customers to 
improve health literacy, education in operational areas, access, networking, and to have a 
stronger voice near legislators and regulators. On a transparent win/win basis, Patients’ 
Associations can also be helpful to pharma in sharing information (e.g. clinical trials, 
pharmacovigilance, co-creation of materials), improving disease awareness, contribute to 
early diagnosis, excel treatment compliance and evaluating impact. 
1.8- Developing a multichannel engagement strategy 
Health professionals are increasingly involved in clinical discussions through digital 
platforms. However, when communicating with their patients, they still use the traditional 
face-to-face, phone-calls, short messaging services or emails. New technologies, namely 
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those based on devices and smart phones, will monitor more closely patient´s parameters 
in the future, reducing or eliminating interviewer influence or inappropriate 
measurements. Communication tools will get more interactive, allowing health 
professionals to receive the information they need, when they need it. Medical Affairs will 
play a role in this customized management of the information, improving awareness and 
recommending the right tools when appropriate. While helping to overcome patient’s 
barriers, this needs to be done in full respect for privacy laws and patient adherence. 
1.9- Measuring impact while striving for continuous improvement and reputation 
The Medical Affairs resources are always scarce and one needs to make pragmatic 
evaluations of activity and impact.  Which activities matter? As Rory O’Connor said: 
“The true measure of medical performance is impact”15. 
All external surveys available from pharma companies as well as from independent 
institutions, appreciated with a very high rank the contribution of Medical Affairs to 
scientific and business operations16. It is hard to gain trust because it takes time, requires 
consistent performance, compliance with standards, scientific rigor, transparency, quality 
of the services provided and an adequate communication. However, the level of trust of 
the general public to the Pharma Industry is not high17.  To change this perception MA need 
to assess everything MA do, by promoting responsibility and accountability at all levels.  
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CHAPTER II – THE MEDICAL AFFAIRS FUNCTION 
“In strategy it is important to see distant things as if they were close and to take a 
distanced view of close things”.  
Miyamoto Musashi 
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CHAPTER II – The Medical Affairs Function 
2.1- What do the Medical Affairs do? 
In the Pharmaceutical Industry’s Medical Affairs professionals are bound to create, 
demonstrate and communicate the clinical value of medicines and devices under their 
responsibility, to listen and understand customers’ needs, identify opportunities and 
respond adequately, ensuring compliance and transparency, whilst maintaining the 
primacy of patient’s best  interests. This activity covers a broad spectrum of specific tasks 
and associated interactions, both at internal and external levels. In recent customer 
surveys, investigators, KOL and prescribers, they all recognize the Medical function as of 
paramount importance, both in Portugal and abroad13,14.  
These MA professionals are a source of accurate and up-to-date scientific information, 
contributing for Medical Education, Clinical and Research Grants efforts. They also 
provide information on support services designed to improve patient access, disease 
awareness and outcomes. The MA role is performed by Medical Directors (MDs), Medical 
Advisors (MAs), Medical Leads (MLs) Medical & Scientific Liaisons (MSLs), Medical & 
Scientific Relations (MSRs) and functions alike.  
The Medical Affairs represent the medical voice within the Pharmaceutical Industry. 
Depending on the company structure, it covers: management of medical activity 
associated with products (medicines or devices), clinical research and production, drug 
safety, compliance with regulatory requirements and internal SOPs, medical information, 
access, communication and customer management. The business structure varies, 
depending on size, type and number of products. The vast majority of Medical Affairs 
professionals are physicians, pharmacists or biologists. Most small businesses have at least 
one MA professional. Medium and large companies frequently have their resources 
organized in a Medical Department or, split the MA resources across different business 
units, reporting directly or indirectly to the MD. 
The Medical Director is usually the responsible for the scientific service requested by 
law18. Along with the Technical Direction, the MD represents the face of the company in 
its regulatory, safety and compliance relations with the health authorities. In a traditional 
model, the MD reports to the General Director and sits in the board of directors. More 
recently, and mainly to secure independence from the commercial line, some MDs report 
directly to their Medical structure at regional level and indirectly to their General Director 
in Portugal. Reporting to the Medical Director one may find Medical Team Leads (MTLs) in 
companies that hold a large portfolio of products but in general, these are MAs, MSRs or 
MSLs, which are in charge of a specific portfolio of products and customers. It is up to MA 
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to grant a good management of these portfolios while ensuring a set of internal training 
activities, research support and customer management. Its greatest value is based on the 
scientific knowledge of the products and therapeutic areas where they operate, 
transmitting these to HCPs while cultivating internal and external relationships with key 
parts. These skills consolidate the sharing of experiences at medium and long-term, 
contributing decisively to a sound relationship, which is essential in building trust.  
The information provided by Medical Affairs need to be: adequate, accurate, balanced 
and provided in a timely manner, not expecting anything in return. The service provided 
aims to complement the added value of the portfolio of medicines which are publically 
available. In the launch preparation of a new product, the action of MA begins a few years 
before, with the review of existing literature and publications, identifying local sources of 
information on the incidence and prevalence of disease, contacting the main opinion 
leaders and researchers, as well as specialized centers, listing potential therapeutic gaps 
and alternatives. It is followed by a long and systematic work collecting, interpreting and 
analyzing data, which will lead to the preparation of the market to receive the new 
medicine/device. During the launch phase, the rapid dissemination of information and 
collection of early market experience is critical to design, differentiate and position the 
product properly. This is also applicable to the launch of a new indication, where the 
process is similar but usually less demanding. In addition to these activities, MA also 
interact with a large number of functions or platforms, such as: Production, Marketing, 
Commercial, Quality of Products, Quality of Processes, Access, Communication (internal 
and external), Finance, Distribution, Logistics, Human Resources, Information Technology 
and Legal (Fig. 5). 
Figure 5 – Medical Affairs scope of activities 
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2.2- Important determinants of the MA function  
• A compelling Mission and Vision 
• A strategic contribution to business  
• A well-defined consistent and coherent  strategy 
• An efficient  business operating model  
• An adequate structure adapted to the country needs 
• Clearly defined Medical governance and Leadership   
• A specific Medical Affairs’ budget  
• Effective collaboration and coordination of stakeholder’s management 
• People’s management  
• Efficient systems and processes  
• A set of pragmatic metrics  
• A continuous improvement mindset 
 
2.2.1- A compelling Mission and Vision  
Most companies are bound to mission statements and values. They state them, they write 
them everywhere: on people’s objectives, on paper walls, corridors, elevators, stands, 
cards, leaflets, etc.… but these are not kept into the people’s heart and mind, unless they 
really understand, live and fight for what they believe worthwhile doing. There needs to 
be a clear alignment between what companies say and do, each and every day. The 
scrutiny made by colleagues is permanent and sets the mood for the actions taken, as well 
as for the pride and devotion to their profession, especially in difficult times. This is 
extremely important not only to reach objectives but for personal satisfaction and sense 
of ownership. To have these principles embedded, companies need to make a good use of 
the competency they have in-house, working efficiently, while maintaining attractiveness, 
recognizing and rewarding accordingly. The decision on how to design the MA mission has 
to do with the core business of the company, its portfolio and the operations maintained 
in a specific region or country. 
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2.2.2- A strategic contribution to business 
Medical should contribute to business decisions both at strategic and at product 
management level, through cross-functional teams, together with Regulatory, Safety, 
Marketing, Sales, Medical Information (MI) and Key Account Managers (KAMs), Legal, 
Multichannel and other supporting functions. The MA ability to interpret and translate 
scientific information into commercial insights, credibly communicate scientific data to 
HCPs and, supporting publications, provides it with a unique position in the business.  
Historically, companies have narrowly defined the set of activities that Medical was 
responsible for, but the current understanding naturally leads to an increasing number of 
activities that Medical undertakes, in order to create added value for the business19  
These activities tend to be common across organizations, but the precise mix of 
responsibilities will vary depending on the nature of the company’s portfolio and its 
business needs. Clinical, regulatory and reimbursement hurdles continue to increase the 
cost of drug development and its risk profile. Some companies are joining resources, 
through acquisitions, mergers and alliances. These combinations would enhance the 
innovative and established portfolios in key markets20.Tightening regulation where 
Medical Affairs plays a paramount role as gatekeepers, compliance reviewers and 
scientific ambassadors to customers to date, their contribution in some cases, still remains 
below its potential.  A model that recognizes the Medical appropriately and compliantly 
integrated with the sales, marketing and other functions will ensure companies to 
maximize the value of their products and of the services provided. 
 
2.2.3- A well-defined, consistent and coherent strategy 
Medical Affairs success requires a well-defined strategy, consistency on the direction to be 
followed, focus on critical actions where people are required to apply their efforts and a 
coherent attitude regarding the objectives, mission and values. Has the company made 
key strategic choices on issues such as priority assets and partnering? Has it created a 
compelling overarching story about the drug being launched?21 Pharma companies should 
not enter a new therapeutic area, invest significant resources to develop new medicines, 
work hard to become a player in that particular field, train people, establish relations, 
launch products, and suddenly divest or close that specific business area. What will 
internal and external customers think?  
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Under these circumstances, credibility and trust become fragile. Similarly, companies 
should not create a new internal structure (unit or function), attract colleagues to apply, 
allow them to develop a business purpose, create operational plans, invest their personal 
life on this endeavor, and then change it, or close it, soon afterwards. One should not 
enter highly competitive areas without a minimum level of investment for adequate 
development but also, to sustain these products against competition, in a way that 
product’s value can be defended. In some companies, Medical still plays a limited role in 
strategy development, often receiving it from the commercial line. In most of them, 
Medical attends meetings during the development of the brand strategy, but tends to play 
a less intervenient role.  
As things evolve, we believe that Medical will act as a critical source of information and 
decision support, since companies try to differentiate themselves in such a highly 
competitive market. In order to do so, Medical must become proactive during strategy 
development. This role is crucial as Medical will convey knowledge about physicians, 
patients and competitors, that will materially impact a given brand’s strategy. Medical can 
contribute to a more robust strategy formulation process by collecting and generating 
information on the epidemiology of the disease, characteristics of the available treatment 
options and differentiating factors, guidelines, local norms and prescribing patterns, 
patient’s preferences and compliance, insights from KOLs and other critical stakeholders. 
 
2.2.4- An efficient business operating model  
Efficiency is the cornerstone of success in pharma. Organizations realize the benefits of 
improving their MA function, making it more visible through customer facing interactions, 
because Medical touches all aspects of the business, including development, sales, 
marketing, and government affairs.  
 
2.2.4.1- What is the most efficient business model?  
The business operating model is mainly driven by the size and reach of the company. In 
small pharmaceutical companies, the senior Medical function, usually the Medical 
Director, reports to the General Manager and takes part of the local administration board. 
In multinational companies with a large portfolio of products, this “country model” has 
evolved to a matrix structure of business units (BUs), where the local Medical Director or 
Medical Lead reports to the regional structure through the global Medical line, 
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maintaining the MA responsibility within or across BUs. There are also mixtures of these 
models in place. A matrix organization tends to be less agile in the decision making 
process, once there are several layers to overcome in order to reach a final decision.  
 
2.2.4.2- Which level of decisions should be taken centrally, regionally or locally? 
Strategic and operational MA decisions should be taken at all levels. The key drivers here 
are: alignment, accountability and pragmatism. Aligned with the company’s strategy, the 
MA function at the local level should have autonomy to take their own decisions, 
following approved operating plans and objectives. Autonomy and delegation are 
certainly topics worthwhile underlining. These are extremely important because they 
bring the accountability and responsibility down to the lowest levels of the organization, 
fostering people’s involvement, excelling opportunities and providing everyone with the 
sense that they have their own share of contribution for the company’s results. In the 
current environment, forecasts and operating plans for five or ten years are not easy to 
make. Therefore, there should be flexibility to adapt and update them, as new critical 
factors arise.  
This does not mean that these forecasts should not be made. They are obviously needed 
but, they should be timely prepared, based on objective parameters that real matter for 
an effective discussion, leaving out a great amount of frequently irrelevant and time 
consuming materials, such as long sets of slides and pictures. Unless a real urgent and 
unexpected event occurs, the approved plans should be respected, monitored and 
accomplished. Changing these plans too frequently creates a sense of instability, which is 
not favorable to performance and business.  
 
2.2.5- An adequate structure adapted to the country needs 
The responsibility of managing the scientific evidence belongs, by nature, to the Medical 
role. In addition to the MA contribution to strategy, insights and development, the 
scientific dialogue with physicians, payers and governmental officials is critical. Their 
contribution to health care does not resume to a specific medicine profile, but it also 
comprises disease awareness, early diagnosis and treatment options of conditions for 
which, some health professionals and managers are frequently not fully updated. There 
are several ways the MA can contribute on this matter such as group presentations and 
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research involvement (clinical trials, investigator initiated research, collection of real life 
data, etc.).  
They make suggestions for its content, invite speakers, and support attendance to these 
meetings while organizing advisory boards, webinars and WebEx’s on specific disease 
management or guidelines. MA contribution for the development of digital tools has also 
been of primary importance, namely in the domains of information sharing and patient 
disease management. The local MA structure has to be able to cope with research and 
development if innovation is core in the company’s operations. Making structural changes 
is useful to adapt to an evolving environment. But, change what? When? Changes should 
be driven by efficiency, added value (responding to an unmet medical need) and return of 
investment.   
2.2.5.1- Should Medical resources be concentrated or decentralized? 
To our understanding it depends on where the business is. Where are the customers 
Medical has to interact with? At a local level, assuming that these customers are randomly 
distributed across the country, the operations can be centralized in one office, if the 
average time of transport follows within a 3-4 hour time frame. This will allow for a better 
coordination within the team and across other functions. If the customers are 
concentrated in specific areas, not near the base office,  the decentralized approach could 
be more convenient (e.g. clinical research mainly conducted in localized settings). The 
multinational coordination should remain at global or regional level. However, the level of 
interaction and the understanding of the country specific archetype need to be well 
understood and balanced. 
2.2.5.2- Should Medical operate from a local office, home based, or virtual? 
Costs and efficiency have boosted the outsourcing of some Medical related functions or 
moved them to a field-based model. Instead of operating from the office, these resources 
work from home, although there is an expectation that some days will still be spent at the 
office. The debate on this is going on. The set of customers that the Medical function has 
to manage, the type of interactions required and the support provided, clearly shows that 
a substantial part of MA work is done in the field. However, there are also internal 
customers to meet and alignment to be ensured, particularly with Marketing, Regulatory, 
KAMs, Sales, Access, Med info, Legal, Digital, etc. These are much more efficiently 
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organized and impactful if driven on site than through teleconferences or webinars. 
Temporary field based job is certainly needed for offshore based personnel, or Medical 
functions responsible for the coordination of a number of multinational sites. Some of 
these virtual assignments work mainly though teleconferences, videoconferences and 
WebEx’s and are also becoming more and more frequent. Again, the best solution should 
be the one that best matches the support to the company’s operations. 
2.2.5.3- Should some Medical competencies be outsourced? 
If the MA competency within the company is good enough to address the challenges and 
keep the rest of the organization compliant, generating real competitive advantage at a 
reasonable cost, than the investment in these talents should be kept, providing a genuine 
edge over their peers. However, this poses a challenge for most industry players; as the 
function grew and shifted its focus, companies did not always ensured they had the right 
talent in place to meet new demands.  
What they frequently need is leaders who can effectively engage with multiple 
stakeholders and senior colleagues. Finding and developing these leaders, and ensuring 
effective succession planning, is not easy. Instead, pharmaceutical companies should first 
identify distinctive strengths and potential within their existing MA teams and then build, 
or fill out, a team with complementary strengths across multiple dimensions22. One of the 
problems with outsourcing is the fact that a third party is representing your organization. 
Therefore, the relationships that a company has created with their customers along the 
years, while building confidence and trust, have now a different intervenient partner. This 
partner can be representing the company “A” today and tomorrow company “B”. Most of 
the Medical related functions are outsourced to Clinical Research Organizations (CROs). 
CROs have evolved from providing transactional support for specific projects, to becoming 
strategic partners to pharmaceutical companies. The effectiveness of CROs to manage 
working relationships with sites has slipped during the past years, with the average CRO 
falling below performance expectations in several critical areas including study monitoring 
and project support - “Relationships are a cornerstone for all of our strategies going 
forward”23. In addition, the rotation rate is high among these third party providers 
meaning that a KOL might have to deal with different persons for a single project or study. 
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2.2.5.4- How many MA resources? 
In Portugal, about fifteen years ago, some companies had only one dedicated full time 
equivalent (FTE), usually the MD and, in some cases, as a part-time job. In order to 
address the changing dynamics of the market requirements, pharmaceutical companies 
have increased their number of Medical staff, especially during the last decade. These 
highly skilled Medical professionals train their sales force appropriately, and provide 
added value to physicians, payers and patients. According to the law24, a pharma company 
operating in Portugal has to have its own technical director and a scientific responsible 
person; however, this person is not always the MD, as we believe it should. Therefore, in 
our view, this should be the minimum that a company should have as a Medical resource 
resident in the country. Depending on the company’s portfolio, a set of other Medical 
functions should be added.  
2.2.5.5- What should be it span of control? 
How many products should be under a MA responsibility? In a medium/large 
pharmaceutical company, while ten years ago a medical advisor could be responsible for 
an average of ten products; now, most of medics with recent launched products might 
deal with one to three, depending on the life cycle stage of the product portfolio.  
For a product in pre-launch phase with an important market potential, a minimum of 0.5 
Medical FTEs are required to support the Medical activities during the 1.5 years before 
launch. During the launch, one or two full dedicated FTEs might be needed, and during the 
following two years, depending on the prevalence of the disease and approved 
indications, these resources might need to be reinforced.  
2.2.5.6- How many customers should they manage? 
Medical Affairs usually manage products from a certain therapeutic area and the scientific 
relations with HCPs of those particular areas. Among these, there is a set of more relevant 
investigators and KOLs, to whom they regularly provide updated information, ask for 
advice, discuss ideas, support programs and educational initiatives, congresses, etc. In 
order to be effective in this role and provide a service of quality, the number of customers 
to deal with might vary between 15 during the launch period, through 30 if one is dealing 
with well-known and established medicine. A balanced customer distribution per Medical 
FTE is of the highest importance, especially if this function is dealing with more than one 
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product, so that adequate priorities can be established. Balanced decisions need also to 
be taken when a particular event is taking place or the life cycle of the product requires it. 
If a product safety or efficacy issue is raised, then the authorities, as well as prescribers 
and other relevant customers need to be immediately informed and, a Medical task force 
might have to be considered, irrespectively of their usual areas of focus. One should not 
forget how to properly exit certain therapeutic areas, maintaining a residual but certainly 
important relationship with these customers.  
2.2.6- A clearly defined Medical governance mandate and leadership 
Medical governance within pharma is a systematic approach to maintain and improve the 
quality of the services provided to customers and patients. Organizations must control 
and proactively manage medical issues to ensure that the patient safety and the 
medicines are protected25. It is also vital that an organization has oversight of local 
operations, while ensuring that global medical standards are consistently applied and 
issues are properly addressed, and corrective actions are taken in due time. There are two 
fundamental components in Medical governance: Strategic and Operational. From a 
strategic point of view, it makes recommendations and helps the decision process and the 
approach alignment to customers. From an operational point of view, it contributes to the 
plan of each product or therapeutic area, being responsible for performing themselves 
tasks accordingly. It is essential to ensure good practice processes and products to ensure 
the effectiveness and safety of drugs that are offered, safeguarding that any problem 
detected in a timely manner will be accompanied by appropriate corrective action.  
The Medical Board represents the company in its institutional relations with the 
authorities, medical societies, research centers, academia, associations and related 
entities. In addition to ensuring the scientific component, it must also communicate 
internally and externally aspects related to new results generated by research that 
develops or support, identify and exploit the opportunities and optimize the management 
of Medical resources, seeking to retain the talent, giving them development opportunities 
and stimulating their external exposure. 
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2.2.6.1 - Research & Development 
The R&D model is changing dramatically and becoming more collaborative across 
companies.  It was also recognized that it was becoming harder to win an approval by the 
Food and Drug Administration (FDA) or the European Medicines Agency (EMA), and in 
addition, there was little to show for the billions invested. As a result, of that and also due 
to a higher influence of patients’ associations, both the pharma companies and the 
authorities are finding new ways to foster accelerated approvals and priority reviews26,27. 
New drugs, namely for patients with serious conditions and where there is an unmet 
need, can go through a fast track approval in the US whereas in Europe, a pilot process on 
adaptive licensing is being explored since May 2014. This is not only relevant because it 
can speed the approval process, but also because most of the decisions are to be taken 
jointly by the authorities and pharma. This is new and quite relevant to strengthen the 
collaboration between these parties, hopefully improving the treatment options to 
patients.  
Some companies have been rolling out their own development strategies, while others 
are outsourcing partially or completely R&D to alliance partners (APs) which act in name 
of the company. Apparently, this strategy is paying off in large countries with lot of sites 
and resources on the field. However, this process has dramatically reduced the R&D 
investments in small countries like in Portugal28, potential reasons being:  
- high competition between countries to gain access to multinational studies 
- limited number of sites fulfilling the highest standards now required 
- complexity of the protocols proposed for feasibility 
- scarce number of patients available to meet the inclusion or exclusion criteria, 
namely due to their previous or ongoing treatment status or comparators used 
- administration boards requesting upfront payments which are not required in 
other countries and might infringe companies SOP 
- number of resources deployed by contractors at the country level (frequently 
operating from outside the country) 
- limited knowledge of the site potential, concurrent investigations ongoing 
there and Investigator’s characteristics 
- unmatched opinion between the company and CROs regarding which 
sites/investigators  to involve 
- monitors’ high rotation rate 
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Due to the disinvestment in R&D in Europe and in Portugal in recent years29, currently it is 
difficult to show an attractive recruitment record. The European Commission classifies the 
Pharmaceutical Industry as a strategic sector for the European economy8, politicians and 
some HCPs at the country level are apparently embedded with the same spirit9; however, 
we need to act decisively to attract these investments and scientific knowledge and 
showcase. The new upcoming regulation of the European Parliament11 also reinforces this 
strategy. 
2.2.6.2 - Risk Management 
Risk Management involves having robust systems in place to understand, monitor and 
minimize the risks to patients and staff and, to learn from mistakes. This includes: 
- compliance with processes, laws, guidelines and protocols 
- reporting adverse events, product quality issues and complaints in a timely 
manner 
- promoting a blame-free culture to encourage everyone to report problems and 
mistakes 
- learning from mistakes/near-misses and introduce corrections, appropriately 
and timely 
2.2.6.3 - Compliance 
Compliance means: acting according to the rules. In pharma, all colleagues ranging from 
the highest levels of management to the most junior employees, are expected to take 
ownership and compliance, performing all tasks with integrity. Companies continuously 
scrutinize internal practices and have put in place procedures for taking immediate action 
when any potential violation is identified30. This is ensured through: 
- written policies and procedures (SOPs) 
- oversight of MA related activities 
- effective training and education  
- efficient lines of communication 
- internal monitoring and auditing 
- enforcement through discipline pursuant to published guidelines 
- prompt response and corrective action of potential problems 
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2.2.6.4 - Adverse Events management 
All company’s employees or third parties that the company contracts, who become aware 
of any product safety issue, lack of efficacy or misuse are required to be reported as 
described in the internal SOPs and local laws. Medication errors, occupational exposure or 
off-label use whether or not there are any associated adverse events31.  
As a precautionary measure, all information captured accidentally or directly reported to 
MA, is required to be expeditely sent to the company safety officer. Having a proper 
pharmacovigilance in place is of capital importance. The safety officer and the safety team 
need to train all new recruited personnel, timely update all colleagues on new procedures, 
regularly evaluate the number of reports received, check them for accuracy and follow-up 
them until the issue is closed. Quality reviews as well as internal and external audits are 
essential to assess accomplishment of these tasks32. 
2.2.6.5 - Quality of processes 
The aim of the audit process is to ensure that Medical, Regulatory, Safety and Quality 
related activities are continuously monitored and that potential gaps or deficiencies in 
relation to standards are identified and promptly corrected. This comprises: 
- having a country quality plan in place 
- awareness of the most important laws and SOPs 
- ensuring regular quality reviews and audits 
- understanding of each colleague reporting responsibilities 
- balancing processes reducing bureaucracy 
- delegation of duties and empowerment  
Always strive to be inspection ready.  Colleagues are trained to do their jobs and are 
always updating their training to keep current with revised SOPs, systems upgrades or 
regulatory changes33.    
2.2.6.6 - Product Quality Issues and Complaints 
The primary objective of the quality & compliance team is to ensure all products in the 
market meet quality according to local regulations and company standards. Medical 
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device complaints and product complaints must also be forwarded as product safety 
reports whether or not there are any associated adverse events.  
• A medical device complaint is any written or oral expression of dissatisfaction 
relative to the appearance, identity, quality, durability, reliability, safety, 
effectiveness, or performance of a medical device or product with a medical device 
component.  
• A product complaint is any written or oral expression of dissatisfaction relative to 
the physical properties, condition, package insert, and/or packaging of a product. 
Main activities deal with: 
- Receiving daily reports with complaint information and check if complaint has 
already been received 
- notifying the company and health authorities   
- reporting out of stocks  
- responding to the external questions 
What can we do differently regarding these topics? To anticipate potential label 
requests changes or out of stocks and preparing accordingly; make unexpected 
visits to the warehouse and check for processes and activities; alert colleagues so 
that they are aware of product quality activities. 
• Counterfeit is the unauthorized production of products represented as an original 
medicine, by anyone other than an authorized company. Counterfeit is a serious 
threat to Public Health and Safety and is increasing about 90.0% since 2005, with 
an estimate associated revenues of about 10.5 billion euros22 Counterfeit can be of 
two types: falsified product (the most common) or falsified origin, if original 
products are stolen to the wholesaler or during any other part of the supply chain 
process. In any of both situations occur the alert should be immediately given.  
 
2.2.6.7 - Education and Training 
Education and training entails providing appropriate available support to enable staff to 
be competent in their jobs and to develop their own skills, so that they are up to date and 
knowledgeable about their role. Professional development is a continuous process and 
should be maintained through lifelong learning. In practice, this involves: 
- attending courses and conferences (continuous professional development) 
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- taking regular assessments to ensure that training is appropriate 
- conduct regular appraisals (meant to identify and discuss weaknesses, and 
opportunities for personal development) 
- coaching and mentoring 
 
2.2.6.8 - Promotional and Educational Materials review 
Promotional and Educational Materials review aims to ensure: 
- the scientific content  of the materials 
- compliance with internal rules and SOPS 
- alignment with local legislation 
- compliance with the Portuguese Association of the Pharmaceutical Industry 
(APIFARMA) Code of Ethics34  
Challenges of this aspect of clinical governance include Digital materials, Webinar and 
WebEx’s contents, and Disclaimers. 
 
2.2.6.9 - Information & Operational alignment 
Information and operational alignment must ensure: 
- regular information sharing 
- awareness and update on most relevant topics 
- operational alignment across functions 
- regular review of strategy and goals  
- promptly adaption  
- follow through 
- focus on meaningful goals and metrics  
 
2.2.7- A specific Medical Affairs’ budget  
To ensure that Medical activities are aligned with business needs, but independent in 
nature from purely commercial interests, it is relevant that a MA budget is available, for 
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the investments MA agrees to support. Most of this MA budget will be used to support 
local studies, registries, publications, posters, medical education activities, etc. These 
investments should be subject to regular screen from finance, to ensure that investments 
are aligned with the approved budget. 
 
2.2.8- An effective collaboration and coordination of stakeholders’ management 
In medium to large organizations, namely those with several BUs, it is essential that 
alignment and collaboration is ensured. Collaboration is based on common goals, regular 
information sharing, update communications, adequate organization of processes and 
team spirit. This applies to both internal and external stakeholders. 
 
2.2.8.1 - Internal alignment 
Communication is a common pitfall of pharma both to internal colleagues and to external 
customers, especially in what concerns the use of the appropriate channels, clarity of the 
message content and opportunity. Very important occasions for alignment are internal 
meetings. However, these should be regular and balanced both in their frequency and 
duration, with a pre-defined agenda. Regular appointments should be made and relevant 
topics discussed in the team. Managers should request regular updates on ongoing 
activities. Feedback and suggestions incorporated in the final decision and actions in 
accordance to appropriate timelines. Minutes about the most important decisions, as well 
as on actions that need follow-up should be written. For urgent/unexpected topics, the 
agenda might be avoided. However, minutes and follow-up notes should be taken 
anyway. Some relevant points to consider are: 
- clear purpose setting 
- define agenda topics to those involved as core members 
- specify personal contributions, order and time allowed for presentation/discussion 
- invite non-core members for specific points under discussion where they are 
experts or potentially impacted  
- distribute agenda at least one day before the meeting takes place 
- respect time limits 
- review minutes from the last meeting 
- define actions and who is responsible to follow-up on them 
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- write minutes and distribute them 
- consider virtual contributions through teleconferences, WebEx’s or webinars. 
- some issues might be discussed directly, not requiring a formal meeting 
2.2.8.2 - External alignment 
Several functions within the organization might interact with the same customer. A 
customer relates the MA, or any other function of a certain company, with the company’s 
name, not to the particularities of the reporting lines or its decision making processes. 
Once the contact is established, an expectation of response is created and should be 
delivered in a coordinated way. A pharma representative can receive a medical question 
that he might not be able to respond and which he has to escalate or, an adverse event he 
has to report. The feedback given to the customer has to be coordinated.  Another 
frequent situation occurs when several functions contact the same customer without 
alignment among them. It could be the Sales Force representative, the Medical Advisor, 
the Marketing Manager or the KAM. To be effective, coordination is obviously the key to 
this process.   
Opportunities to consider improvements on this topic include: 
- better planning and communication between MKT/sales/KAMs and Medical in 
order to prioritize these meetings (not only: first come first serve) 
- ensure the value of what its delivered to customers 
- establish and maintain strong and enduring customer relations 
- develop effective scientific communications in a manner that enhances trust 
- deploy appropriate resources to support the highest value opportunities 
- run advisory boards of KOLs/stakeholders to identify needs and opportunities 
- support  relevant training and disease awareness programs 
- contribute with scientific evidence to guidelines, their development and 
dissemination 
- coordinate these activities in accordance with the operational plan and objectives 
- involve other relevant internal experts when appropriate (e.g. R&D, regulatory, 
pharmacoeconomics, safety, legal, etc) 
- save MA availability for special audiences and customer interactions 
Page 38 
2.2.9- People’s management  
2.2.9.1 - Managing the MA workforce 
Nine thousand five hundred and eighty people were working for the Pharmaceutical 
Industry in Portugal during 201035, of which around two hundred in MA. Whatever they 
are at large or small springing up companies, most people have something in common: 
they want to make a difference36. Human resources (HR) and MA share a common goal of 
facilitating, monitoring and enforcing employee compliance. In order to be able to 
coordinate and manage these HR activities, the number of dedicated headcount is critical 
to guarantee a proper support to the organization and to MA. Otherwise, their perceived 
contribution to the overall wellbeing of the organization has fewer chances to be properly 
recognized.  
For MA these are key colleagues because their collaboration also extends to recruitment, 
standardization of job descriptions, salary processing, rewards management and equity. 
People are frequently considered the best asset of an organization. However, companies 
have to translate this statement into actions that can be perceived and recognized to 
bring value to their daily lives. These can be done through: 
- work conditions: office layouts, updated equipment, canteens, support to their 
busiest days 
- training: which should be aligned with development needs 
- incentives: payment levels and rewards on targeted objectives, career 
opportunities 
- interaction: promote interaction among colleagues, especially within medium/big 
companies where some functions operate greatly apart (discussion forums; team 
building activities) 
- respect working hours, weekends and holidays 
- health care: provide medical and medical related services regularly 
- healthy life: promote and support activities that could lead to an healthier life 
- convenience services: help people’s daily life compromises 
Commitment takes three forms. It can be “affective” if the individual shares values with 
the company, “normative” if the individual feels pressured into complying and 
“continuance” when the employee cannot afford to leave. Only affective commitment 
leads to proactive behavior that creates value; the others encourage rule following and 
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over cautiousness37. I should be cultivated a culture of excellence, through performance, 
transparency, compliance and accountability, while leading by example. 
2.2.9.2 - People’s development 
MA development should be discussed according to the individual expectations and 
company needs. It is important to define learning objectives and prioritize. Suggestions: 
- ask MA opinion about important decisions that your group has to take 
- ask them to think on alternative solutions 
- incentivize direct reports to manage projects themselves, ensuring coaching and 
surveillance 
- look for pragmatic approaches and recognize success promptly 
- make sure that important decisions and shared problems are discussed face to 
face and not by email or telephone 
- encourage delegation, send a clear message that Medical staff is just as essential 
as achieving financial objectives 
- expose them to diverse leadership styles through mentoring relationships outside 
the usual hierarchy, and give those assignments where they have to master 
negotiating and influencing, rather than pulling. 
2.2.9.3 - Recognition 
Recognition does not need to be translated in financial benefits; non-financial recognition 
is also highly appreciated. Consider: 
- recognition as part of your usual practice 
- communication of  impactful stories 
- best sharing of ideas and practices 
- welcome nominations from colleagues with a small description of the reason 
behind 
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2.2.10- Efficient systems and processes 
2.2.10.1 - Laws, norms and guidelines 
The number of laws, norms, codes and guidelines has been increasing, in particular during 
the last five years. Guidelines, both at international and national level, define criteria that 
should be used for the diagnosis, management, and treatment in specific areas. However, 
their interpretation and practical use has been controversial, namely because quality and 
innovation are sometimes overruled by direct cost-containment interpretation. Evidence 
should be collected, particularly local and reliable evidence, to sustain your arguments, 
present and discuss these both with decision makers and prescribers. 
2.2.10.2 - Standard operating procedures 
The internal SOPs of most pharma companies also increased dramatically in their number, 
as well as in their volume, updated versions and acronyms, making the reading and 
interpretation processes difficult to manage. Collaborators should ask for regular 
summaries of what is new, discuss about major changes, provide training and share 
illustrative examples. 
2.2.10.3 – Electronic systems 
New electronic systems have been created to respond to the record management, 
logistics and decision processes. Here again, some systems are frequently redundant and 
not fully compatible across businesses. Despite the currently existence of dozens of these, 
they are seldom used to respond to a specific request. Why? Because they might not be 
comprehensive enough, they might not be updated, they might not contain all the 
information that is requested and they might not cover a specific time frame of interest. 
Above all it is always better if there is somebody endorsing the report, instead of having a 
system generated sheet. There must be made an efficient use of the available systems. 
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2.2.10.4 – Multichannel communications 
Medical knowledge is increasingly complex and specialized. The amount of information 
requested or important to respond to our specific customer needs, involve 
communication channels and networks that have to be better used.  
HCPs but also patients and the general public are now regularly accessing internet chat 
rooms and web sites looking for health related information.  In our days, 73.0% of the 
European patients search the internet looking for health information before they meet 
with their physician38. Two thirds of the Portuguese physicians search the internet on a 
daily basis looking for medical information and 96.0% do it at least once a week, while 
28.0% of the HCPs use social media to inform, share and debate professional topics39. MA 
should listen and understand what is going on in such platforms, such as: hot topics, 
recurrent questions, needs/gaps of information, identify opportunities in some more 
neglected areas, and clarify concerns and misperceptions. 
2.2.11-  A set of pragmatic metrics 
As the role of Medical continues to evolve, measuring Medical Affairs efficiency is of 
paramount importance. In order to ensure the right level of resources, teams are being 
pressured to provide greater management with metrics who demonstrate Medical Affairs 
activity, value and impact. Internal and external stakeholders benefit from the scientific, 
consistent, credible, proactive communication and the value added propositions made by 
MA, but it is important to agree on a set of pragmatic metrics that are able to translate 
the result of this effort. The traditional metrics applied to Sales and Marketing are mostly 
quantitative in nature and, if they are the only ones available, they will be inadequate to 
assess Medical Affairs outcomes. These are mainly based on the quality of the interaction, 
the insights gathered, the support delivered and the established relationship. However, 
they need to be accurate, adequately described, not too complicated and clear in terms of 
the impact generated. 
2.2.11.1 - Hard vs soft metrics 
The most fundamental, difference between a “target” and a “goal” resides in the way 
these are interpreted. Hard metrics are based on quantity, volume and dates, whereas 
soft metrics are much refined in nature and try to capture the activities that really have 
impact, irrespectively of their number. For example, a team might be delivering 
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consistently a target number of interactions requested by their manager; however, they 
may have gathered superficial opinions or responses, without gaining the real insight from 
the customers. This may lead to a biased strategic approach. By contrast, gaining deeper 
understanding of the environment, finding out the perceived value of our medicines, 
identifying opportunities to intervene and support the differentiation from competitors, 
makes all the difference. These value-creating aspects of the MA activity are soft, 
intangible things like information sharing or building relationships, which cannot be 
measured easily and only happen in committed, motivated teams. Another very important 
aspect of success on this regard is full accountability of the relationship which is being 
established.  
In my understanding, every MA should have a list of customers under his/her 
responsibility. If these are shared, everyone is partly responsible and no one feels fully 
accountable. As motivation theories predict, individuals put in less effort when they know 
the blame for failure will be shared37.  If the study objective is in line with the company 
strategy, it shows the effectiveness of the MA.38 When starting a Clinical Trial, if the set of 
sites that MA has recommended achieved their targets in terms of patient enrolment, it is 
the quality of the outcome that are being measured too. To assess the Medical Affairs 
activity as a whole, then the third parties are the most appropriate to be used, in order to 
ensure a homogeneous approach and proper benchmark among companies39,40.         
2.2.11.2 - A comprehensive approach to metrics 
While planning a set of metrics, one should consider them to be comprehensive 
(quantitative & qualitative), balanced, and relatively easy to understand and to measure. 
All in all they should be SMART (Specific, Measurable, Attainable, Relevant and Time 
bounded). The process should then move to a stage where a defined number of 
customers are attributed to MA person to engage with, develop relationships, identify 
their needs and interests and exchange scientific information. These interactions will 
hopefully allow the customer to increase the awareness of a certain therapeutic area, 
product or device, the upcoming studies and developments and the safety requirements, 
in order to improve the quality of the care provided to their patients (a series of examples 
are available for consultation in Chapter VI). 
Page 43 
2.2.12-  A continuous improvement mindset 
2.2.12.1 - Concentrate on core activities 
Medical Affairs spend an important part of their time in non-core activities, such as: 
promotional and educational material reviews, presentation reviews, support to medical 
information queries, etc. It is more efficient to focus MA contribution in added value 
activities such as: 
- permanent actualization and innovation  
- identification of customer needs, proposing/supporting actions 
- capture insights and explore opportunities  
- incorporate new concepts/science in messages and processes 
- incentivize research, publications and posters 
- contribute for the adoption of more advanced, agile and less bureaucratic 
processes 
2.2.12.2 - Incentivize pro-activeness and accountability 
As in other areas of business, some Medical resources are more pro-active in organizing 
their work and prioritizing their activities, while others tend to wait until requests come 
or, orders are given to act. Having agreed on a specific set of objectives, MA should be 
allowed some freedom to act. Suggestions: 
- prepare and commit the Medical team with the company’s objectives 
- regularly monitor the attainment of these, adapting whenever needed 
- develop a greater sense of accountability and autonomy 
- ask their own perspective on how to solve issues allowing them to lead some 
processes. If they succeed, fine! Otherwise analyses what went wrong and provide 
opportunities for improvement 
- show appreciation and recognize positive inputs and results 
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2.2.12.3 - Gain additional support from global or regional levels 
Multinational companies can centralize some common activities like educational and 
promotional core materials, slide kits, product monographs, translating and adapting 
them according to the core country requirements. These will then be reviewed locally, 
easing the burden from the affiliates. Anyway, there will always be opportunity for local 
material development, namely due to the country specificities such as: trainings, local 
congresses and symposia, but in general these could be substantially reduced. Some best 
practices include: 
- centralization production of core educational and promotional materials 
- producing them from the beginning according to the country specific requirements 
- adapting label indications accordingly 
- taking in consideration the prominent competitors at the country level 
- preparing them on time (consider product launches and cycle meetings) 
- monitoring quality and compliance at global and country level 
 
2.2.12.4 - Improve communication 
Communication is key, both for internal and/or external interactions namely in what 
concerns the use of the appropriate channels, clarity of the message content and 
opportunity. Therefore, MA should: 
- convey clear and timely messages 
- use the appropriate communication channels to eliminate conflicting perceptions  
- avoid replication of emails and similar messages coming from different sources 
- disseminate updated information on critical business topics on a regular basis  
- monitor acknowledgment, identify gaps and solve them promptly 
- share best practices 
- use informal communication processes when appropriate 
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2.2.12.5 - Eliminate redundancies 
Most of us experience requests of tables to fill in with data, or information that could be 
directly obtained from the actual systems in place. Therefore: 
- make good use of the available systems 
- make them more user friendly 
- keep these regularly updated 
- for questions, allow a reasonable time for response 
- do not ask the same data from different channels – coordinate 
2.2.12.6 - Regularly assess workload distribution 
Due to an increase demand on Medical one should assess the workload and work/life 
balance, by:   
- adopting internal metrics 
- plan a reasonable workload and a balanced distribution 
- benchmark workload among other colleagues  
- discuss on regular meetings  
- make pro-active suggestions for improvement 
- manage time properly 
- try to achieve a better workload/life balance for the team 
2.2.12.7 - Make pragmatic evaluations of activity and impact 
There should be a review of the focus of the activities (Fig. 6). Which ones are really 
impactful? Seize the opportunity: if developed in a considered and holistic way, Key 
Performance Indicators (KPIs) in Medical Affairs can provide a valuable platform for 
continuous improvement and capability development, as well as organizational alignment. 
One should consider how measuring, tracking and reporting any KPI will influence events 
in the organization. If the KPI does not influence decisions or behaviors then, we should 
not bother measuring it41. 
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    Figure 6: Evolution of performance management in Medical Affairs organizations (adapted from Kinapse Consulting, 2011) 
An external survey performed across Europe by Pfizer in 2012, with a participation rate of 
92.0% of the 595 customers interviewed, showed that Medical interaction is being 
appreciated and valued, with 88.0% of the responses attaining 5 or 6 in a scale of six 
points16,42.   
2.2.12.8 - Nourish a continuous improvement mindset 
"There's always room for improvement, for doing things better, more effectively and more 
efficiently. Continuous improvement is part of our ordinary course of business,"43  This is 
mainly based on seven main features: 
- systematic and sustained: characteristics performed on a consistent basis, 
understanding that if not closely managed, processes tend to degrade over time 
- rigorous & data driven: teach colleagues to measure efficiency, effectiveness, 
customer needs and return of investment. Explore examples. Be pragmatic 
- focused on the customer: ask colleagues to think from the customers’ point of view 
what they believe are the most valuable and critical needs 
- improve processes: seek to improve overall process performance. Try to minimize 
errors, steps and time wasted, maximizing speed 
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- consistent: avoid customer experience variability  
- empowerment and collaboration: involve and empower people closest to the problem 
and solve it. Share examples and promote a problem solving attitude   
- track outcomes: emphasize continually tracking outcomes to ensure that the results 
achieved are consolidated and excelled. 
 
2.2.12.9 - Fight for Reputation  
It is hard to gain trust, because it takes time, requires consistent performance, compliance 
with standards, scientific rigor, transparency and quality of the services provided. 
However, the level of trust from the general public to the Pharma Industry is not high.  To 
change this perception, one should: 
- increase scrutiny in everything MA does by promoting responsibility and 
accountability at all levels 
- avoid inadequate promotional messages or attitudes 
- approve only  materials of flawless quality 
- respond in time and fully to specific questions 
- despite all this cautions, if an error occurs, admit it and correct it promptly 
- use new communications channels, be creative, anticipate tendencies 
- focus on key messages 
- invest in an open door policy, invite customers in. If allowed, make your premises 
available for scientific and patient associations or societies to run their own 
meetings.  
- talk proudly about what you do 
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CHAPTER III - PHARMACEUTICAL INDUSTRY PERSPECTIVE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“ Even when they are doing good, we always suspect that they have hidden interests” 
                                Alexandre Borges, in Introdução ao Pessimismo 
 
 
 Page 50 
 
  
 
 
 Page 51 
 
CHAPTER III - The Pharmaceutical Industry perspective 
3.1- Introduction 
This report analyses the results of the questionnaire presented to Pharmaceutical Industry 
professionals at all levels and functions, aiming to capture their perception of the Medical 
Affairs contribution to the business operations, both at national and multinational 
companies.  
 
3.2- Methods 
A structured questionnaire (Appendix I) covering the most relevant activities performed 
by the Medical Affairs personnel on a daily basis was created, tested and made available 
through email, to a sample of professionals people working in the Pharmaceutical Industry 
in Portugal, covering all areas of responsibility. These emails contained a link directly to 
Google44 where the anonymous answers could be inserted. All the collected data were 
entirely confidential, governed under the observation of the law on Data Protection45, and 
was automatically transposed to an Excel sheet, with the only purpose to produce this 
report. The data analysis was performed using the software: SAS Enterprise V446, Statistics 
V947 and JASP 0.8.6.048. 
Our sample included Pharmaceutical Industry professionals at all levels and functions, 
both from national and multinational companies. Consulting the literature on this subject 
we found out that similar surveys performed through e-mail got a response rate of 17.3% 
while survey monkeys 27.7%49. A recent survey conducted in Portugal by Banco de 
Portugal for the International Monetary Fund with a similar method, got a response rate 
of 17.4%50. Taking in consideration that, according to APIFARMA51, there were 6231 
people working for pharma in 2013, we estimated the minimal requested sample size:  
• Population: 6231 
• Expected response rate:    27.7 % 
• Worst acceptable result:   17.3 % 
• Requested n for 95% confidence limits:   70 
• Requested n for a confidence level of 99%: 120 
Assuming a more demanding 99% confidence level and that 20.0% (24) of the responses 
could be incomplete, the minimum sample requested would be 144 (120 + 24). We have 
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not defined quotas per type of company because we did not have such level of detail. The 
author sent 400 emails, 61 of which were rejected (wrong email address), therefore 
considered invalid. The remaining 339 inviting emails generated a total of 169 
questionnaires which were duly completed and considered for analysis. The response rate 
to this e-mail/web questionnaire was of 49.9% (169/339) and the incompleteness of some 
variables 10.0%, much better than expected. 
 
3.3- Results: Descriptive Analysis 
The range of specific roles of the 169 responders is illustrated below (Fig. 7). Medical 
Affairs, Commercial, Marketing and Medical Information acounts for 56.2% of the total 
respondents. 
 
 
Figure 7 – Responders activity in pharma 
 
In terms of gender the distribution was quite balanced with a small percentage in favor of 
the females (Fig. 8). 
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Figure 8 – 
Responders distribuition according to gender 
 
The overall mean age was 42.4 years old (minimum=23; median=42; maximum=71; 
standard deviation (std)=9.04). The great majority of pharma professionals belong to age 
group of 35 to 44 years old (Fig. 9).  
 
 
Figure 9 – Age distribuition 
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The average age of the male responders was 44.4 years old (median=45.0 years old) while 
40.6 years old for females (median= 40years old). This difference was statistically 
significant (t=2.81; p=0.0055) and there was homogeneity of the variances of both groups 
(F=1.08; p=0.7263). There were no age differences between respondents per type of 
Company (t=0.43; p=0.6766 for unequal variances -F=2.25; p=0.0237), although National 
companies keep some colleagues at higher ages (Fig. 10).  
 
 
Figure 10 – Age distribution per type of pharmaceutical company  
 
The majority of responders to this survey (92.3%) work for Multinational companies (Fig. 
11).  
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Figure 11 – Responders per type of pharma company they work to 
In National companies, strategic decisions are taken by default at Local level. In 
Multinational companies, strategic decisions are thought to be taken at All levels (37.9 %) 
followed by Regional (22.5 %), Local (21.9 %) and Global level (10.1 %) - (Fig. 12). This 
distribution does not differ significantly by responders business area/ condition (Medical 
Affairs vs other; p=0.5754). 
 
Figure 12 – Level of Strategic Medical Affairs Decisions in Multinational Companies  
 
7.7% 
n=13 
92.3% 
n=156 
Portuguese Company
Multinational Company
10.7% 
n=18 
22.5% 
n=38 
23.7% 
n=40 
37.9% 
n=64 
5.3% 
n=9 
0%
5%
10%
15%
20%
25%
30%
35%
40%
Global Level Regional Level Local Level At all levels Not Aplicable
 
 
 Page 56 
 
In Multinational companies, Medical Affairs should preferably report at “Both Central and 
Local levels” (50.3 %), “Locally to the General Manager” (27.2%), or “Centrally/Regionally” 
(16.6%) – (Fig. 13).  
This distribution does not differ significantly by condition (Medical Affairs vs other; 
p=0.18654), meaning that the observed pattern is used not only for Medical Affairs, but 
across other functions. 
 
 
Figure 13 – In multinational companies, Medical Affairs should preferably report 
 
In this sample 11.8% of the responders exercise their activity in companies with less than 
100 employees, 9.5% up to 199 employees and 78.7% equal or over 200 people,  with a 
minimum of 5 and a median of 220 (Fig. 14).  
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Figure 14 – Number of employees per pharma company of the responders 
 
At National level, two persons worked for companies with “<100”employees, while 10 
developed their activity in companies with “>=200”workers (there was one missing value). 
The sample distribution in Multinational companies was: 18 (11.5%) for the “<100” class, 
16 (10.3%) for the “100-199” class and 122 (78.2%) for the “>=200” class.  
The minimum number of Medical Affairs reported employees was one, with a median of 
13 both in National and Multinational companies, whereas the maximum in Multinational 
was 52 while 13 at National ones (Fig. 15). 
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Figure 15 – Number of Medical Affairs resources in the Company 
 
The importance of the Medical Affairs to the overall results of the company was very high 
rated; in fact, more than 90.0% ranked it as level 4 or 5 (mean=4.35; median=4.0; Fig. 16). 
 
 
Figure 16 – Importance of the MA contribution to  the overall results of the company 
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In terms of the contribution of Medical Affairs to “Strategic Activities”, higher scores were 
given to: “Product Launch support” (median=5) and KOL mapping (median=5). 
Engagement, Business Development, Training, Medical Education and Medical 
Information were among the activities reported as “other” (Fig. 17, Table 1). 
 
 
Figure 17 – Medical Affairs contribution to Strategic Activities 
 
Table 1. Medical Affairs contribution to Strategic Activities 
Parameter Average Median Levels 4 and 5 
Clinical Research 4.3 4 85.2% 
Market Access 3.9 4 76.3% 
Operating Plans 3.8 4 68.0% 
Product Launch support 4.6 5 98.2% 
Safety and 
Pharmacovigilance 
4.3 4 84.6% 
Compliance 4.2 4 82.8% 
KOL mapping 4.4 5 89.3% 
Management of Customers 4.2 4 83.4% 
Other 2.2 1 23.1% 
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Higher scores were given to the following operational activities: “Education Materials 
preparation and review”, “Symposium preparation”, “Internal Training” and “Advisory 
Board preparation and management” (above 90% gave it 4 or 5 scores). Activities such as: 
Support to Clinical Research, Disease Awareness, Virtual Training and Virtual Forum, as 
well as Compliance, were mentioned as “other” (Fig. 18, Table 2). 
 
 
Figure 18 – Medical Affairs contribution to Operational Activities 
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Table 2. Medical Affairs contribution to Operational Activities 
Parameter Average Median Levels 
4 and 5 
Cross-functional  meetings 
4.05 4 81.1% 
Education Materials preparation 
and review 
4.60 5 95.9% 
Promotional Material Preparation 
and review 
4.35 4 88.2% 
Advisory Board preparation and 
management 
4.52 5 90.5% 
Symposium preparation, invitation 
and content review 
4.43 5 91.7% 
Contribution to reimbursement 
dossiers 
4.11 4 83.4% 
Internal training of Sales Force and 
other colleagues 
4.34 4 90.5% 
Presentation to customers 4.33 4 87.6% 
Product related response to 
questions 
4.34 4 88.8% 
Safety reporting 4.13 4 75.7% 
Digital and multichannel 3.67 4 61.5% 
Other 1.98 1 16.6% 
 
The contribution of Medical Affairs to the “Digital & Multichannel Development and 
Implementation” did not score as high as the “Contribution to Strategic and Operational 
Activities”, previously analyzed. However, there were some items that were rated by more 
than 80.0% as 4 our 5 , such as: “Preparing/reviewing Materials for Self-detailing” and 
“Training Materials for Health Care Professionals” (self-education); Market Research, 
Educational Quizzes, Linking Scientific interests were mentioned as “other” (Fig. 19, Table 
3).  
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Figure 19 – Medical Affairs contribution to Digital & Multichannel implementation  
 
Table 3. Medical Affairs contribution to Digital & Multichannel implementation 
Parameter Average Median Levels  
4 and 5 
Health Care Professionals websites/Portal 
 
3.82 4 70.4% 
Preparing/reviewing materials for self-
detailing 
4.18 4 82.2% 
Training materials for Health Care 
Professionals 
4.23 4 83.4% 
Newsletters 3.83 4 70.4% 
Webex's 
 
3.82 4 72.2% 
Webinars live 
 
3.96 4 75.7% 
Webinars on demand 
 
3.83 4 71.0% 
Mobile Applications 3.72 4 65.1% 
Social media 
 
3.47 4 55.0% 
Other 2.03 1 17.1% 
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Considering the three main domains under evaluation:  
• Strategic activities  
• Operational activities and  
• Digital and Multichannel development 
 
a similar number of scores were created for these major areas, related to the Medical 
Affairs contribution. The score is 0% if a respondent rated all items with “1” and 100% if a 
respondent rated all items with “5”.  From Table 4 one can conclude that respondents give 
higher importance to “Operational activities”, followed by “Strategic activities”, and finally 
“Digital/ Multichannel Development activities”. 
 
Table 4. Scores given to MA main domain activities 
Score Minimum Q1 Median Q3 Maximum Average STDev 
Strategic 
activities 
40.6% 75.0% 81.2% 87.5% 100.0% 79.9% 11.5% 
Operational 
activities 
40.9% 72.7% 84.0% 90.9% 100.0% 81.5% 12.1% 
Digital and 
Multichannel 
0.0% 63.9% 75.0% 83.3% 100.0% 71.8% 18.7% 
Note: The score did not include rates for the question “Other” 
 
Analyzing these scores by condition (Medical Affairs vs Others), statistical significant 
differences were only found for “Operational activities” (Median Test; p=0.0274) with 
higher scores for Medical Affairs respondents. 
When recruiting a Medical Affairs person, the perceived most important Medical Affairs 
Characteristics to take in consideration by the responders were a “Problem Solving  
Attitude”, ”Pro-activeness” and “Flexibility” (median=5, above 90.0% rated 4 or 5) closely 
followed by “Competency”. Academic Skills, Strategic Thinking, Leadership Skills, 
Communication Skills, Willingness to Learn, Creativity, Networking, Emotional Intelligence, 
Ethics and Compliance were also mentioned as “other” (Fig.20, Table 5). 
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Figure 20 – Medical Affairs most valued characteristics upon recruitment 
 
        Table 5. Medical Affairs most valued characteristics upon recruitment 
Parameter Average Median Levels 4 and 5 
Competence in a specific 
area 
4.30 4 
87.0% 
Experience 
 
4.05 4 81.1% 
Flexibility 4.44 5 94.1% 
Fluency in foreign 
Languages 
 
4.13 4 
87.0% 
Pro-activeness 
 
4.54 5 94.7% 
Problem solving attitude 
 
4.66 5 97.0% 
Posture/Aspect 
 
4.02 4 76.9% 
Other 
 
2.27 1 24.9% 
 
The number of products considered reasonable for a Medical Affairs FTE to handle was 
considered by 35.1% of the responders to be “2”, while 23.2% mentioned “3” (average= 
3.58 and median= 3). Nevertheless, 11.3% of the responders considered that “6 or more 
medicines” could be acceptable (Fig. 21). 
Interestingly, in National companies the reasonable acceptable number of products has a 
median of “5” (38.5% of the answers) while in Multinational Companies it is only “3” 
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(24.4% of the answers). In these companies the preference goes to “2” (37.8% of the 
answers). 
 
Figure 21 – Number of products a Medical Affairs FTE should have under her/his responsibility 
 
During a product life cycle, the expected Medical Affairs FTEs considered to be needed 
was mainly reported to be 1 or 2. Some differences, however, can be acceptable along the 
way. “One year before launch” 36.7% of the responders believe that 1 FTE will be enough 
and that remains valid “Six months before launch” (36.1%).  “At Launch” 2 Medical Affairs 
FTEs are stated as required, and this number of resources remains valid up to “Two years 
after launch”. Thirty seven percent of the responders think that this allocation can be 
eventually reduced to 1 FTE three through five years after launch, or even “0.5” (40.2%) 
“After 5 years”.   
This is, of course, very much dependent on the prevalence of the disease, approved 
indications, product characteristics and competitors but, gives an insight on what level of 
resources are thought to be required (Fig. 22, Table 6). 
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Figure 22 – Medical Affairs FTEs thought to be needed to support a medicine along its life cycle 
 
Table 6. Medical Affairs FTEs thought to be needed to support a medicine along its life 
cycle 
Time \ Nº of FTEs 0 0.5 1.0 1.5 2.0 2.5 3.0 >3 Total % 
1 year before 0.0 18.9 36.7 8.9 23.7 1.8 4.1 5.9 100.0 
6 Months before 0.0 3.6 36.1 12.4 26.6 5.3 9.5 6.5 100.0 
At Launch 0.0 1.8 23.1 14.2 30.2 3.6 16.0 11.2 100.0 
6 Months after 0.0 3.0 23.7 13.6 30.2 5.9 17.8 5.9 100.0 
1 year after 0.0 7.7 24.9 14.2 27.2 7.1 14.2 4.7 100.0 
2 years after 0.0 10.1 36.7 14.2 20.1 6.5 9.5 3.0 100.0 
3 to 5 years after 0.6 24.3 43.8 8.3 12.4 5.3 3.6 1.8 100.0 
> than 5 years after 5.3 40.2 34.9 5.9 8.9 2.4 1.8 0.6 100.0 
 
Customer facing activity is highly regarded both by pharmaceutical companies and 
customers. In fact, 17.8% of the responders suggest that a Medical Affairs person should 
regularly interact with less than 5 customers, 18.9% considered that “5-10” would be 
reasonable and 63.3% accepted even a higher number (Fig. 23). 
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Figure 23 – Number. of customers a MA person should manage on his/her customer facing activity. 
 
In general, all of the listed Medical Affairs activities were considered highly valuable (Fig. 
24, Table 7), with average rating scores above 4. All activities mentioned below got high 
scores, being “Scientific Arguments“ and “Scientific Updates” the most highly rated. 
Contribution for Brand Plans, Support to Clinical Research, Compliance, Contribution to 
Adequate Preparation and Review of Educational and Promotional Materials, Respond to 
Queries (Medical Information) and Coaching to Colleagues were among the activities 
regarded as “other”.  
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Figure 24 – Value of some Medical Affairs activities 
 
Table 7. Value of some Medical Affairs activities 
Parameter Average Median Levels 4 and 5 
Customer's scientific update 
 
4.44 5 93.5% 
Identification and response to customer's 
needs 
4.38 4 
91.7% 
Capture insights and explore opportunities 4.27 4 91.7% 
Incorporate new scientific arguments or 
differentiation messages 
4.47 5 
93.5% 
Incentivize local research, publications and 
posters 
4.21 4 
83.4% 
Provide evidence for the customer's 
decision making process 
4.40 4 
92.9% 
Respond to scientific/educational 
customer's requests 
4.41 4 
92.3% 
Other 1.99 1 17.8% 
 
When asked about the level of efficiency of Medical Affairs if “Office based”, “Home 
based” or “Virtual”, about 74.0% respond that Medical Affairs resources are more efficient 
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Capture insights and explore opportunities
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Other
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when Office based (Fig. 25). The option “Other” was mentioned by 13.0% of the 
responders and basically referred to a hybrid or combined model.  
No statistically significant differences were found regarding the responder’s condition 
(χ2=40.4; df 42; p= 0.5436), gender (t=-1.1; p=0.2811), or type of company (χ2= 0.47; df 3; 
p=0.9251).  
 
 
Figure 25 – How do see Medical Affairs resources being more efficient for the business. 
 
In what concerns the Clinical Research Management “Internally with Company Resources” 
or by “Outsourced resources - CROs”, about half of the responders think that Clinical 
Research is more efficient if performed by Company resources, whereas about 40.0% are 
in favor of a combination of both Company and Outsourced resources (Fig. 26). 
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Figure 26 – Efficiency of Clinical Research per Internal or Contracted-out Resources 
 
The most relevant factors impacting Medical Affairs Retention were: “Opportunities for 
Personal Development”, “Recognition” and “Work conditions”, which were rated by more 
than 89% as “4” or “5“(Fig. 27, Table 8).  
Other aspects to take in consideration were: Culture & Values, Motivation and 
Commitment, Team Spirit, Brand Awareness, Professional Development and Credibility. 
 
54.4% 
n=92 
5.9% 
n=10 
39.6% 
n=67 
Company resources
Outsourced resources
Both
 
 
 Page 71 
 
 
Figure 27 – Factors impacting Madecal Affairs retention 
 
Table 8. Factors impacting Madecal Affairs retention 
Parameter  Average Median Levels 4 and 5 
R&D pipeline 4.23 4 84.6% 
Salary and fringe benefits 4.24 4 84.6% 
Work conditions 4.35 4 91.1% 
Team inclusiveness 4.30 4 87.6% 
Opportunities for personal 
development 
4.51 5 
94.1% 
Coaching 3.92 4 72.8% 
Leadership 4.21 4 87.0% 
Recognition 4.45 5 92.3% 
Other 1.98 1 17.8% 
 
The contribution of the Medical Affairs to the “Company Reputation and “Credibility” was 
rated as “5” by 70.4% of the responders, and as “4” by 27.8% (Fig.28). There were no rates 
below “3” for this dimension. 
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Figure 28 – Medical Affairs contribution to the Company Reputation and Credibility. 
 
As for the future, 68.0% of all respondents forsee “More” operations involving Medical 
Affairs, while 29.0% believe that it will be “About the same”. Only a minority of 3.0% 
admit that these could be reduced (Fig.29). 
 
 
Figure 29 – Expected Medical Affairs contribution for the business operations in the future 
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3.4- Bivariate analysis 
In addition to the descriptive analysis previously described, we have also explored through 
bivariate analysis (Appendix II) the results of the variables: 
• V9 - Medical Affairs contribution to the overall results of the company  
• V10- How do you rate the Medical Affairs contribution to Strategic activities 
• V12 - How do you rate the Medical Affairs contribution to Operational activities 
• V14 – Assessment of the Medical Affairs contribution to Digital & Multichannel 
and their relation with some responders characteristics such as: Participant Condition 
(V1), Gender (V2), Age Class (V3) and Company Type (V4), using the Man-Whitney test 
and One-Way ANOVA (with Bonferroni and Turkey Post-Hoc comparison test), and 
considering a significance level of 0.05.  
The bivariate analysis of V9 Medical Affairs vs V1 Participant Condition, where (V1) was 
stratified as “Medical Affairs” vs “Other”; Gender (V2) “Male” vs “Female”; Age Classes 
(V3) “≤34” “35-44” “45-54” “≥55”; and Company Type (V4) “National” vs “Multinational”, 
showed no significant differences between groups (Table 9).  
 
Table 9. “Medical Affairs contribution to the overall results of the company” by 
Condition, Gender, Age Class and Company Type 
 Condition (V1) Gender (V2) Age classes (V3) Company type (V4) 
 W* p W* p F& p W* p 
V9 2873.000 0.108 3094.000 1.000 1.207 0.309 826.000 0.219 
* Mann-Whitney test; & One-way ANOVA 
 
However, it is worthwhile mentioning that the association V9:V1 estimated by the Odds 
Ratio was 1.65 (0.8016; 3.4219) χ2= 1.87 (p=0.1708). Meaning that, although not 
statistically significant, there was a probability 65.0% higher of Medical Affairs 
contributing to the overall results of the Company. 
 
  
 
 
 Page 74 
 
The bivariate analysis of Strategic Activities (V10) vs Condition (V1), Gender (V2), Age 
Classes (V3) and Company type (V4) are presented in Table 10. 
 
Table 10. “How do you rate the Medical Affairs contribution to Strategic Activities” by 
Condition, Gender, Age Class and Company Type 
 Condition (V1) Gender (V2) Age classes (V3) Company type (V4) 
V10 W* p W* p F& p W* p 
V10.01 2471.000 0.943 3666.500 0.725 1.609 0.189 813.500 0.197 
V10.02 2428.500 0.800 3170.500 0.166 2.557 0.057 914.000 0.511 
V10.03 3058.000 0.020 2835.500 0.013 0.761 0.517 892.000 0.436 
V10.04 2939.000 0.044 3262.000 0.260 2.618 0.053 1008.500 0.972 
V10.05 2437.000 0.833 3631.500 0.819 3.874 0.010 1144.000 0.406 
V10.06 2896.500 0.096 3283.500 0.338 3.050 0.030 885.500 0.412 
V10.07 3028.000 0.024 2760.500 0.005 1.903 0.131 620.000 0.010 
V10.08 2886.500 0.105 2590.500 <0.001 0.736 0.532 891.500 0.436 
Average 
(V10.01:V10.08) 2959.000 0.076 2845.500 0.023 2.352 0.074 739.500 0.104 
* Mann-Whitney test; & One-way ANOVA 
Medical Affairs contribution was rated by MA responders with higher values to Strategic 
Activities such as Operating Plans V10.03 (p=0.020), Product Launch & Support V10.04 
(p=0.044) and KOL Mapping V10.07 (p=0.024), when compared with other pharmaceutical 
industry professionals. 
Females valued more than males the contribution of MA to Operating Plans V10.03 
(p=0.013), KOL Mapping V10.07 (p=0.005) and the Management of Customer Relations 
V10.08 (p<0.001), as well as, the overall average of Strategic Activities (p=0.023). 
Responders aged between 45 and 54 valued more the MA contribution to Safety and 
Pharmacovigilance V10.5, when compared to responders from lower age classes 
(p=0.010). Also, the 45 to 54 year old responders gave more value to MA contribution to 
Compliance V.10.6 than the ones with 34 years or less (p=0.030). 
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Responders from multinational companies recognize greater value to MA contribution to   
KOL Mapping V10.07 (p=0.010), when compared with responders from Portuguese 
companies. 
The bivariate analysis of Operational Activities (V12:V1) by Condition, Gender, Age classes 
and Company type are presented in Table 11. 
 
Table 11. “How do you rate the Medical Affairs contribution to Operational Activities” 
by Condition, Gender, Age Class and Company Type 
 Condition (V1) Gender (V2) Age classes (V3) Company type (V4) 
V12 W* p W* p F& p W* p 
V12.01 2789.500 0.209 2921.500 0.025 2.620 0.053 628.500 0.012 
V12.02 2819.000 0.138 3556.500 0.979 1.162 0.326 807.500 0.147 
V12.03 2292.500 0.416 3286.000 0.336 0.037 0.990 996.500 0.912 
V12.04 3160.500 0.003 2801.500 0.005 0.578 0.630 810.000 0.157 
V12.05 2815.500 0.167 2874.500 0.015 1.453 0.229 1019.000 0.976 
V12.06 2555.000 0.785 3594.000 0.918 1.810 0.147 991.500 0.886 
V12.07 2764.500 0.251 3121.000 0.123 3.143 0.027 1102.500 0.565 
V12.08 3293.500 <0.001 3224.000 0.240 1.919 0.128 718.500 0.056 
V12.09 2731.000 0.315 3572.500 0.978 3.930 0.010 1204.500 0.216 
V12.10 2766.000 0.267 3371.500 0.519 1.745 0.160 1030.500 0.920 
V12.11 2520.000 0.902 3175.000 0.190 2.880 0.038 1092.000 0.624 
Average 
(V12.01:V12.11) 2995.500 0.056 2971.500 0.062 2.529 0.059 883.000 0.440 
* Mann-Whitney test; & One-way ANOVA 
 
Medical Affairs contribution for Operational Activities such as Product Launch & Support 
V12.04 (p=0.003) and Management of Customer Relations V12.08 (p<0.001), were better 
valued by responder MA colleagues, in comparison with other pharmaceutical industry 
professionals. 
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The support of MA for Operational Activities such as Clinical Research V12.01 (p=0.025), 
Product Launch & Support V12.04 (p=0.005) and Safety & Pharmacovigilance V12.05 
(p=0.015), was evaluated with higher values by females than by male responders. 
The younger responders (≤ 34 years) valued less the MA contribution to the Operational 
Activities of - Social media V12.09 when compared to responders with 35-54 years old and 
45-54 years old (p=0.010), as well as, to Digital and Multichannel activities V12.11 
(p=0.038). The contribution of MA to Webinars V12.07 was also evaluated with lower 
values by the responders with ≤ 34 years old or less, when compared with the older ones 
(p=0.027). 
Responders from multinational companies recognized more value to the contribution of 
the MA to Clinical Research V12.01 (p=0.012) when compared with responders from 
Portuguese companies. 
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The bivariate analysis of Digital & Multichannel Activities (V14:V1) by Condition, Gender, 
Age classes and Company type are presented in Table 12. 
 
Table 12. “Assessment of the Medical Affairs contribution to Digital & Multichannel” by 
Condition, Gender, Age Class and Company Type 
 Condition (V1) Gender (V2) Age classes (V3) Company type (V4) 
V14 W* p W* p F& p W* p 
V14.01 2239.000 0.312 894.500 0.450 1.552 0.203 894.500 0.450 
V14.02 2549.500 0.807 830.000 0.242 1.495 0.218 830.000 0.242 
V14.03 2609.000 0.625 811.000 0.195 0.939 0.423 811.000 0.195 
V14.04 2590.000 0.684 1151.500 0.385 1.622 0.186 1151.500 0.385 
V14.05 2314.500 0.474 1074.000 0.701 0.679 0.566 1074.000 0.701 
V14.06 2268.500 0.376 953.000 0.703 0.721 0.541 953.000 0.703 
V14.07 2131.000 0.150 988.000 0.872 0.599 0.617 988.000 0.872 
V14.08 2480.000 0.973 852.500 0.310 0.718 0.542 852.500 0.310 
V14.09 2256.000 0.350 973.000 0.799 2.298 0.079 973.000 0.799 
Average 
(V14.01:V14.09) 2320.500 0.526 
912.000 0.548 1.069 0.364 912.000 0.548 
* Mann-Whitney test; & One-way ANOVA 
 
No statistically significant differences were found to the assessment of Medical Affairs 
contribution to Digital & Multichannel Activities, across: Condition, Gender, Age classes 
and Company type. 
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3.5- Modeling 
In addition to the descriptive and bivariate analysis already presented, we have also 
explored through regression analysis, to which extent the independent variables V10, V12 
and V14 best explain (best fit) the results expressed by the dependent variable V9. 
• V9 – Medical Affairs contribution to the overall results of the company  
• V10 - How do you rate the Medical Affairs contribution to strategic activities 
• V12 - How do you rate the Medical Affairs contribution to operational activities 
• V14 – Assessment of the Medical Affairs contribution to Digital & Multichannel 
 
3.6- Logistic regression 
As, in general, most of the responses to these variables got very high ratings, the 
frequency distribution was skewed to the right (many 4s and 5s), we have decided to 
make a Logistic Regression approach (Appendix III), by considering two alternatives: 
a) plotting the highest ranks (4-5) against the other ratings (1-3), so that the rating (4-
5) would be “1” while all the others (1-3) would be “0”  
 
b) plotting the highest rank (5) against the other ratings (1-4), so that the rating (5) 
would be “1”, while all the others (1-4) would be “0”. 
 
 
For the plotting the (4-5) against (1-3) the area under the curve (AUC) of 0.9832 indicates 
a good discriminant power regarding the evaluation of the Medical Affairs contribution to 
the overall results of the company. It also means that 98.2% of the cases in the current 
model correctly predict this contribution, with a 100% sensitivity, 93.3% specificity and 
99.4% precision.  
 
The explicative variables are: Product Related Response to Questions V12.09 (p=0.018), 
HCP Websites/Portals V14.01 (p=0.015), Preparing/reviewing Materials for Self-detailing 
V14.02 (p=0.020), Mobile Applications V14.08 (p=0.005) and Social Media V14.09 
(p=0.018). 
 
This option (a) turned out to be one with highest concordance and the one we ended-up 
choosing (Table 13).  Option (b) showed a lower AUC (0.848), sensitivity (76.7%), 
specificity (82.3%) and precision (76.7%) and therefore was left out. 
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Table 13. Logistic regression analysis by “Enter” method - response variable V9 
(independent  variables: V10, V12 and V14); (4-5) vs. (1-3) 
  Estimate Robust  Standard Error z p 
(Intercept) -76.125 40.020 -1.902 0.057 
V10.01 5.536 3.316 1.669 0.095 
V10.02 -0.149 1.183 -0.126 0.900 
V10.03 5.292 3.579 1.478 0.139 
V10.04 9.432 5.652 1.669 0.095 
V10.05 -6.539 4.149 -1.576 0.115 
V10.06 -1.021 0.922 -1.108 0.268 
V10.07 0.759 0.894 0.849 0.396 
V10.08 4.354 3.263 1.335 0.182 
V12.01 2.721 2.452 1.110 0.267 
V12.02 -3.992 2.263 -1.764 0.078 
V12.03 1.323 0.772 1.715 0.086 
V12.04 2.848 1.683 1.692 0.091 
V12.05 -3.501 2.639 -1.327 0.185 
V12.06 -0.362 0.844 -0.428 0.668 
V12.07 -1.098 1.682 -0.653 0.514 
V12.08 3.615 4.162 0.869 0.385 
V12.09 1.786 0.755 2.366 0.018 
V12.10 6.854 3.857 1.777 0.076 
V12.11 3.438 2.267 1.516 0.129 
V14.01 7.156 2.933 2.440 0.015 
V14.02 -3.546 1.520 -2.333 0.020 
V14.03 -3.024 1.962 -1.542 0.123 
V14.04 -7.195 4.498 -1.600 0.110 
V14.05 -3.428 1.758 -1.950 0.051 
V14.06 -1.817 3.649 -0.498 0.618 
V14.07 4.324 3.335 1.297 0.195 
V14.08 3.392 1.197 2.834 0.005 
V14.09 -5.432 2.287 -2.375 0.018 
 
3.7- Discussion 
The results of this questionnaire were based on a sample of 169 responders with a wide 
range of roles. According to APIFARMA, there was a consistent decrease of professionals 
working for the Pharmaceutical Industry in Portugal of at least -18.0% since 2010 (-21.0% 
in Multinational Companies), being the estimated number of resources in 2013 of about 
623151. Therefore, although not representative in nature, the results of this survey should 
have been able to capture the feedback of about 2.7% of the Pharma Industry 
professionals at all levels.  
In fact, in addition to Medical Affairs, the opinion of General Managers, Business Units 
Directors, Regulatory, Pharmacovigilance, Medical Information, Marketing, Sales, Legal, 
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Quality, Access, Business Technology, Distribution and Communication, contributed to a 
comprehensive evaluation of the relevance of the Medical function in a broad range of 
perspectives. 
Most of the responders (92.3%) work for Multinational Companies, in line with the results 
published by APIFARMA where 82% of the Companies operating in Portugal are of such 
nature51. In terms of gender, the survey shows a greater percentage of female 
professionals working for Pharmaceutical Industry (52.1% vs 47.9% males). This 
percentage is even higher within Medical Affairs (63.2%). In another survey led by 
AMPIF52,53 the percentage of female collaborators working in Medical Affairs Departments 
reached 78.0%.  
The overall average age of the responders was of 42.4 years old, males being five years 
older than females. The great majority these pharma professionals belonged to the age 
group of 35 to 44 years old. A predominance of this age group has also been reported by 
AMPIF52,53 (51.3%). National companies tend to have older professionals.  
In National companies, strategic decisions are taken, by default, at local level, while in 
Multinational companies, these are thought to be taken at all levels, followed by Regional, 
Local and Global. This distribution is similar between Medical Affairs and other functions, 
meaning that this is a consensual evaluation across all areas of activity. Considering that 
the main strategy should come from the headquarters, it is relevant that about 22.0% of 
these strategic decisions are thought to be taken at Local level. 
According to respondents, the reporting of the Medical Affairs in Multinational companies 
should be split both at Central and Local levels (50.3 %). However, locally is the preferred 
option to the General Manager, leaving centrally/regionally reporting in second place. This 
pattern is observed across all functions and reinforces the importance of the Local 
decision making power.  
Out of the 169 responders to this survey, less than 10% worked for National, whereas 
92.3% for Multinational companies. In this sample, nearly 80% exercise their activity in 
companies with less 200 employees, and the other were equally distributes among 
companies with 100 or 101 to 199 workers. Compared with the distribution made 
available by APIFARMA51 on this regard, despite the different class intervals provided, it is 
likely that there was an over representation of responders from larger multinational 
companies in this survey, which was purely accidental. 
There was no correlation between the number of total employees and MA resources per 
company, the ratio “Medical Affairs/total employees” varying from 3 to 120, with a 
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median value of 20. In addition, according with the AMPIF report, there are 
pharmaceutical companies operating in Portugal without a formal Medical Department in 
place52,53. 
The importance of the Medical Affairs on the overall results of the company was rated 
very high, with more than 90% of responses scoring level “4” or “5”. This is in line with the 
majority of papers and reports on the Medical Affairs role in Pharmaceutical 
Industry19,52,53,54. 
The association of the Medical Affairs contribution to strategic activities is higher for 
“Product Launch Support” and “KOL Mapping”, however, all the remaining listed 
dimensions such as “Clinical Research”, “Safety and Pharmacovigilance”, “Customer 
Management” and “Compliance” ranked very high.  
Higher scores were also given to Operational Activities such as “Education Materials”, 
“Symposium Preparation”, “Internal Training” and “Advisory Board preparation and 
management”. A great deal of Medical effort is spent in “Content creation, Preparation 
and Review”, as well as in “Product Related Responses”, “Presentations”, “Contribution to 
Reimbursement Dossiers”, “Safety Management and Reporting” and internal “Cross 
Functional Meetings”, although some of these actions are not so visible, especially to 
general public. Therefore, it is interesting to acknowledge the recognition provided to it by 
these Pharma Industry professionals.  
The “Digital and Multichannel Medical” labor is a relatively new component and as such, a 
little bit below the average rank. When specifically analyzed, there were some items that 
were rated by more than 80.0% as“4” and “5”, such as: “Preparing/reviewing Materials for 
Self-detailing” and “Training Materials for Health Care Professionals” (self-education). 
Other components of customer interaction like “Webexes and Webinars”, or 
“Newsletters” were also important and “Mobile Applications” in a crescendo of interest.   
Despite its importance, “Social Media” was regarded at a lower level but it plays a major 
role in ensuring the adequate level of communication internally and externally, also in 
crisis management. 
When analyzing the highest scores for the overall contribution of Medical Affairs to 
Strategic, Operational and Digital activities, stratified by condition (Medical Affairs vs 
Others), statistical significant differences were only found for “Operational activities” 
probably because colleagues pay more attention to the operational component of MA. 
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The recruitment of Medical Affairs positions requested to head hunters in our market, 
increased from 19.0% (2005-2010) to 47.0% (2010-2015), while Commercial positions 
decreased during the same time period, from 42.0% to 29.0%, and Marketing positions 
from 39.0% to 24.0%12.   
When recruiting a Medical Affairs person, the characteristics perceived as most relevant 
to take into consideration by the responders were: a “Problem Solving Attitude”, “Pro-
activeness and Flexibility” closely followed by “Competency”.  
The “Aspect” and “Posture” were seen as much less important”. Other important 
attributes pointed out were: “Academic Skills”, “Strategic Thinking”, “Leadership Skills”, 
“Communication Skills”, “Willingness to Learn”, “Creativity”, “Networking”, “Emotional 
Intelligence”, “Ethics” and “Compliance”.  
The number of medicines considered reasonable for a Medical Affairs FTE to handle was 
found to be between “2 and 3”. Nevertheless, 11.3% of the responders considered that “6 
or > medicines” could be acceptable. This is certainly difficult to achieve in particular if 
one is dealing with several therapeutic areas but, unfortunately, it is not so uncommon. 
During a product life cycle the expected number of Medical Affairs requested to ensure an 
adequate level of support was mainly reported to be “1 or 2” FTEs, even “3” during a 
certain period . This is of course very much dependent of the disease prevalence, disease 
awareness, target population, product characteristics, therapeutic gap supposed to be 
filled, type of market (Hospital vs Health Center driven), available budget and potential 
return of investment. Even so, it provides an insight on which level of resources is thought 
to be required and when to have them in place. 
Customer facing activity is highly regarded both by pharmaceutical companies and 
customers. In fact, 17.8% of the responders suggest that a Medical Affairs person “should 
regularly interact with less than 5 customers”, 18.9% considered that “5-10 would be 
reasonable” and 63.3% accepted even a higher number. In current practice the number of 
customers a Medical Affairs person interacts with is higher, frequently reaching “15 to 
25”. Again, the dedicated approach to these customers is similarly related with most of 
the parameters mentioned above. One thing is clear; the number of customers under the 
reach of a Medical Affairs person is much higher than what was expected, even by 
colleagues with other functions.  
All listed Medical Affairs activities m got high scores, being “Scientific Arguments“ and 
“Scientific Updates” the most highly rated. “Contribution for Brand Plans”, “Support to 
Clinical Research”, “Compliance”, “Contribution to Adequate Preparation and Review of 
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Educational and Promotional Materials”, “Responses to Inquiries” (Medical Information) 
and “Coaching to Colleagues” were among the activities regarded as “other”. 
When asked about the efficiency of Medical Affairs being “Office based” vs “Home based” 
or “Virtual”, about three thirds responded that Medical Affairs resources are “More 
efficient Office based“ and some mentioned a hybrid or combined model. The responders’ 
condition, gender, or type of company did not impact this evaluation.  
In what concerns the management of Clinical Research “Internally with Company 
Resources” vs “Conducted by Clinical Research Organizations”, about half of the 
responders think that Clinical research is more efficient if performed by company 
resources, while about 40% defended a combination of both company and outsourced 
resources. The delegation of R&D activities on contracted resources (CROs) is of major 
relevance and concern, not only because they assume the face of the company while 
interacting with the investigators and investigational teams, but also because they 
frequently operate from outside the country, sometimes they are not native Portuguese 
speakers, they do not make the follow-ups so closely, nor they are so easily at reach. In 
addition, they tend to use the usual list of sites, limiting new entries; they do rotate quite 
frequently, making it difficult to establish a medium long-term relationship with the 
investigational teams and, they are frequently more costly12.   
The most relevant factors impacting Medical Affairs Retention were: “Opportunities for 
Personal Development”, “Recognition” and “Work Conditions”, which were rated the 
highest punctuations for more than 90.0% of respondents. Other aspects to take in 
consideration were: “Culture & Values”, “Motivation and Commitment”, “Team Spirit”, 
“Brand Awareness”, “Professional Development” and “Credibility”. “Being proud of 
working for pharma”, “Demonstrating the value of M. Affairs for patients, HCP and the 
population as a whole55, is something that worthwhile mentioning too. The contribution of 
the Medical Affairs to the Company Reputation and Credibility was very highly rated.  
This is the reflex of seriousness, rigor and compliance directly associated with the Medical 
Affairs contribution for the business and the differentiation from Marketing and 
Commercial activities. This is also recognized by other external surveys54. 
Looking at the future, the majority of the respondents forsee a “Greater Involvement of 
Medical Affairs”; nevertheless nearly one third believe that it will be “similar” or even 
”reduced”. 
The exercise of multivariate analysis and modeling reinforced the recognition of the 
Medical Affairs contribution to the overall results of the company, both from the Strategic 
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and Operational point of view. Clinical Research, Product Launch and Safety & 
Pharmacovigilance, were better rated by females. Younger responders (≤34 years) valued 
less the MA contribution to Social Media, Digital and Multichannel activities, while 
multinational industry professionals recognize greater value in the MA contribution to 
Clinical Research.  
Product Related Response to Questions, support to HCP Websites/Portals, the Preparation 
and Review of Materials for Self-detailing, Mobile Applications and Social Media were the 
variables that better explain the higher response rates on this dimension.  
 
3.8- Conclusions derived from the questionnaire to Pharma 
In National companies Medical Affairs usually report to the General Manager, while in 
multinational companies MA should report to both central and local levels. 
The strategic contribution of MA is considered particularly important to: 
- Support product launch 
- KOL mapping and management 
- Clinical Research 
- Safety and Pharmacovigilance 
- Customer management 
- Compliance 
- Support to Market Access but, Business Development, Training and Medical 
Education were also mentioned. 
 
The Operational contribution of MA is particularly rated in terms of: 
- Education materials preparation and review 
- Symposia preparation 
- Internal Training 
- Advisory Boards preparation and management 
- Clinical Research 
The contribution of MA to Digital and Multichannel development and implementation is 
particularly valued in: 
- Preparation & review of materials for self-detailing 
- Training materials for HCP 
- Webinars 
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- Newsletters 
- WebEx’s 
- Mobile applications 
When recruiting a MA person, the most important attributes were said to be: 
- A problem solving attitude 
- Proactiveness 
- Flexibility 
- Competency 
- Experience 
- Posture/aspect 
- Academic skills 
- Strategic thinking 
- Leadership skills 
- Communication skills 
- Willingness to learn 
- Creativity 
- Networking 
- Emotional intelligence 
- Ethics and compliance 
MA are said to be more efficient if they are office-based, although a combined model 
(office/home) could be also considered, depending on size and reach. 
Clinical Research should be managed preferably internally with company resources; 
outsourcing is a second choice. 
The most important factors to influence MA retention are: 
- Opportunities for personal development 
- Recognition 
- Work conditions (salary & fringe benefits) 
Other relevant aspects to consider are:  team inclusiveness, R&D pipeline and leadership. 
The MA contribution to both company reputation and credibility was considered 
paramount. 
In the future, MA resources will tend to increase. 
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The exercise of multivariate analysis and modeling reinforced the recognition of the 
Medical Affairs contribution to the overall results of the company both from the Strategic 
and Operational point of view. 
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CHAPTER IV - THE CUSTOMERS PERSPECTIVE 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The real voyage of discovery consists not in seeking new lands but, in seeing with new 
eyes”.  
Marcel Proust 
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CHAPTER IV - The Customer’s perspective on the value of Medical Affairs 
4.1- Introduction 
The following section presents the results of the questionnaire addressed to customers 
with whom Medical Affairs interact on a daily basis, such as Physicians, Pharmacists, 
Nurses, Health Administrators, Regulatory Authorities, Investigators, Faculty Professors 
and Administrative staff. It aimed to capture their perception of the Medical Affairs 
contribution to service provided by pharmaceutical companies.   
 
4.2- Methods 
A structured questionnaire was sent out by email to an unselected sample of customers 
on April 2015 (Appendix I). These emails contained a link directly to Google56 where the 
anonymous answers could be inserted. All the data collected was entirely confidential, 
observing the law on Data Protection45 and were automatically transposed to an Excel 
database with the only purpose to produce this report. The data analysis was performed 
using the software SAS Enterprise V446, Statistics V947 and EpiInfo V648. 
For this questionnaire no sample size was previously determined. All customers we had an 
e-mail address were targeted. Due to the limited number of customers for which we had 
an e-mail address, we have not defined quotas per type of institution. A total of 197 
emails were sent, 13 of them were rejected (wrong e-mail address), and 40 answers were 
received (40/184). This translates in a response rate of 21.7%. From these 40, the data 
was only available for all the variables in 36 (90.0%).  
 
4.3- Results 
The participation per type of responding customer shows that 58.3% of the valid 
contributions came from Physicians, 22.2% from Universities, 5.6% from Regulatory 
Authorities or Pharmacists, and 8.3% from other sources such as: Legal, Health 
Administration Board Members and Administrative Support staff (Fig.30).  
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Figure 30- Type of responding customer 
 
In terms of gender (Fig. 31), most of the responders were males (72.2%), the majority 
having 45 years old or more (Fig. 32), with a mean age of 56.1 years old and a median of 
58.0 years old (Fig.33). 
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Figure 31- Customer distribution according to Gender 
 
The females account for 27.8% of the responders (Fig. 31) with a mean age of 48.8 years 
old and a median of 48.0 years old (Fig. 33) .  
 
 
Figure 32- Customers distribution according to the Age group  
 
There was homogeneity of the variances of the age distribution in both groups (F=2.65; 
p=0.0651), therefore the T Test for these independent groups was applied (T=1.91; 
p=0.0641) showing no statistical significant difference of the means. 
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Figure 33 – Age distribution by gender  
 
In what concerns the type of institution they work for (Fig. 34), 36.1% of respondents 
develop their activity for the “National Health Service”, while a similar percentage (33.3%) 
work in “Private settings”. Seventeen percent have “State related activities other than 
SNS” (most Universities or Research Centers) and 13.9% work in “Other areas”. 
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Figure 34 - Type of Institution Customers’ work for 
 
Regarding the number of employees per institution, most responders work for institutions 
with “200 or more employees” (55.6%), while 36.1% work at institutions with “Less than 
100 people”, only a minority of 8.3% work for entities with resources “Between 110 and 
199 employees” (Fig. 35). The third stratum encompasses the vast majority of responders 
who work for the “NHS” or “State other than NHS”. Half of the respondents from the first 
group, and all from the second, work for private institutions, including Social Solidarity 
ones.  
 
36.1%  
(n=13) 
16.7% 
(n=6) 
33.3% 
 (n=12) 
13.9%  
(n=5) 
0% 10% 20% 30% 40% 50%
National Health Service (SNS)
State other than SNS
Private
Other
 
 
 Page 94 
 
 
Figure 35- Number of employees per institution  
 
In terms of the number of Direct Reports, all responders had at least one direct report, 
47.2% “Up to 5 reports”, while 52.8% had “More than 5 reports”, and 13.9% of these with 
“More than 10 reports” (Fig. 36).   
 
 
Figure 36- Number of customers’ direct reports  
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When comparing the rates attributed to the value of the interactions with different 
Pharmaceutical Industry Representatives (Fig. 37), 60.0% rank the Medical Affairs 
interaction very high (“4”). Interestingly, a small percentage of customers attributed the 
highest score to other functions such as Key Account Managers showing that they have 
clear managerial responsibilities in their organizations. 
 
 
Figure 37- Value of interactions with different Pharmaceutical Industry representatives 
 
Based on their experience, the scientific knowledge of Medical Affairs was very much 
recognized by the majority of the responders (97.2%, Fig. 38). 
 
Figure 38 - Scientific knowledge of Medical Affairs  
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The Medical Affairs contribution to the different activities usually performed by pharma 
was also very much appreciated. Not surprisingly the “Response to Product Related 
Questions”, as well as “Safety Reporting”, “Pharmacovigilance” and “Advisory Boards 
Management”, were among the ones capturing higher attention.  The rating of 
“Management of Customer Relations” is certainly lower than expected, while “Digital & 
Multichannel Development and Support” achieved a very interesting result (Fig. 39). 
 
 
Figure 39 – Customers’ rating of Medical Affairs contribution to selected activities 
 
The use of Digital Communication Channels ranks very high in some categories such as “e-
mails” and the average assessment of the remaining ones like “Webinars” and “Webexes” 
were also good. Not surprisingly, there was already some experience with Virtual Advisory 
Boards in Portugal, which is not so common across Europe (Fig. 40). 
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Figure 40 - Comfortable usage of digital communication channels 
 
The current contribution of Medical Affairs to the Digital & Multichannel Development 
and Implementation is particularly relevant to the use of “Websites/Portals”, “Self-
Detailing”, “Training materials” but also to ”Newsletters”, “Webinars” (live and on 
demand) and for the adoption of some “Mobile Applications”. Although less notorious, 
“Social Media” ranked high by more than 30.0% of the responding customers (Fig. 41). 
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Figure 41 – Current Medical Affairs contribution to Digital & Multichannel development 
 
 
Figure 42 – Future contribution of MA for the Digital & Multichannel Processes 
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In order to ensure an adequate level of support to all these activities, companies need to 
grant an adequate level of Medical Affairs’ resources, namely by considering a reasonable 
number of medicines a Medical Affairs person should be responsible for. In our survey 
38.9% of the customers considered that “3 medicines” per Medical Affairs would be 
reasonable, whereas 16.7% consider “5” and 11.1% agree on only “2 products” (Fig. 43).  
Being the Product Launch one of the most important milestone of a medicine, the 
customer expectations are that these Full Time Equivalent (FTEs) resources should be in 
place sometime before, during and after the product is on the market.  
 
 
Figure 43 - Reasonable number of medicines a Medical Affairs should be responsible for 
 
This is, of course, very much dependent on the prevalence of the disease, target 
indications and competitors, but gives an insight on what level of resources are thought to 
be required. 
Consistency is clearly shown around one and two FTEs across the different launch phases, 
with some greater resource variance across the remaining options (Fig. 44; Table 14). 
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Figure 44 – Medical Affairs resources though to be needed to support a medicine launch 
 
Table 14. Expected number of Medical Affairs FTEs around product launch 
Time \ Nº of FTEs 0 0.5 1.0 1.5 2.0 2.5 3.0 >3.0 Total % 
1 Year before 6.3 15.6 31.3 6.3 15.6 0.0 9.4 15.6 100.0 
6 Months before 0.0 0.0 18.8 34.4 9.4 3.1 18.8 15.6 100.0 
At Launch 0.0 0.0 6.3 6.3 40.6 3.1 12.5 31.3 100.0 
6 Months after 0.0 0.0 9.4 21.9 12.5 15.6 21.9 18.8 100.0 
1 Year after 0.0 0.0 22.6 12.9 6.5 25.8 16.1 16.1 100.0 
2 Years after 0.0 0.0 33.3 6.7 30.0 13.3 6.7 10.0 100.0 
3 to 5 Years after 0.0 10.0 46.7 6.7 23.3 6.7 0.0 6.7 100.0 
> than 5 Years after 10.7 21.4 50.0 7.1 36 0.0 0.0 7.1 100.0 
 
 
On the other hand, the perception regarding the number of customers a Medical Affairs 
person should manage shows a wide variability (Fig. 45). About 53.0% of customers 
mentioned “> 10”, while 32.4 % think that “5-10” would be an appropriate number and, 
14.7% believe that ”< 5” would be reasonable number for Medical to manage during 
her/his customer facing activity. 
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Figure 45 – Number of customers a Medical Affairs person is thought to manage 
 
The value attributed by customers to some of the major Medical Affairs activities is 
translated in the following graph (Fig. 46). “Clinical Research“ stands out and, as in Fig. 37. 
“Product Support”, “Safety and Pharmacovigilance”, as well as “Management of Customer 
Relations”, are among the highest rated. 
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Figure 46 - How much do you value the Medical Affairs activities? 
 
Customers involvement according to study type show that they seem to have more 
experience with the Clinical Trials, than with Investigator Initiated Research (IIRs); 
however, the different type of studies have been experienced by most of the respondents 
(Fig. 47). There were no statistically significant differences between the rates attributed to 
the three groups (χ2=0.034; 2df; p=0.983). 
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Figure 47 – Customers’ involvement according to study type 
 
In terms of value attributed to the different Clinical Research type of projects, more credit 
is granted to Clinical Trials when compared with other types of information gathering, 
namely Institutional Real World Data, IIRs or other non-interventional studies (Fig. 48).  
 
 
Figure 48 – Value attributed to the different Clinical Research type of projects 
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There are statistical significant differences between the value given to the four groups 
(χ2=16.3; 3df; p=0.001). This differences are particularly evident between “Clinical Trials” 
and “Other Non-interventional studies” (χ2=15.5; 1df; p=0.0001), the former presenting 
higher scores.  
The “Interest and perceived value” is pointed out as the most important driver to improve 
the efficiency of Clinical Research in Portugal having been selected by 55.6% of the 
customers, and followed by “Proper conditions” (25.0%) and “Available budget” (16.7%). 
Only one customer responded that time could be a limiting factor (Fig. 49). 
 
 
Figure 49 – Most important drivers to improve efficiency in Clinical Research in Portugal  
 
The major roadblocks for Clinical Trials implementation were identified as “Long approval 
timelines”, “Lack of resources” and “Low Curriculum Vitae impact”. Factors of other 
nature such as: lack of appropriate coordination and support, were also pointed out (Fig. 
50). 
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Figure 50 - Major roadblocks for Clinical Trials implementation in Portugal 
 
To check the specific contribution of Medical Affairs around a topic that is relevant for 
both the Pharma Industry and health care professionals, customers were asked about the 
relevance of the work done by the Medical Affairs informing them about the the European 
Federation of Pharma Industry Association (EFPIA) Code of Ethics and Transparency 
implementation. The results are remarkable, with 61.1% responses ranking as “High” and 
36.1% as “Medium”. Only one customer (2.8%) considered this impact to be low (Fig. 51). 
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Figure 51 – Impact of MA in the implementation of the EFPIA disclosure code of Ethics and 
Transparency, between the Pharma Industry and HCPs 
 
The Pharmaceutical Industry in Portugal cannot communicate directly with patients. In 
order to indirectly address the impact of the Medical Affairs on this matter, customers 
were asked: How can patients benefit from the Medical Affairs activity? 
According to customers, patients can benefit most from the Medical Affairs activity by 
”Providing HCPs with updated Information on Available Medicines”, by “Helping to bring 
these Medicines Into the Market”, by  “Raising Disease Awareness” and “Contributing to 
develop more efficient treatment options” (Fig. 52). “Treatment adherence” and the 
“Support to Patients’ Associations” were also mentioned. 
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Figure 52 - How can patients benefit from the Medical Affairs activity? 
 
In terms of Health Gains achieved so far (Fig. 53), 80.6% of customers considered the 
Pharmaceutical Industry contribution as “High”, while 16.7% ranked it as “Medium” and 
one responder assessed it as “Low” (2.8%). 
 
 
Figure 53 - Pharmaceutical Industry contribution to the health gains achieved so far 
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The majority of the customers (52.8%), considered the Image of the Pharmaceutical 
Industry as “Good”,  25.0% assessed it as “Satisfactory”, while 11.1% found it “Fair” and a 
similar percentage labeled it as “Poor” (Fig. 54).  
 
 
Figure 54 – Customer perception of the Pharmaceutical Industry image 
 
Research, New drug development, Health care and Scientific information sharing, are 
among the additional arguments mentioned supporting a good image, whereas, Prices, 
Profit and some cases of Lack of transparency and fraud justified less positive 
assessments. 
Almost 2/3 of customers find the scientific Medical Affairs support to be unbiased (69.4%), 
while 30.6% have a different opinion (Fig. 55). 
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Figure 55 – Does Medical Affairs provide unbiased scientific support? 
 
Among the most relevant outcomes resulting from a Medical Affairs/customer interaction, 
the “Scientific update” ranks first, followed by the “Safety” and “Efficacy profile” of 
medicines and “Differentiation vs competitors” and “Scientific Update on publications”. 
Webinars are not yet very much recognized by these customers (Fig. 56). 
 
 
Figure 56 - Valued outcomes resulting from a Medical Affairs/customer interaction 
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A majority of customers foresee greater Medical Affairs involvement in the future (72.2%), 
whereas 22.2% believe that this contribution will be similar, and 5.6% expect it to be “less 
of” (Fig. 57). 
 
Figure 57 – Involvement of Medical Affairs in the future 
 
4.4- Discussion 
Receiving customer feedback on the Medical Affairs activity is very important. The 
response rate to this e-mail/web questionnaire was not very high (21.7%), but in line with 
what has been reported by other authors, namely by surveys performed through e-mail 
(17.3%) or Survey Monkey (27.7%)49. A recent survey conducted in Portugal by Banco de 
Portugal for the International Monetary Fund with a similar design, got a response rate of 
17.4%50. Therefore, despite not being a large group of customers, the response rate was 
within what was initially expected. To be able to respond to this questionnaire, customers 
should have access to a computer and internet. We know that internet users are not 
representative of the general population. However, that was not considered to be a 
problem since, as Medical Affairs, we do not interact with the general population. These 
customers are the ones with whom we regularly meet and from whom we wanted 
feedback.  
Among the advantages we have considered by using this survey method, one could 
underline: speed, the virtual elimination of data entry costs, convenience to both sides, 
the likelihood of getting more accurate answers to sensitive questions and the elimination 
of interviewer bias. We understand also that there was limited control of people 
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potentially responding multiple times, which we did try to validate by comparing the 
responder’s age, gender and type of institution.  
The image of the Pharmaceutical Industry has been affected in recent years by several 
unfortunate events that could, in a way, reduce the customer’s willingness to respond to 
such questionnaires. In addition, customers could easily quit in the middle of the 
questionnaire. However, since it was not long, this only happened in 10.0% of the cases. 
Those who contributed to this survey came from quite a broad variety of institutions, 
state owned or private. These customers were experienced people with several direct 
reports, working for national and international companies. 
The value attributed to interactions with Medical Affairs show a high combined score. 
Interestingly, Key Account Managers work was also very much appreciated, showing that 
some of these responders share clear managerial responsibilities in their organizations. 
The scientific knowledge of Medical Affairs was duly recognized by the majority of the 
responders (97.2%), and their contribution to the different activities was also noted. Not 
surprisingly, the response to Product Related Questions, as well as Safety Reporting and 
Pharmacovigilance, Advisory Boards Preparation and Management, were among the ones 
capturing higher customer’s attention.   
The Management of customer relations being rated as “reasonable” was lower than 
expected. This was probably influenced by the limited number of Medical Affairs 
resources available and the number of products they have to support. In fact, not only the 
reality shows that the number of FTEs available is less than expected52, but also that the 
number of customers they need to cover is much higher. 
Customers’ usage of digital and multichannel communications, namely with e-mails, 
WebEx’s, Webinars, virtual Advisory Boards and Mobile applications is relatively common, 
less so with Facebook, Tweeter, or on-call webinars. The current contribution of Medical 
to Digital & Multichannel Development and Support achieved a very interesting result, 
particularly in what concerns Websites and Portals, Training materials, Self-detailing, 
Newsletters, Webinars and mobile applications. Social Media was considered less 
important, but still got some attention. Future expectations on this field are even higher. 
The Medical Affairs contribution to Digital and Multichannel tend to grow in all areas. In 
order to ensure an adequate level of support to all the activities attributed to Medical 
Affairs, companies need to recruit and develop a reasonable number of resources to 
adequately manage the different therapeutic areas and product portfolio. Three 
medicines per Medical Affairs FTE was the most voted opinion (nearly 40%), varying from 
2 to a maximum of 5 products.  
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The Product launch is one of the most important milestones of the life cycle of a medicine. 
Resources should be in place several months before the launch, during, and sometime 
after the product is on the market. The perception regarding the number of customers a 
MA person should manage shows a wide variability, although the majority of customers 
suggest ten or more. According to our best knowledge, this really varies very much across 
companies, and it is mainly determined by the prevalence of the disease, number of 
KOLs/prescribers and payers involved, product characteristics, competitors in the market 
and product life cycle. In some companies the number of customers a MA has to manage 
may easily reach 20 or 30. 
The value attributed by customers to some of the major Medical Affairs activities, 
highlights Clinical Research, Product Support, Safety and Pharmacovigilance, as well as 
Management of Customer relations and Compliance. These are indeed activities 
predominantly performed by Medical. It is very good to see them recognized and 
differentiated from Commercial. Customers are more experienced with the Clinical Trials, 
than with IIRs or other types of studies. In fact, much more credit is granted to Clinical 
Trials when compared with the other options.  
The most important driver to improve the efficiency of Clinical Research in Portugal is 
Interest and Perceived value. Other determinants are: Proper Conditions to develop 
research and an Available Budget. Time was rarely mentioned as limiting factor. The major 
roadblocks for Clinical Trials implementation were said to be: “Long approval timelines”, 
Lack of Resources” and “Low Curriculum Vitae impact” whereas “Lack of appropriate 
coordination and support”, was pointed out as a contributing factor. 
In terms of Ethics namely in what regards the implementation of the EFPIA disclosure 
Code of Ethics and Transparency, which governs the relationship between pharma and 
HCPs, the awareness of the impact of MA in the implementation of such measures was 
very high. Medical Affairs were key elements in informing and explaining to HCPs the 
additional procedures reinforcing the APIFARMA code of Ethics, as well as the ones 
derived from the need of reporting into the INFARMED platform any potential support 
given or received. 
The Pharmaceutical Industry is one of the few, if not the only business, where prescription 
medicine producers cannot directly interact with their consumers. In order to indirectly 
address the impact of the Medical Affairs on this matter, customers were asked the 
question: How can patients benefit from the Medical Affairs activity? ”Providing HCPs with 
updated Information”, “Helping to bring Medicines Into the Market”, “Raising Disease 
Awareness” and “Contributing to develop more efficient treatment options” were the 
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most voted statements. “Treatment adherence” and the “Support to Patients’ 
Associations” were also mentioned.  All pre-identified dimensions were considered valid.  
In terms of Health Gains the contribution of pharma was outstanding, with 81% classifying 
it with high punctuations, and the majority of the customers considered the image of the 
Pharmaceutical Industry as “Good”, while a quarter assessed it as “Satisfactory”. 
Therefore, there is clear room for improvement. The Scientific support given by Medical 
was considered unbiased by almost 2/3 of the customers, being the “Scientific update on 
new drug development”, “Safety”, “Efficacy” and “Differentiation vs competitors” among 
the most recognized. In the future, a majority of customers foresee greater Medical 
Affairs involvement. 
 
4.5- Conclusions derived from the questionnaire to Customers 
The value attributed by customers to the interactions with MA show a high level of 
appreciation, supported on the recognition of scientific expertise and contribution to the 
different activities, such as: 
- Response to Product Related Questions 
- Safety Reporting and Pharmacovigilance 
- Advisory Boards Preparation and Management 
Customers’ usage of digital and multichannel communications, namely with e-mails, 
WebEx’s, Webinars, virtual Advisory Boards and Mobile applications is relatively common, 
less so with Facebook, Tweeter, or on-call webinars. 
The current contribution of MA to digital & multichannel development and support was 
very positively mentioned, particularly in what concerns Websites and Portals, Training 
materials, Self-detailing, Newsletters, Webinars and mobile applications. The Medical 
Affairs contribution to Digital and Multichannel tend to increase in all areas.  
In order to ensure an adequate level of support to all the activities attributed to MA, 
companies should consider having a maximum of 3 to 5 medicines per FTE. The product 
launch is one of the most important milestones of the life cycle of a medicine. Resources 
should be in place several months before the launch, during, and sometime after the 
product is on the market.  
The perception regarding the number of customers a MA person should manage shows a 
wide variability, the majority of customers suggesting ten or more.  
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Customers are more experienced with the Clinical Trials, than with Investigator Initiated 
Research (IIRs) or other types of studies. The most important driver to improve the 
efficiency of Clinical Research in Portugal is Interest and Perceived value. Other 
determinants are: Proper Conditions to develop research and an Available Budget. Time 
was rarely mentioned as limiting factor. The major roadblocks for Clinical Trials 
implementation were said to be: 
- Long approval timelines 
- Lack of Resources 
- Low Curriculum Vitae impact d 
- Lack of appropriate coordination and support, was pointed out as a contributing 
factor. 
In terms of ethics and transparency, Medical Affairs were key in informing and explaining 
to HCPs the additional procedures reinforcing the APIFARMA code of Ethics, as well as the 
ones derived from the need of reporting into the INFARMED platform any potential 
support given or received.  
According to customers, the indirect impact of MA in patient’s lives can be translated by: 
- Providing HCPs with updated information 
- Helping to bring Medicines Into the Market 
- Raising Disease Awareness 
- Contributing to develop more efficient treatment options 
Treatment adherence and the support to Patient’s Associations were also mentioned and 
this is quite important, because it shows the awareness of MA progressive involvement, 
also at this level.   
The perceived contribution of Pharma to health related gains was outstanding. Although 
more than half of the customers considered the image of the Pharmaceutical Industry as 
“Good”, one quarter assessed it as “Satisfactory”; therefore, there is clear room for 
improvement.  
The scientific support given by Medical was considered unbiased by almost 2/3 of the 
customers, underlying on this respect: 
- Scientific update on new drug development 
- Safety 
- Efficacy 
- Differentiation vs competitors 
In the future, the majority of customers foresee greater Medical Affairs involvement. 
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CHAPTER V – CONCLUSIONS AND SUGGESTIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Good common sense is something that everybody talks about but it’s lacking the most” 
                                  José Manuel Fernandes 
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CHAPTER V - Conclusions and suggestions 
In our current environment, resource allocation within Pharma is key. We have shifted 
from a structure based on sales reps who repeatedly convey a set of structured messages, 
to a level where discussion takes place on the roots of scientific arguments, and 
investments are balanced according to the expected value and impact. Customers such as 
health care professionals, patients, regulators, payers and the general population, expect 
Pharmaceutical companies to deliver not only medicines but a continuum of care, ranging 
from disease awareness, prevention, diagnosis and efficient treatment options. These 
customers request increasing attention, patients and Patients’ Associations are more vocal 
and intervenient, payers and regulatory authorities look much closer no only to the efficacy 
and safety of the medicines, but also to its economic value and differentiating factors. 
Medical Affairs are the best prepared and the most credible to communicate service value 
messages, discuss health topics, pave the way for new medicines launch and hopefully 
improve the quality of care. 
 
5.1- Questionnaires results’ comparison 
When results from both questionnaires (Pharma vs customers) were compared, regarding 
the variables that were similarly collected, one can see that: 
a) In terms of gender, customer responders were predominantly males (72.2%), while in 
pharma they only account for 47.9 % (χ2= 7.02; p=0.008) of the participants. As most 
customers have one or more direct reports and are leaders in their settings, this 
unbalanced distribution of gender with only 27,8% of females responding to  
customers’ survey, is probably influenced by the general pattern of the European 
companies  administration boards members/directors, where women are still only 
occupying 23.0% of the places57. 
b) the age class distribution was also statistically different (χ2=34.4; 3df; p=0.000) with a 
predominantly younger population at pharma vs customers; 
c) the number of employees per institution show a statistically different class distribution 
(χ2=13.0; 2df; p=0.0015) mainly due to the higher percentage of “<100” employees per 
institution responding to the customer’s survey;  
Looking at the different markers of evolution (from 1 year before through 5 years and 
more) we found that there is a good fit between the results of questionnaires from 
Pharma Industry professionals and customers (Fig. 58). The total absolute numbers of 
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suggested FTEs from these two samples are different due to sample sizes considered 
(industry professionals (1352) vs customers (247); χ2=59.7; 7df (p=0.0000).  
However, the distribution pattern is quite similar up to 3 years after launch (Pearson 
correlation coefficient= 0.8275), diverging from then on.  
 
 
Figure 58 – Medical Affairs resources estimates on Pharma Industry (Table 6) and customers’  
(Table 14) surveys  
 
Comparing the evaluation from customers with the one provide by colleagues from the 
Pharmaceutical Industry one can see that Clinical Research is even more valued, being the 
difference marginally not statistically significant (χ2=9.3; 4df; p=0.0531). For Market Access 
(χ2=4.2; 3df; p=0.2417), Operating Plans (χ2= 8.4; 4df; p=0.0787), Safety & 
Pharmacovigilance (χ2=5.5; 3df; p=0.1406), Compliance (χ2= 4.5; 3df; p=0.2091) KOL 
mapping (χ2=6.6; 4df; p=0.1574) and Customers’ Management (χ2=3.2; 3df; p=0.3686) no 
statistically significance differences were found between pharma and customers 
assessments. In Product Launch and Support pharma colleagues valued more the 
involvement of Medical, being the difference statistically significant (χ2=9.1; 2DF; 
p=0.0105) versus customers. 
 
 
0
5
10
15
20
25
30
35
0 0.5 1.0 1.5 2.0 2.5 3.0 >3
Ind Profes. (Quest 19)
Customers (Quest 14)
% 
Number of MA resources 
 
 
 Page 119 
 
5.2- Major conclusions  
The Pharmaceutical Industry is a strategic sector for health and the country economy, 
translated in innovation, qualified work and health gains. Medical Affairs should contribute 
to strategic decisions namely at local level. The MA view and scientific advice are 
independent from commercial, and this should be clearly stated and shown in the field. 
Clinical Research is paramount to understand in depth the disease characteristics and 
treatment options. Complementary investigations such as real world data and 
pharmacoeconomic studies are important to demonstrate the value of medicines and 
devices in the usual settings. Access to innovative medicines is critical for the continuous 
improvement of the quality of care. Customers expect Pharmaceutical companies to 
deliver not only medicines but a continuum of care – Medical Affairs must drive this effort! 
Pharma needs to be closer to the customer, understanding its needs, capturing insights, 
communicating and responding timely and appropriately. Medical Affairs are the best 
resources to manage expectations and respond to this challenge. Communication is a 
common pitfall, in Pharma, especially in what concerns the use of the appropriate 
channels, clarity of the message content and opportunity to intervene. Medical Affairs are 
trained to make timely assessments and identify gaps, use the appropriate 
communication channels to eliminate conflicting perceptions, share best practices and 
convey clear and pragmatic messages. Health managers at all levels need to understand 
and better explore digital and multichannel tools that are already available, to provide a 
better service to the populations. 
The exercise of multivariate analysis and modeling reinforced the recognition of the 
Medical Affairs contribution to the overall results of the company both from the Strategic 
and Operational point of view. 
 
5.3- Key suggestions to ensure a Medical Affairs winning strategy in Pharma 
• Search for the best structure to operate in a rapid changing environment 
• Focus the pipeline and portfolio on areas of unmet medical need  
• Prove the value of innovative medicines and communicate adequately 
• Overcome market access challenges by providing robust clinical and real 
world evidence 
• Invest in win/win partnerships 
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• Ensure access to new customers and decision makers (stakeholder scope) 
• Find new ways of supporting heath care providers and patients, namely 
through digital and multichannel capabilities 
• Strive for continuous improvement 
• Develop and apply performance metrics and measure impact 
• Gain reputation and trust through transparency, compliance and ethical 
behavior 
• Invest in open door policy, invite customers in, share experiences 
• Talk proudly about what you do 
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CHAPTER VI - METRICS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Not counting all the interactions but, counting the interactions that count!...” 
                                                                                                            Rory O’Connor 
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CHAPTER VI - Metrics 
Metrics are valuable to guide the decision making process and to evaluate progress 
regarding specific objectives. This is not about reporting everything we do, or about an 
aimless progress but, towards objectives we are trying to accomplish. Since Medical Affairs 
resources are always scarce, one needs to make a pragmatic evaluation of those metrics 
that worthwhile using, in order to track the achievement of our business goals. If one does 
not know where to go, metrics will be helpless. A good metric should be meaningful, 
comparable, reproducible, understandable, preferably based on rates or ratios than on 
absolute numbers (e.g. “number of products/Medical Affairs”; “number of 
publications/year”, etc.)58. 
 
6.1- Quantitative metrics  
These are the most commonly used. They are easy to understand, they are valuable to 
record the variety and volume of the MA most relevant activities, namely requests 
responded, trainings performed, number of studies, support provided, and advisory boards 
organized.  
 
6.2- Qualitative metrics 
Qualitative metrics are more difficult to gather. They are more subjective in nature and 
imprecise59. Qualitative data makes you go out and talk, interview, identify opportunities 
(gaps or areas in need), provide solutions, capture insights, create a relationship and build 
confidence. These metrics can be generated: 
• Internally, by colleagues from other areas such as: Business Unit Leaders, Key 
Account Managers, Sales Reps, Medical and Nursing personnel), or/and  
• Externally, by customers 
 
6.3- Combined Metrics 
Mix both quantity (volume, rates or ratios) with quality, aiming to assess impact (low, 
medium or high). In addition to internal quantitative metrics (what do we do? how much 
we do? how many resources/time/investments are we allocating to? etc.), external 
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metrics such as interviews and surveys, focus groups or case studies, are extremely 
important to collect our customers’ opinion (how we do it? why we do it? how efficient 
were we in supporting their needs? what can we do better? which things we are not 
doing? which things are the others doing better than us?). The traditional metrics applied 
are mostly quantitative in nature, and not discriminative enough to fully assess Medical 
Affairs outcomes. These last ones are mainly based on the quality of the interaction, the 
insights gathered, the support delivered and the relationship established. However, they 
need to be accurate, adequately described, not too complicated and clear in terms of the 
impact generated. For these types of metrics, the difficulty resides in clearly defining not 
only the outcome, but also the major influencing factors. Some of these are just 
“contributing factors” (ex: lack of time, stress, inappropriate moment of interaction, 
wrong perception, etc…); while others can critically influence the MA/customer 
interaction, either negatively (a complaint) or positively (a research grant; a very 
successful treatment; an opportunity for personal development). Customer and 
stakeholder metrics are important to communicate the value of Medical, and a powerful 
indicator of the way MA and the Company is performing. If these sound negative, they 
most probably require a reassessment and, eventually, a change in customer’s 
management. Action needs to be quick! If these assume the form of complaints, 
implement correction measures immediately, in order to secure current relationship and 
minimize future impacts.  
 
Strategically, one needs to understand to which extent there is a causal association 
between the topic highlighted by the customer as a “threat” or “opportunity” and the 
perceived outcome. Sometimes these could be biased by the area of expertise, product 
portfolio, etc., or even confounded by other variables. MA should not make quick 
assessments without taking in consideration all potential intervenient factors listing those 
that might contribute and the ones which could be “potentially causal”. For these, not 
only the association with the underlying factor is needed, but they must also be directly 
linked with the outcome. For example: the number of meaningful MA interactions with a 
site might directly correlate with the number of sales of that particular unit, just by 
chance. The association might exist but it is not causal, because there is no commercial 
activity directly developed by Medical. A different situation would be, if the number of 
Investigator Initiated Research grants has a similar correlation pattern, once in addition to 
the association of both activities, the probability of MA to support directly these kinds of 
initiatives is much stronger.  
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A complaint not properly and timely addressed might undermine a MA/customer 
relationship, irrespectively of the moment when it occurred, stressed experienced, 
availability to meet/discuss and other aspects that could be cumulative but not necessary 
causal. One needs to look at the metrics, analyze them and understand. To me, the 
highest level of confidence is reached when the customer himself proactively alerts you 
for threats, identifies areas where you should focus, suggests approaches, make 
recommendations and is willing to be take part on the solution. Some of these insights 
are just information that could be worth pursuing. They don’t need to change your 
business model completely, but could make a difference regarding differentiation or 
highlighting opportunities that could be further explored. For instance, just focus on a 
group of customers that are truly engaged and could make a difference, instead of 
interacting with the all group (ex: Cardiologists vs general practitioners).  
A set of potential quantitative, qualitative and combined metrics is listed as examples. 
Some of them can be used separately or in a combined manner (e.g. the “number of 
educational materials” is a quantitative metric, which can be refined if we add a 
denominator: “number of educational materials/month”, or “per MA”“. They can be also 
combined with a qualitative assessment measuring the level of impact as presented next. 
 
Examples of Medical Affairs Metrics 
 
 
Measurement
Frequency 
of 
collection
Impact
Administration Board meetings Number of meetings tbd
Time spent Number of hours
Country Medical meetings Number of meetings tbd
Time spent Number of hours
Talent Management meetings Number of meetings tbd
Time spent Number of hours
People's Development meetings Number of meetings tbd
Time spent Number of hours
Other Internal activities Number of meetings tbd
Time spent Number of hours
Internal Customer feedback survey Number of hours yearly High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
Internal Stakeholder Management 
High; Med; Low
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Measurement 
(quantitative)
Frequency 
of 
collection
Impact 
(qualitative)
Internal meetings                                                        Number of meetings tbd
Time spent Number of hours tbd
Internal Training delivered                                                    Number of meetings tbd
Time spent Number of hours tbd
Educational materials reviewed            Number of materials tbd
Pages Number of pages tbd
Slides Number of slides tbd
Videos Number of videos tbd
Time spent Number of hours tbd
Promotional materials reviewed         Number of materials tbd
Pages Number of pages tbd
Slides Number slides tbd
Videos Number of videos tbd
Time spent Number of hours tbd
Clinical Research Number of studies tbd
Protocol & Country feasib ilities Number of feasibilities tbd
Site feasib ilities Number of feasibilities tbd
Oversight Number of hours tbd
Value Dossiers prepared                            Number of dossiers tbd
Pages Number of pages tbd
Time spent Number of hours tbd
High; Med; Low
High; Med; Low
High; Med; Low
Strategic Product Support 
High; Med; Low
High; Med; Low
High; Med; Low
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Measurement
Frequency 
of 
collection
Impact
Customer interactions Number of interactions tbd High; Med; Low
Face to face Number of interactions tbd High; Med; Low
WebEx; webinars                                                              Number of interactions tbd High; Med; Low
Other Significant Interactions (Phone, e-mail with a meaningful content) Number of interactions tbd High; Med; Low
Time spent Number of hours tbd High; Med; Low
Congress and Symposia Number of events tbd High; Med; Low
Content development (concept; invitations; materials) Number of hours tbd High; Med; Low
Customer attendance Number of attendees tbd High; Med; Low
Customer presentations Number of presentations tbd High; Med; Low
Time spent Number of hours tbd High; Med; Low
Institutional Management
Reg Bodies Number of meetings tbd
Time spent Number of hours tbd
Med Societies; Med Associations Number of meetings tbd
Time spent Number of hours tbd
Universities; Research Sites Number of meetings tbd
Time spent Number of hours tbd
Requests 
Unsolicited requests Number of requests tbd High; Med; Low
Support to scientific events / activities Number of activities tbd
Amount invested Value in €uros tbd
Support to partnerships & other business opportunities Number of activities tbd
Amount invested Value in €uros tbd
Time spent Number of hours tbd High; Med; Low
Advisory Boards Number of sessions tbd
Customer attendance Number of participants tbd
Time spent Number of hours tbd
Group Presentations                                           Number of sessions tbd
Customer attendance Number of participants tbd
Time spent Number of hours tbd
Non-interventional studies Number of studies tbd
Initiated Number of studies tbd
Ongoing Number of studies tbd
Completed Number of studies tbd
Amount invested Value in €uros tbd
Time spent Number of hours tbd
Investigator Initiated Research Number of studies tbd
Initiated Number of studies tbd
Ongoing Number of studies tbd
Completed Number of studies tbd
Amount invested Value in €uros tbd
Time spent Number of hours tbd
Other studies Number of studies tbd
Initiated Number of studies tbd
Ongoing Number of studies tbd
Completed Number of studies tbd
Amount invested Value in €uros tbd
Time spent Number of hours tbd
Publications  Number of publications tbd
Amount invested Value in €uros tbd
Time spent Number of hours tbd
Posters Number of posters tbd
Amount invested Value in €uros tbd
Time spent Number of hours tbd
Digital Applications Number of applications tbd
Amount invested Value in €uros tbd
Time spent Number of hours tbd
Other External activities Number of activities tbd
Amount invested Value in €uros tbd
Time spent Number of hours tbd
External Customer feedback survey yearly High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
External Customer Stakeholder Management
High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
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Measurement 
(quantitative)
Frequency 
of 
collection
Impact 
(qualitative)
Institutional Review (Public Affairs/Media) Number of requests tbd
Time spent Number of hours tbd
Compliance Review
Quality of processes (SOPs; Guidelines; Norms) Number of events tbd High; Med; Low
Quality of Products; Recalls; Stock-outs Number of events tbd High; Med; Low
Contracts Number of contracts tbd High; Med; Low
Fair Market Value (FMV) Number of FMV requests tbd High; Med; Low
Transparency Platform Number of reports tbd High; Med; Low
Audits & Inspections Number of events tbd High; Med; Low
Time spent Number of hours tbd High; Med; Low
Reports Number of reports tbd High; Med; Low
Pharmacovigilance Number of reports tbd High; Med; Low
Medical Information Number of reports tbd High; Med; Low
Telephone Number of reports tbd High; Med; Low
Fuel Number of reports tbd High; Med; Low
Travel Number of reports tbd High; Med; Low
Time spent Number of hours tbd High; Med; Low
Requests Number of requests tbd High; Med; Low
Scientific Support Number of requests tbd High; Med; Low
Financial Support Number of requests tbd High; Med; Low
Time spent Number of hours tbd High; Med; Low
Personal Training Number of sessions tbd
Time spent Number of hours tbd
Team Objectives 
Setting Number of hours tbd High; Med; Low
Review Number of hours tbd High; Med; Low
Evaluation Number of hours tbd High; Med; Low
e-mail Management Number of e-mails tbd
Time spent Number of hours tbd
Other Cross Product Activities Number of activities tbd
Time spent Number of hours tbd
Cross Product Involvement 
High; Med; Low
High; Med; Low
High; Med; Low
High; Med; Low
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APPENDIX I – PHARMA AND CUSTOMERS’ QUESTIONNAIRES 
Questionnaire to professionals working for the  
Pharma Industry 
The current questionnaire is part of a study “Contribution to an efficient Medical Management in 
Pharmaceutical Industry” which is being carried out by José Augusto Aleixo Dias MD at the University of 
Aveiro, within the Doctoral Program in Sciencies and Health Technologies, under the supervision of Professor 
José Manuel Calheiros. This questionnaire aims to collect the perception of the Medical Affairs (MA) 
contribution to the Pharmaceutical companies and to the customers they serve, in several dimensions. Your 
participation is voluntary and highly valuable to obtain a clear picture on how the work performed by these 
professionals is perceived, as well as, to identify areas of potential improvement. All the data collected is 
entirely confidential and will be treated anonymously, exclusively for the purpose of this study. 
Thanks very much for your participation! 
The investigator: 
José Augusto Aleixo Dias, MD 
Contacts: jose.a.dias@pfizer.com; Mobile: +351 91 725 47 26 
* Required
1- In which condition do you answer this questionnaire? * 
o General Manager / Business Unit Director
o Medical Affairs
o Marketing / Customer Marketing
o Regulatory
o Safety / Pharmacovigilance
o Medical Information
o Quality of Products / Processes
o Pharmacoeconomics / Access / Health & Value
o Finance
o Trade/ Distribution/ Logistics
o Human Resources
o Commercial
o Legal
o Business technology
o Assistant
o Other:
This is a required question 
2- Gender * 
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o Male
o Female
This is a required question 
3- Age * 
Must be a whole number 
This is a required question 
4- Type of company you work to? * 
Select one option 
o Portuguese Company (If you chose this option, select "not applicable" in the following
2 questions) 
o Multinational Company
This is a required question 
5- In multinational companies, strategic Medical Affairs decisions should be taken preferably at: * 
(If you work for a Portuguese Company, please select "not applicable") 
o Global level
o Regional level
o Local level
o At all levels
o Not applicable
This is a required question 
6- In multinational companies, Medical Affairs should preferably report: * 
(If you work for a Portuguese Company, please select "not applicable") 
o Centrally
o Locally to the General Manager
o Both
o Not applicable
This is a required question 
7- How many people work in your Company in Portugal? * 
Please fill with an entire number 
Must be a number 
This is a required question 
8- How many Medical Affairs persons do you have in your Company in Portugal? * 
Please fill with an entire number 
Must be a number greater than 0 
This is a required question 
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9- How important is for you the Medical Affairs contribution for the overall results of the Company? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 
This is a required question 
10- How do you rate the Medical Affairs contribution to strategic activities, such as: * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5
Clinical Research  
Market access 
Operating Plans  
Product launch 
and support  
Safety and 
Pharmacovigilance 
Compliance 
KOL mapping 
Management of 
Customer 
relations  
Other (rate and 
describe bellow) 
Please enter one response per row 
11- If "other" please describe 
This is a required question 
12- How do you rate the Medical Affairs contribution to operational activities, such as: * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5
Cross-
functional 
meetings  
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1 2 3 4 5
Education 
Materials 
preparation 
and review 
Promotional 
Materials 
preparation 
and review 
Advisory 
Board 
preparation 
and 
management 
Symposium 
preparation, 
invitations and 
content 
review  
Contribution to 
reimbursement 
dossiers 
Internal 
training of 
Sales Force 
and other 
colleagues  
Presentations 
to customers  
Product 
related 
response to 
questions 
Safety 
reporting 
Digital and 
multichannel  
Other (rate 
and describe 
bellow) 
Please enter one response per row 
13- If "other" please describe 
This is a required question 
14- What is your assessment of the Medical Affairs contribution for the digital & multichannel 
development and implementation processes? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5
Health Care 
Professionals 
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1 2 3 4 5
websites/Portals 
Preparing 
/reviewing  materials 
for self detailing  
Training materials 
for Health Care 
Professionals (self 
education)  
Newsletters 
Webexe’s 
Webinars live 
Webinars on 
demand 
Mobile Applications 
(e.g. disease 
awareness)  
Social media  
Other (rate and 
describe bellow) 
Please enter one response per row 
15- If "other" please describe 
This is a required question 
16- When recruiting a Medical Affairs person, how do you value her/his personal characteristics? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5
Competence in 
a specific area 
Experience 
Flexibility 
Fluency in 
foreign 
languages  
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1 2 3 4 5
Pro-
activeness  
Problem 
solving 
attitude  
Posture/Aspect
Other (rate and 
describe 
bellow) 
Please enter one response per row 
17- If "other" please describe 
This is a required question 
18- In general, what is the reasonable number of products a Medical Affairs FTE should have under 
her/his responsibility? * 
(FTE - Full time equivalent) 
Must be a number 
This is a required question 
19- How many Medical Affairs FTEs do you think would be needed to support a product during its life 
cycle? * 
(Indicate the current number of FTEs) 
0 0,5 1 1,5 2 2,5 3 >3
1 year 
before 
the 
launch 
6 
months 
before 
the 
launch  
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0 0,5 1 1,5 2 2,5 3 >3
At 
launch  
6 
months 
after  the 
launch  
1 year 
after the 
launch   
2 year 
after the 
launch   
3 to 5 
years 
after 
launch 
More 
than 5 
years 
after 
launch  
Please enter one response per row 
20- In general, how many customers should a Medical Affairs person manage during her/his customer 
facing activity? * 
This is a required question 
21- How much do you value Medical Affairs activities, such as: * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5
Customer’s scientific 
update  
Identification and 
response to 
customer’s needs 
Capture insights and 
explore 
opportunities 
Incorporate new 
scientific arguments 
or differentiation 
messages  
Incentivize local 
research, 
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1 2 3 4 5
publications and 
posters  
Provide evidence for 
the customer’s 
decision making 
process 
Respond to 
scientific/educational 
customer’s requests  
Other (rate and 
describe bellow)  
Please enter one response per row 
22- If "other" please describe 
This is a required question 
23- How do you see Medical Affairs resources being more efficient for the business? * 
o Office based
o Home based
o Virtual
o Other:
This is a required question 
24- How do you see Clinical Research being more efficient for the business? * 
o Company resources
o Outsourced resources
o Both
o Other:
This is a required question 
25- How do you value each of the following aspects impacting Medical Affairs retention? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5
R&D pipeline 
Salary and 
fringe 
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1 2 3 4 5
benefits 
Work 
conditions  
Team 
inclusiveness 
Opportunities 
for personal 
development 
Coaching   
Leadership 
Recognition  
Other (rate 
and describe 
bellow) 
Please enter one response per row 
26- If "other" please describe 
This is a required question 
27- How do you assess Medical Affairs contribution for the Company reputation and credibility? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 
This is a required question 
28- How do you forsee MA contribution for the business operations evolving in the future? * 
o More of
o About the same
o Less of
This is a required question 
29- Are there skills or services that are not offered currently by Medical Affairs, that you would like to 
see being explored? 
This is a required question 
30- Any other comment or suggestion on Medical Affairs activity that you would like to make? 
This is a required question 
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Questionnaire to Customers 
The current questionnaire is part of a study “Contribution to an efficient Medical Management in 
Pharmaceutical Industry” which is being carried out by José Augusto Aleixo Dias MD at the University of 
Aveiro, within the Doctoral Program in Sciencies and Health Technologies, under the supervision of Professor 
José Manuel Calheiros. This questionnaire aims to collect the perception of the Medical Affairs (MA) 
contribution to the Pharmaceutical companies and to the customers they serve in several dimensions. 
Your participation is voluntary and highly valuable to obtain a clear picture on how the work performed by 
these professionals is perceived, as well as, to identify areas of potential improvement. All the data collected 
are entirely confidential and will be treated anonymously, exclusively for the purpose of this study. 
Thanks very much for your participation! 
The investigator: 
José Augusto Aleixo Dias, MD 
Contacts: jose.a.dias@pfizer.com; Mobile: +351 917254726 
* Required
1- Customer type: In which condition do you answer this questionnaire? * 
 Physician 
 Pharmacist 
 Nurse 
 Administration Board member  (ARS, ECEs, USFs, ACSS, SPMS, etc…) 
 Regulatory Authorities (Infarmed, DGS, Ministry of Health, etc…) 
 Faculty (Professor, Investigator, etc…) 
 Other: 
2- Gender * 
 Male 
 Female 
3- Age * 
4- Type of Institution you work for? * 
 National Health Service (SNS) 
 State other than SNS 
 Private 
 Other: 
5- How many people work for your Institution/Company in Portugal ? * 
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6- How many people report directly to you ? * 
7- How do you rate the value of your interactions with the following Pharmaceutical Industry 
representatives: * 
1 2 3 4 5 Don't know 
Not 
applicable 
Medical 
Affairs  
Sales Force 
representative
Marketing 
Manager 
Key Account 
Manager 
Digital 
Marketing 
Manager 
Other  
8- If you have selected "other" in the previous question, please rate and specify. 
9- Based on your experience, how do you rate the scientific knowledge of Pfizer Medical 
Affairs ? * 
1 2 3 4 5 
Low High
10- How do you rate the Medical Affairs contribution to activities such as: * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 Don't know 
Not 
applicable 
Education Materials 
Preparation and 
review      
Promotional 
Materials 
preparation and 
review       
Advisory Board 
preparation and 
management 
Symposium 
preparation, 
invitations and 
content  
Contribution to 
reimbursement 
dossiers 
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1 2 3 4 5 Don't know 
Not 
applicable 
Sales Force training 
Response to 
product related 
questions  
Safety Reporting 
and 
Pharmacovigilance  
Compliance of 
processes and 
procedures 
Management of 
Customer relations 
Digital & 
Multichannel 
development  and 
support 
Other  
11- If you have selected other in the previous question, please rate and specify. 
12- How comfortable are you using digital communication channels, such as: * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 Don't know Not applicable 
Emails  
Webex’s 
Live 
Webinars 
On call 
webinars 
Social 
media 
(facebook, 
tweeter, 
etc.) 
Virtual 
Advisory 
Boards 
Health 
related 
Mobile 
Applications
Other  
13- If you have selected other in the previous question, please rate and specify. 
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14- What is your specific assessment of the Medical Affairs current contribution for the Digital 
& Multichanel development and implementation processes ? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 Don't know 
Not 
applicable 
Health Care 
Professionals 
Websites/Portals   
Preparing/reviewing 
materials for self-
detailing 
Training Materials 
for Health Care 
Professionals (self-
education) 
Newsletters 
Webinars (live) 
Webinars (on 
demand) 
Mobile Applications 
(e.g. disease 
awareness) 
Social Media 
(facebook; twitter; 
other?) 
Other 
  
15- If you have selected other in the previous question, please rate and specify. 
16- What is your specific assessment of the Medical Affairs future contribution for the Digital 
& Multichanel development and implementation processes ? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 Don't know 
Not 
applicable 
Health Care 
Professionals 
Websites/Portals   
Preparing/reviewing 
materials for self-
detailing 
Training Materials 
for Health Care 
Professionals (self-
education) 
Newsletters 
Webinars (live) 
Webinars (on 
demand) 
Mobile Applications 
(e.g. disease 
awareness) 
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1 2 3 4 5 Don't know 
Not 
applicable 
Social Media 
(facebook; twitter; 
other?) 
Other 
17- If you have selected "other" in the previous question, please rate and specify. 
18- In general, what is the reasonable number of medicines a Medical Affairs person should 
have under her/his responsibility? *
19- How many Medical Affairs persons do you think would be needed to support a medicine 
launch during its life cycle ? * 
(indicate the number of Medical Affairs persons you think is reasonable at each stage; e.g. 0,5 
means half person) 
0 0,5 1 1,5 2 2,5 3 >3 Don't know 
Not 
applicable 
1 year 
before 
launch 
6 
months 
before 
launch 
At 
launch 
6 
Months 
after 
launch 
1 year 
after 
launch 
2 years 
after 
launch 
3 to 5 
years 
after 
launch 
More 
than 5 
years 
after 
launch 
20- In general, how many customers should a Medical Affairs person manage during her/his 
customer facing activity ? *
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21- How much do you value the Medical Affairs activities such as: * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 Don't know 
Not 
applicable 
Clinical Research 
Market access 
Operating Plans 
Product launch 
and support 
Safety and 
Pharmacovigilance
Compliance 
KOL mapping 
Management of 
Customer relations 
Other (rate and 
describe bellow) 
22- If "other" please describe 
23- Have you ever been involved in performing some of these studies? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 Don't know 
Not 
applicable 
Clinical Trials
Investigator 
Initiated 
Research 
(IIRs) 
Other non-
interventional 
studies 
24- How do you value the following Clinical Research type of projects ? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 Don't know 
Not 
applicable 
Clinical 
Trials   
Institutional 
Real World 
Data 
(Studies and 
Registries) 
Investigator 
Initiated 
Research  
Other non-
interventional 
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1 2 3 4 5 Don't know 
Not 
applicable 
studies 
25- in order to make Clinical Research more efficient in Portugal what would be for you the 
most important driver ? * 
(choose the most important one) 
 Interest /perceived value 
 Proper conditions 
 Available time 
 Available budget 
 Other: 
26- In your view, what are the major roadblocks for Clinical Trials implementation in Portugal 
? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 Don't know Not applicable 
Lack of 
interest 
Lack of 
time  
Lack of 
resources 
Long 
approval 
timelines  
Difficult 
protocols 
Low 
Curriculum 
impact 
Other  
27- If you have selected other in the previous question, please rate and specify. 
28- What do you think is the contribution of the Medical Affairs in the implementation of the 
EFPIA disclosure code of transparency between the Pharmaceutical Industry and Health Care 
Professionals and healthcare organizations? * 
(choose one) 
 High 
 Medium 
 Low 
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29- How can patients benefit from the Medical Affairs activity? * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 Don't Know 
Not 
applicable 
Contributing 
to develop 
more 
efficient 
treatment 
options 
Contributing 
to bring 
these 
medicines 
into our 
market 
Providing 
HCPs with 
updated 
information 
on available 
medicines 
so that they 
can make 
the best 
treatment 
choices for 
patients 
Stimulating 
patient's 
treatment 
adherence 
and 
compliance 
Contributing 
to raise 
disease 
awareness 
Support 
Patients 
Associations
Other 
  
30- If you have selected other in the previous question, please rate and specify. 
31- In your opinion what has been the Pharmaceutical Industry Contribution to the health 
gains achieved so far ? * 
(choose one) 
 High 
 Medium 
 Low 
Page	155	
32- What is your perception of the Pharmaceutical Industry image ? * 
(choose one) 
 Poor 
 Fair 
 Satisfactory 
 Good 
 Excellent 
33- Why ? * 
(please provide a short explanation) 
34- How can the Medical Affairs contribute to improve the Pharmaceutical Industry image? * 
(please choose the most important option) 
 Promote a better understanding of the compliance rules under which it operates? 
 Contribute to the transparency of the interactions with Health Care Professionals 
 Provide scientific support for a better informed treatment choices (value of Medicines) 
 Show independency from Marketing/Commercial  interests 
 Other: 
35- In your opinion, do Medical Affairs provide unbiased scientific support? * 
(choose one) 
 Yes 
 No 
36- How do you value the outcomes resulting from your interaction with Medical Affairs in 
what regards: * 
(rate 1 to 5, being 1 the lowest and 5 the highest) 
1 2 3 4 5 Don't know 
Not 
applicable 
Efficacy 
profile of 
medicines 
Safety profile 
of medicines 
Differentiation 
versus 
competitors 
Scientific 
update - New 
drug 
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1 2 3 4 5 Don't know 
Not 
applicable 
development 
Scientific 
update - 
Research 
Grants  & 
IIRs 
(investigator 
Initiated 
Research)   
Scientific 
update  - 
Congresses 
& Symposia 
Scientific 
update  – 
Publications 
Scientific 
update -
  Webinars 
Other 
37- If "other" please rate and specify. 
38- How do you see Medical Affairs evolving in the future? * 
(choose one) 
 More of 
 About the same 
 Less of 
39- Are there any other comment/suggestion you would like to make, so that Medical Affairs 
can be more efficient? 
Submit
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APPENDIX II – BIVARIATE ANALYSIS 
Independent Samples T-Test 
Condition 
Independent Samples T-Test 
W p 
V9 2873.000 0.108
Note.  Mann-Whitney U test. 
Assumption Checks 
Test of Normality (Shapiro-Wilk) 
W p 
V9 Medical Affairs 0.673 < .001
Other 0.767 < .001
Note.  Significant results suggest a deviation from normality.
Test of Equality of Variances (Levene's) 
F df p 
V9 0.144 1 0.705
Descriptives 
Group Descriptives 
Group N Mean SD SE
V9 Medical Affairs 38 4.474 0.647 0.105
Other 131 4.282 0.705 0.062
Independent Samples T-Test 
Gender 
Independent Samples T-Test 
W p 
V9 3094.000 0.100
Note.  Mann-Whitney U test. 
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Assumption Checks 
Test of Normality (Shapiro-Wilk) 
W p 
V9 Male 0.762 < .001
Female 0.743 < .001
Note.  Significant results suggest a deviation from normality.
Test of Equality of Variances (Levene's) 
F df p 
V9 0.032 1 0.859
Descriptives 
Group Descriptives 
Group N Mean SD SE 
V9 Male 81 4.235 0.729 0.081
Female 88 4.409 0.655 0.070
ANOVA 
Age classes 
ANOVA - V9 
Cases Sum of Squares df Mean Square F p 
Classes 1.742 3.000 0.581 1.207 0.309
Residual 79.359 165.000 0.481
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.648 3.000 165.000 0.180
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Descriptives 
Descriptives - V9 
Classes Mean SD N 
<=34 4.387 0.761 31.000
35-44 4.239 0.665 71.000
45-54 4.458 0.683 48.000
>=55 4.211 0.713 19.000
Independent Samples T-Test 
Company type 
Independent Samples T-Test 
W p 
V9 826.000 0.219
Note.  Mann-Whitney U test. 
Assumption Checks 
Test of Normality (Shapiro-Wilk) 
W p 
V9 Portuguese Company 0.827 0.015
Multinational Company 0.755 < .001
Note.  Significant results suggest a deviation from normality. 
Test of Equality of Variances (Levene's) 
F df p 
V9 9.997 1 0.002
Descriptives 
Group Descriptives 
Group N Mean SD SE
V9 Portuguese Company 13 3.923 1.188 0.329
Multinational Company 156 4.359 0.632 0.051
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Independent Samples T-Test 
Condition 
Independent Samples T-Test 
W p 
V101 2471.000 0.943
V102 2428.500 0.800
V103 3058.000 0.020
V104 2939.000 0.044
V105 2437.000 0.833
V106 2896.500 0.096
V107 3028.000 0.024
V108 2886.500 0.105
Strategic_m 2959.000 0.076
Note.  Mann-Whitney U test. 
Assumption Checks 
Test of Normality (Shapiro-Wilk) 
W p 
V101 Medical Affairs 0.776 < .001
Other 0.756 < .001
V102 Medical Affairs 0.813 < .001
Other 0.818 < .001
V103 Medical Affairs 0.833 < .001
Other 0.846 < .001
V104 Medical Affairs 0.528 < .001
Other 0.676 < .001
V105 Medical Affairs 0.786 < .001
Other 0.792 < .001
V106 Medical Affairs 0.748 < .001
Other 0.817 < .001
V107 Medical Affairs 0.639 < .001
Other 0.757 < .001
V108 Medical Affairs 0.747 < .001
Other 0.811 < .001
Strategic_m Medical Affairs 0.936 0.030
Other 0.967 0.003
Note.  Significant results suggest a deviation from normality.
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Test of Equality of Variances (Levene's) 
F df p 
V101 0.337 1 0.563
V102 0.633 1 0.427
V103 0.067 1 0.796
V104 19.000 1 < .001
V105 2.483 1 0.117
V106 3.260 1 0.073
V107 3.754 1 0.054
V108 0.058 1 0.810
Strategic_m 0.586 1 0.445
Descriptives 
Group Descriptives 
Group N Mean SD SE 
V101 Medical Affairs 38 4.263 0.891 0.145
Other 131 4.290 0.855 0.075
V102 Medical Affairs 38 3.895 0.689 0.112
Other 131 3.893 0.816 0.071
V103 Medical Affairs 38 4.053 0.837 0.136
Other 131 3.733 0.773 0.068
V104 Medical Affairs 38 4.763 0.431 0.070
Other 131 4.565 0.542 0.047
V105 Medical Affairs 38 4.184 0.926 0.150
Other 131 4.275 0.713 0.062
V106 Medical Affairs 38 4.289 0.898 0.146
Other 131 4.122 0.723 0.063
V107 Medical Affairs 38 4.632 0.589 0.096
Other 131 4.313 0.814 0.071
V108 Medical Affairs 38 4.395 0.755 0.122
Other 131 4.153 0.855 0.075
Strategic_m Medical Affairs 38 4.311 0.483 0.078
Other 131 4.170 0.453 0.040
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Independent Samples T-Test 
Gender 
Independent Samples T-Test 
W p 
V101 3666.500 0.725
V102 3170.500 0.166
V103 2835.500 0.013
V104 3262.000 0.260
V105 3631.500 0.819
V106 3283.500 0.338
V107 2760.500 0.005
V108 2590.500 < .001
Strategic_m 2845.500 0.023
Note.  Mann-Whitney U test. 
Assumption Checks 
Test of Normality (Shapiro-Wilk) 
W p 
V101 Male 0.751 < .001
Female 0.773 < .001
V102 Male 0.840 < .001
Female 0.784 < .001
V103 Male 0.854 < .001
Female 0.823 < .001
V104 Male 0.664 < .001
Female 0.634 < .001
V105 Male 0.784 < .001
Female 0.785 < .001
V106 Male 0.825 < .001
Female 0.784 < .001
V107 Male 0.778 < .001
Female 0.681 < .001
V108 Male 0.843 < .001
Female 0.745 < .001
Strategic_m Male 0.963 0.018
Female 0.967 0.026
Note.  Significant results suggest a deviation from normality.
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Test of Equality of Variances (Levene's) 
F df p 
V101 0.552 1 0.459
V102 6.422 1 0.012
V103 2.404 1 0.123
V104 1.001 1 0.319
V105 1.007 1 0.317
V106 0.003 1 0.957
V107 3.078 1 0.081
V108 0.392 1 0.532
Strategic_m 0.785 1 0.377
Descriptives 
Group Descriptives 
Group N Mean SD SE 
V101 Male 81 4.284 0.912 0.101
Female 88 4.284 0.816 0.087
V102 Male 81 3.790 0.862 0.096
Female 88 3.989 0.703 0.075
V103 Male 81 3.667 0.775 0.086
Female 88 3.932 0.799 0.085
V104 Male 81 4.568 0.523 0.058
Female 88 4.648 0.526 0.056
V105 Male 81 4.247 0.830 0.092
Female 88 4.261 0.703 0.075
V106 Male 81 4.111 0.758 0.084
Female 88 4.205 0.775 0.083
V107 Male 81 4.198 0.886 0.098
Female 88 4.557 0.623 0.066
V108 Male 81 3.975 0.922 0.102
Female 88 4.420 0.690 0.074
Strategic_m Male 81 4.107 0.489 0.054
Female 88 4.289 0.421 0.045
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Independent Samples T-Test 
Company type 
Independent Samples T-Test 
W p 
V101 813.500 0.197
V102 914.000 0.511
V103 892.000 0.436
V104 1008.500 0.972
V105 1144.000 0.406
V106 885.500 0.412
V107 620.000 0.010
V108 891.500 0.436
Strategic_m 739.500 0.104
Note.  Mann-Whitney U test. 
Assumption Checks 
Test of Normality (Shapiro-Wilk) 
W p 
V101 Portuguese Company 0.799 0.007
Multinational Company 0.766 < .001
V102 Portuguese Company 0.429 < .001
Multinational Company 0.831 < .001
V103 Portuguese Company 0.790 0.005
Multinational Company 0.851 < .001
V104 Portuguese Company 0.628 < .001
Multinational Company 0.654 < .001
V105 Portuguese Company 0.646 < .001
Multinational Company 0.796 < .001
V106 Portuguese Company 0.627 < .001
Multinational Company 0.809 < .001
V107 Portuguese Company 0.746 0.002
Multinational Company 0.720 < .001
V108 Portuguese Company 0.857 0.035
Multinational Company 0.792 < .001
Strategic_m Portuguese Company 0.939 0.444
Multinational Company 0.964 < .001
Note.  Significant results suggest a deviation from normality. 
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Test of Equality of Variances (Levene's) 
F df p 
V101 9.925 1 0.002
V102 0.024 1 0.877
V103 0.025 1 0.875
V104 0.114 1 0.736
V105 1.509 1 0.221
V106 4.962 1 0.027
V107 2.655 1 0.105
V108 0.605 1 0.438
Strategic_m 0.416 1 0.520
Descriptives 
Group Descriptives 
Group N Mean SD SE 
V101 Portuguese Company 13 3.769 1.423 0.395
Multinational Company 156 4.327 0.788 0.063
V102 Portuguese Company 13 3.692 0.855 0.237
Multinational Company 156 3.910 0.782 0.063
V103 Portuguese Company 13 3.692 0.751 0.208
Multinational Company 156 3.814 0.802 0.064
V104 Portuguese Company 13 4.615 0.506 0.140
Multinational Company 156 4.609 0.528 0.042
V105 Portuguese Company 13 4.462 0.519 0.144
Multinational Company 156 4.237 0.780 0.062
V106 Portuguese Company 13 4.000 0.707 0.196
Multinational Company 156 4.173 0.772 0.062
V107 Portuguese Company 13 3.923 0.760 0.211
Multinational Company 156 4.423 0.771 0.062
V108 Portuguese Company 13 4.000 1.000 0.277
Multinational Company 156 4.224 0.824 0.066
Strategic_m Portuguese Company 13 4.021 0.450 0.125
Multinational Company 156 4.217 0.462 0.037
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ANOVA 
Age classes 
ANOVA - V101 
Cases Sum of Squares df Mean Square F p 
Classes 3.535 3.000 1.178 1.609 0.189
Residual 120.832 165.000 0.732
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.939 3.000 165.000 0.125
Descriptives 
Descriptives - V101 
Classes Mean SD N 
<=34 4.323 0.653 31.000
35-44 4.296 0.818 71.000
45-54 4.396 0.869 48.000
>=55 3.895 1.197 19.000
ANOVA 
ANOVA - V102 
Cases Sum of Squares df Mean Square F p 
Classes 4.624 3.000 1.541 2.557 0.057
Residual 99.459 165.000 0.603
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
2.337 3.000 165.000 0.076
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Descriptives 
Descriptives - V102 
Classes Mean SD N 
<=34 3.613 0.882 31.000
35-44 3.887 0.708 71.000
45-54 4.104 0.722 48.000
>=55 3.842 0.958 19.000
ANOVA 
ANOVA - V103 
Cases Sum of Squares df Mean Square F p 
Classes 1.454 3.000 0.485 0.761 0.517
Residual 105.102 165.000 0.637
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.585 3.000 165.000 0.626
Descriptives 
Descriptives - V103 
Classes Mean SD N 
<=34 3.677 0.871 31.000
35-44 3.789 0.695 71.000
45-54 3.938 0.885 48.000
>=55 3.737 0.806 19.000
ANOVA 
ANOVA - V104 
Cases Sum of Squares df Mean Square F p 
Classes 2.100 3.000 0.700 2.618 0.053
Residual 44.124 165.000 0.267
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
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Test for Equality of Variances (Levene's) 
F df1 df2 p 
6.671 3.000 165.000 < .001
Descriptives 
Descriptives - V104 
Classes Mean SD N 
<=34 4.419 0.620 31.000
35-44 4.592 0.523 71.000
45-54 4.750 0.438 48.000
>=55 4.632 0.496 19.000
ANOVA 
ANOVA - V105 
Cases Sum of Squares df Mean Square F p 
Classes 6.452 3.000 2.151 3.874 0.010
Residual 91.607 165.000 0.555
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.072 3.000 165.000 0.362
Post Hoc Tests 
Post Hoc Comparisons - Classes 
Mean Difference SE t p tukey p bonf 
<=34 35-44 -0.058 0.160 -0.363 0.983 1.000
45-54 -0.466 0.172 -2.713 0.035 0.044
>=55 -0.008 0.217 -0.039 1.000 1.000
35-44 45-54 -0.408 0.139 -2.927 0.020 0.023
>=55 0.050 0.192 0.258 0.994 1.000
45-54 >=55 0.457 0.202 2.264 0.108 0.149
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Descriptives 
Descriptives - V105 
Classes Mean SD N 
<=34 4.097 0.746 31.000
35-44 4.155 0.690 71.000
45-54 4.563 0.649 48.000
>=55 4.105 1.100 19.000
ANOVA 
ANOVA - V106 
Cases Sum of Squares df Mean Square F p 
Classes 5.186 3.000 1.729 3.050 0.030
Residual 93.501 165.000 0.567
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.649 3.000 165.000 0.180
Post Hoc Tests 
Post Hoc Comparisons - Classes 
Mean Difference SE t p tukey p bonf 
<=34 35-44 -0.181 0.162 -1.119 0.673 1.000
45-54 -0.430 0.173 -2.480 0.065 0.085
>=55 -0.518 0.219 -2.361 0.086 0.116
35-44 45-54 -0.249 0.141 -1.769 0.286 0.473
>=55 -0.337 0.194 -1.731 0.305 0.512
45-54 >=55 -0.088 0.204 -0.430 0.973 1.000
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Descriptives 
Descriptives - V106 
Classes Mean SD N 
<=34 3.903 0.831 31.000
35-44 4.085 0.692 71.000
45-54 4.333 0.834 48.000
>=55 4.421 0.607 19.000
ANOVA 
ANOVA - V107 
Cases Sum of Squares df Mean Square F p 
Classes 3.411 3.000 1.137 1.903 0.131
Residual 98.589 165.000 0.598
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.557 3.000 165.000 0.644
Descriptives 
Descriptives - V107 
Classes Mean SD N 
<=34 4.452 0.675 31.000
35-44 4.465 0.734 71.000
45-54 4.375 0.866 48.000
>=55 4.000 0.816 19.000
ANOVA 
ANOVA - V108 
Cases Sum of Squares df Mean Square F p 
Classes 1.556 3.000 0.519 0.736 0.532
Residual 116.196 165.000 0.704
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
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Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.995 3.000 165.000 0.397
Descriptives 
Descriptives - V108 
Classes Mean SD N 
<=34 4.355 0.608 31.000
35-44 4.183 0.833 71.000
45-54 4.229 0.951 48.000
>=55 4.000 0.882 19.000
ANOVA 
ANOVA - Strategic_m 
Cases Sum of Squares df Mean Square F p 
Classes 1.474 3.000 0.491 2.352 0.074
Residual 34.483 165.000 0.209
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.109 3.000 165.000 0.955
Descriptives 
Descriptives - Strategic_m 
Classes Mean SD N 
<=34 4.106 0.399 31.000
35-44 4.184 0.445 71.000
45-54 4.338 0.500 48.000
>=55 4.082 0.479 19.000
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Independent Samples T-Test 
Condition 
Independent Samples T-Test 
W p 
V1201 2789.500 0.209
V1202 2819.000 0.138
V1203 2292.500 0.416
V1204 3160.500 0.003
V1205 2815.500 0.167
V1206 2555.000 0.785
V1207 2764.500 0.251
V1208 3293.500 < .001
V1209 2731.000 0.315
V1210 2766.000 0.267
V1211 2520.000 0.902
Operat_m 2995.500 0.056
Note.  Mann-Whitney U test. 
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Assumption Checks 
Test of Normality (Shapiro-Wilk) 
W p 
V1201 Medical Affairs 0.799 < .001
Other 0.802 < .001
V1202 Medical Affairs 0.550 < .001
Other 0.681 < .001
V1203 Medical Affairs 0.757 < .001
Other 0.762 < .001
V1204 Medical Affairs 0.456 < .001
Other 0.716 < .001
V1205 Medical Affairs 0.662 < .001
Other 0.718 < .001
V1206 Medical Affairs 0.814 < .001
Other 0.812 < .001
V1207 Medical Affairs 0.637 < .001
Other 0.770 < .001
V1208 Medical Affairs 0.589 < .001
Other 0.788 < .001
V1209 Medical Affairs 0.673 < .001
Other 0.766 < .001
V1210 Medical Affairs 0.768 < .001
Other 0.829 < .001
V1211 Medical Affairs 0.874 < .001
Other 0.853 < .001
Operat_m Medical Affairs 0.914 0.007
Other 0.959 < .001
Note.  Significant results suggest a deviation from normality.
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Test of Equality of Variances (Levene's) 
F df p 
V1201 2.446 1 0.120
V1202 9.877 1 0.002
V1203 1.607 1 0.207
V1204 22.567 1 < .001
V1205 0.126 1 0.723
V1206 0.118 1 0.731
V1207 3.464 1 0.064
V1208 1.946 1 0.165
V1209 0.008 1 0.929
V1210 0.144 1 0.704
V1211 2.320 1 0.130
Operat_m 0.227 1 0.634
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Descriptives 
Group Descriptives 
Group N Mean SD SE 
V1201 Medical Affairs 38 4.184 0.730 0.118
Other 131 4.015 0.712 0.062
V1202 Medical Affairs 38 4.737 0.446 0.072
Other 131 4.557 0.622 0.054
V1203 Medical Affairs 38 4.289 0.694 0.113
Other 131 4.366 0.746 0.065
V1204 Medical Affairs 38 4.816 0.457 0.074
Other 131 4.435 0.776 0.068
V1205 Medical Affairs 38 4.553 0.686 0.111
Other 131 4.389 0.750 0.066
V1206 Medical Affairs 38 4.132 0.741 0.120
Other 131 4.107 0.704 0.062
V1207 Medical Affairs 38 4.500 0.507 0.082
Other 131 4.298 0.772 0.067
V1208 Medical Affairs 38 4.658 0.627 0.102
Other 131 4.237 0.773 0.068
V1209 Medical Affairs 38 4.421 0.826 0.134
Other 131 4.321 0.757 0.066
V1210 Medical Affairs 38 4.263 0.795 0.129
Other 131 4.092 0.827 0.072
V1211 Medical Affairs 38 3.658 1.047 0.170
Other 131 3.679 0.853 0.075
Operat_m Medical Affairs 38 4.384 0.458 0.074
Other 131 4.227 0.489 0.043
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Independent Samples T-Test 
Gender 
Independent Samples T-Test 
W p 
V1201 2921.500 0.025
V1202 3556.500 0.979
V1203 3286.000 0.336
V1204 2801.500 0.005
V1205 2874.500 0.015
V1206 3594.000 0.918
V1207 3121.000 0.123
V1208 3224.000 0.240
V1209 3572.500 0.978
V1210 3371.500 0.519
V1211 3175.000 0.190
Operat_m 2971.500 0.062
Note.  Mann-Whitney U test. 
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Assumption Checks 
Test of Normality (Shapiro-Wilk) 
W p 
V1201 Male 0.813 < .001
Female 0.787 < .001
V1202 Male 0.661 < .001
Female 0.655 < .001
V1203 Male 0.787 < .001
Female 0.730 < .001
V1204 Male 0.745 < .001
Female 0.594 < .001
V1205 Male 0.749 < .001
Female 0.679 < .001
V1206 Male 0.822 < .001
Female 0.783 < .001
V1207 Male 0.771 < .001
Female 0.737 < .001
V1208 Male 0.784 < .001
Female 0.750 < .001
V1209 Male 0.729 < .001
Female 0.766 < .001
V1210 Male 0.796 < .001
Female 0.817 < .001
V1211 Male 0.862 < .001
Female 0.846 < .001
Operat_m Male 0.960 0.013
Female 0.952 0.003
Note.  Significant results suggest a deviation from normality.
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Test of Equality of Variances (Levene's) 
F df p 
V1201 1.409 1 0.237
V1202 0.278 1 0.599
V1203 2.055 1 0.154
V1204 22.040 1 < .001
V1205 2.915 1 0.090
V1206 1.918 1 0.168
V1207 0.282 1 0.596
V1208 1.069 1 0.303
V1209 0.904 1 0.343
V1210 0.083 1 0.773
V1211 0.664 1 0.416
Operat_m 0.847 1 0.359
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Descriptives 
Group Descriptives 
Group N Mean SD SE 
V1201 Male 81 3.938 0.677 0.075
Female 88 4.159 0.741 0.079
V1202 Male 81 4.605 0.563 0.063
Female 88 4.591 0.618 0.066
V1203 Male 81 4.284 0.778 0.086
Female 88 4.409 0.689 0.073
V1204 Male 81 4.333 0.866 0.096
Female 88 4.693 0.533 0.057
V1205 Male 81 4.272 0.837 0.093
Female 88 4.568 0.603 0.064
V1206 Male 81 4.099 0.784 0.087
Female 88 4.125 0.640 0.068
V1207 Male 81 4.247 0.783 0.087
Female 88 4.432 0.657 0.070
V1208 Male 81 4.247 0.830 0.092
Female 88 4.409 0.689 0.073
V1209 Male 81 4.321 0.849 0.094
Female 88 4.364 0.698 0.074
V1210 Male 81 4.099 0.800 0.089
Female 88 4.159 0.843 0.090
V1211 Male 81 3.605 0.817 0.091
Female 88 3.739 0.965 0.103
Operat_m Male 81 4.187 0.508 0.056
Female 88 4.332 0.456 0.049
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Independent Samples T-Test 
Company type 
Independent Samples T-Test 
W p 
V1201 628.500 0.012
V1202 807.500 0.147
V1203 996.500 0.912
V1204 810.000 0.157
V1205 1019.000 0.976
V1206 991.500 0.886
V1207 1102.500 0.565
V1208 718.500 0.056
V1209 1204.500 0.216
V1210 1030.500 0.920
V1211 1092.000 0.624
Operat_m 883.000 0.440
Note.  Mann-Whitney U test. 
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Assumption Checks 
Test of Normality (Shapiro-Wilk) 
W p 
V1201 Portuguese Company 0.628 < .001
Multinational Company 0.805 < .001
V1202 Portuguese Company 0.772 0.003
Multinational Company 0.646 < .001
V1203 Portuguese Company 0.776 0.004
Multinational Company 0.766 < .001
V1204 Portuguese Company 0.787 0.005
Multinational Company 0.662 < .001
V1205 Portuguese Company 0.750 0.002
Multinational Company 0.716 < .001
V1206 Portuguese Company 0.799 0.007
Multinational Company 0.804 < .001
V1207 Portuguese Company 0.750 0.002
Multinational Company 0.755 < .001
V1208 Portuguese Company 0.820 0.012
Multinational Company 0.754 < .001
V1209 Portuguese Company 0.628 < .001
Multinational Company 0.753 < .001
V1210 Portuguese Company 0.757 0.002
Multinational Company 0.807 < .001
V1211 Portuguese Company 0.812 0.010
Multinational Company 0.858 < .001
Operat_m Portuguese Company 0.956 0.690
Multinational Company 0.954 < .001
Note.  Significant results suggest a deviation from normality. 
Page	183	
Test of Equality of Variances (Levene's) 
F df p 
V1201 0.081 1 0.776
V1202 0.535 1 0.466
V1203 4.092 1 0.045
V1204 0.973 1 0.325
V1205 0.129 1 0.720
V1206 2.122 1 0.147
V1207 0.056 1 0.813
V1208 2.224 1 0.138
V1209 1.877 1 0.172
V1210 0.063 1 0.802
V1211 0.240 1 0.625
Operat_m 0.052 1 0.820
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Descriptives 
Group Descriptives 
Group N Mean SD SE 
V1201 Portuguese Company 13 3.615 0.506 0.140
Multinational Company 156 4.090 0.722 0.058
V1202 Portuguese Company 13 4.385 0.650 0.180
Multinational Company 156 4.615 0.584 0.047
V1203 Portuguese Company 13 4.231 1.013 0.281
Multinational Company 156 4.359 0.709 0.057
V1204 Portuguese Company 13 4.231 0.927 0.257
Multinational Company 156 4.545 0.712 0.057
V1205 Portuguese Company 13 4.462 0.660 0.183
Multinational Company 156 4.423 0.745 0.060
V1206 Portuguese Company 13 4.077 0.862 0.239
Multinational Company 156 4.115 0.700 0.056
V1207 Portuguese Company 13 4.462 0.660 0.183
Multinational Company 156 4.333 0.730 0.058
V1208 Portuguese Company 13 4.000 0.707 0.196
Multinational Company 156 4.359 0.762 0.061
V1209 Portuguese Company 13 4.615 0.506 0.140
Multinational Company 156 4.321 0.787 0.063
V1210 Portuguese Company 13 4.077 1.038 0.288
Multinational Company 156 4.135 0.804 0.064
V1211 Portuguese Company 13 3.846 0.801 0.222
Multinational Company 156 3.660 0.905 0.072
Operat_m Portuguese Company 13 4.182 0.446 0.124
Multinational Company 156 4.269 0.490 0.039
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ANOVA 
Age classes 
ANOVA - V1201 
Cases Sum of Squares df Mean Square F p 
Classes 3.934 3.000 1.311 2.620 0.053
Residual 82.587 165.000 0.501
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.447 3.000 165.000 0.720
Descriptives 
Descriptives - V1201 
Classes Mean SD N 
<=34 3.806 0.792 31.000
35-44 4.169 0.632 71.000
45-54 4.125 0.733 48.000
>=55 3.842 0.765 19.000
ANOVA 
ANOVA - V1202 
Cases Sum of Squares df Mean Square F p 
Classes 1.213 3.000 0.404 1.162 0.326
Residual 57.426 165.000 0.348
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
3.163 3.000 165.000 0.026
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Descriptives 
Descriptives - V1202 
Classes Mean SD N 
<=34 4.516 0.677 31.000
35-44 4.535 0.629 71.000
45-54 4.708 0.504 48.000
>=55 4.684 0.478 19.000
ANOVA 
ANOVA - V1203 
Cases Sum of Squares df Mean Square F p 
Classes 0.062 3.000 0.021 0.037 0.990
Residual 90.341 165.000 0.548
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.082 3.000 165.000 0.358
Descriptives 
Descriptives - V1203 
Classes Mean SD N 
<=34 4.323 0.791 31.000
35-44 4.366 0.702 71.000
45-54 4.333 0.808 48.000
>=55 4.368 0.597 19.000
ANOVA 
ANOVA - V1204 
Cases Sum of Squares df Mean Square F p 
Classes 0.938 3.000 0.313 0.578 0.630
Residual 89.240 165.000 0.541
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
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Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.743 3.000 165.000 0.528
Descriptives 
Descriptives - V1204 
Classes Mean SD N 
<=34 4.452 0.675 31.000
35-44 4.535 0.693 71.000
45-54 4.604 0.765 48.000
>=55 4.368 0.895 19.000
ANOVA 
ANOVA - V1205 
Cases Sum of Squares df Mean Square F p 
Classes 2.350 3.000 0.783 1.453 0.229
Residual 88.975 165.000 0.539
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.227 3.000 165.000 0.302
Descriptives 
Descriptives - V1205 
Classes Mean SD N 
<=34 4.516 0.626 31.000
35-44 4.437 0.649 71.000
45-54 4.479 0.825 48.000
>=55 4.105 0.937 19.000
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ANOVA 
ANOVA - V1206 
Cases Sum of Squares df Mean Square F p 
Classes 2.704 3.000 0.901 1.810 0.147
Residual 82.160 165.000 0.498
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.391 3.000 165.000 0.247
Descriptives 
Descriptives - V1206 
Classes Mean SD N 
<=34 3.871 0.670 31.000
35-44 4.141 0.639 71.000
45-54 4.146 0.772 48.000
>=55 4.316 0.820 19.000
ANOVA 
ANOVA - V1207 
Cases Sum of Squares df Mean Square F p 
Classes 4.762 3.000 1.587 3.143 0.027
Residual 83.333 165.000 0.505
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.718 3.000 165.000 0.542
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Post Hoc Tests 
Post Hoc Comparisons - Classes 
Mean Difference SE t p tukey 
<=34 35-44 -0.465 0.153 -3.038 0.014
45-54 -0.375 0.164 -2.290 0.102
>=55 -0.368 0.207 -1.779 0.281
35-44 45-54 0.090 0.133 0.676 0.904
>=55 0.096 0.184 0.525 0.952
45-54 >=55 0.007 0.193 0.034 1.000
Descriptives 
Descriptives - V1207 
Classes Mean SD N 
<=34 4.000 0.856 31.000
35-44 4.465 0.629 71.000
45-54 4.375 0.789 48.000
>=55 4.368 0.496 19.000
ANOVA 
ANOVA - V1208 
Cases Sum of Squares df Mean Square F p 
Classes 3.285 3.000 1.095 1.919 0.128
Residual 94.159 165.000 0.571
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.385 3.000 165.000 0.764
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Descriptives 
Descriptives - V1208 
Classes Mean SD N 
<=34 4.065 0.772 31.000
35-44 4.338 0.696 71.000
45-54 4.479 0.825 48.000
>=55 4.368 0.761 19.000
ANOVA 
ANOVA - V1209 
Cases Sum of Squares df Mean Square F p 
Classes 6.674 3.000 2.225 3.930 0.010
Residual 93.420 165.000 0.566
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.866 3.000 165.000 0.137
Post Hoc Tests 
Post Hoc Comparisons - Classes 
Mean Difference SE t p tukey 
<=34 35-44 -0.501 0.162 -3.094 0.012
45-54 -0.544 0.173 -3.136 0.011
>=55 -0.380 0.219 -1.735 0.303
35-44 45-54 -0.043 0.141 -0.303 0.990
>=55 0.121 0.194 0.622 0.923
45-54 >=55 0.163 0.204 0.801 0.851
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Descriptives 
Descriptives - V1209 
Classes Mean SD N 
<=34 3.935 0.998 31.000
35-44 4.437 0.603 71.000
45-54 4.479 0.652 48.000
>=55 4.316 1.003 19.000
ANOVA 
ANOVA - V1210 
Cases Sum of Squares df Mean Square F p 
Classes 3.479 3.000 1.160 1.745 0.160
Residual 109.657 165.000 0.665
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.588 3.000 165.000 0.624
Descriptives 
Descriptives - V1210 
Classes Mean SD N 
<=34 3.871 0.922 31.000
35-44 4.113 0.803 71.000
45-54 4.292 0.743 48.000
>=55 4.211 0.855 19.000
ANOVA 
ANOVA - V1211 
Cases Sum of Squares df Mean Square F p 
Classes 6.723 3.000 2.241 2.880 0.038
Residual 128.378 165.000 0.778
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
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Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.385 3.000 165.000 0.764
Post Hoc Tests 
Post Hoc Comparisons - Classes 
Mean Difference SE t p tukey 
<=34 35-44 -0.488 0.190 -2.572 0.051
45-54 -0.513 0.203 -2.523 0.058
>=55 -0.584 0.257 -2.273 0.106
35-44 45-54 -0.024 0.165 -0.148 0.999
>=55 -0.096 0.228 -0.420 0.974
45-54 >=55 -0.071 0.239 -0.298 0.991
Descriptives 
Descriptives - V1211 
Classes Mean SD N 
<=34 3.258 0.965 31.000
35-44 3.746 0.840 71.000
45-54 3.771 0.857 48.000
>=55 3.842 0.958 19.000
ANOVA 
ANOVA - Operat_m 
Cases Sum of Squares df Mean Square F p 
Classes 1.742 3.000 0.581 2.529 0.059
Residual 37.886 165.000 0.230
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.400 3.000 165.000 0.753
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Descriptives 
Descriptives - Operat_m 
Classes Mean SD N 
<=34 4.056 0.469 31.000
35-44 4.299 0.473 71.000
45-54 4.345 0.501 48.000
>=55 4.254 0.461 19.000
Independent Samples T-Test 
Condition 
Independent Samples T-Test 
W p 
V1401 2239.000 0.312
V1402 2549.500 0.807
V1403 2609.000 0.625
V1404 2590.000 0.684
V1405 2314.500 0.474
V1406 2268.500 0.376
V1407 2131.000 0.150
V1408 2480.000 0.973
V1409 2256.000 0.350
Digital_m 2320.500 0.526
Note.  Mann-Whitney U test. 
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Assumption Checks 
Test of Normality (Shapiro-Wilk) 
W p 
V1401 Medical Affairs 0.858 < .001
Other 0.850 < .001
V1402 Medical Affairs 0.767 < .001
Other 0.808 < .001
V1403 Medical Affairs 0.699 < .001
Other 0.799 < .001
V1404 Medical Affairs 0.852 < .001
Other 0.845 < .001
V1405 Medical Affairs 0.863 < .001
Other 0.816 < .001
V1406 Medical Affairs 0.848 < .001
Other 0.800 < .001
V1407 Medical Affairs 0.875 < .001
Other 0.811 < .001
V1408 Medical Affairs 0.843 < .001
Other 0.859 < .001
V1409 Medical Affairs 0.869 < .001
Other 0.865 < .001
Digital_m Medical Affairs 0.879 < .001
Other 0.942 < .001
Note.  Significant results suggest a deviation from normality.
Test of Equality of Variances (Levene's) 
F df p 
V1401 6.569 1 0.011
V1402 5.782 1 0.017
V1403 2.677 1 0.104
V1404 5.638 1 0.019
V1405 5.157 1 0.024
V1406 10.064 1 0.002
V1407 6.965 1 0.009
V1408 1.678 1 0.197
V1409 1.007 1 0.317
Digital_m 2.207 1 0.139
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Descriptives 
Group Descriptives 
Group N Mean SD SE 
V1401 Medical Affairs 38 3.632 1.125 0.183
Other 131 3.885 0.829 0.072
V1402 Medical Affairs 38 4.132 1.070 0.174
Other 131 4.206 0.741 0.065
V1403 Medical Affairs 38 4.184 1.136 0.184
Other 131 4.244 0.785 0.069
V1404 Medical Affairs 38 3.816 1.136 0.184
Other 131 3.840 0.840 0.073
V1405 Medical Affairs 38 3.684 1.068 0.173
Other 131 3.863 0.830 0.073
V1406 Medical Affairs 38 3.763 1.218 0.198
Other 131 4.015 0.894 0.078
V1407 Medical Affairs 38 3.605 1.175 0.191
Other 131 3.901 0.927 0.081
V1408 Medical Affairs 38 3.684 1.093 0.177
Other 131 3.725 0.912 0.080
V1409 Medical Affairs 38 3.316 1.093 0.177
Other 131 3.511 0.915 0.080
Digital_m Medical Affairs 38 3.758 0.930 0.151
Other 131 3.910 0.689 0.060
Independent Samples T-Test 
Gender 
Independent Samples T-Test 
W p 
V1401 894.500 0.450
V1402 830.000 0.242
V1403 811.000 0.195
V1404 1151.500 0.385
V1405 1074.000 0.701
V1406 953.000 0.703
V1407 988.000 0.872
V1408 852.500 0.310
V1409 973.000 0.799
Digital_m 912.000 0.548
Note.  Mann-Whitney U test. 
Assumption Checks 
Test of Normality (Shapiro-Wilk) 
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W p 
V1401 Portuguese Company 0.891 0.099
Multinational Company 0.845 < .001
V1402 Portuguese Company 0.820 0.012
Multinational Company 0.794 < .001
V1403 Portuguese Company 0.720 < .001
Multinational Company 0.778 < .001
V1404 Portuguese Company 0.675 < .001
Multinational Company 0.857 < .001
V1405 Portuguese Company 0.791 0.005
Multinational Company 0.832 < .001
V1406 Portuguese Company 0.791 0.005
Multinational Company 0.817 < .001
V1407 Portuguese Company 0.821 0.012
Multinational Company 0.831 < .001
V1408 Portuguese Company 0.846 0.025
Multinational Company 0.858 < .001
V1409 Portuguese Company 0.688 < .001
Multinational Company 0.868 < .001
Digital_m Portuguese Company 0.909 0.180
Multinational Company 0.919 < .001
Note.  Significant results suggest a deviation from normality. 
Test of Equality of Variances (Levene's) 
F df p 
V1401 0.003 1 0.956
V1402 1.915 1 0.168
V1403 0.467 1 0.495
V1404 6.533 1 0.011
V1405 0.101 1 0.751
V1406 0.011 1 0.916
V1407 1.117 1 0.292
V1408 1.135 1 0.288
V1409 0.046 1 0.831
Digital_m 0.048 1 0.827
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Descriptives 
Group Descriptives 
Group N Mean SD SE 
V1401 Portuguese Company 13 3.692 0.855 0.237
Multinational Company 156 3.840 0.912 0.073
V1402 Portuguese Company 13 4.000 0.707 0.196
Multinational Company 156 4.205 0.833 0.067
V1403 Portuguese Company 13 3.923 1.038 0.288
Multinational Company 156 4.256 0.857 0.069
V1404 Portuguese Company 13 4.077 0.494 0.137
Multinational Company 156 3.814 0.935 0.075
V1405 Portuguese Company 13 3.846 1.068 0.296
Multinational Company 156 3.821 0.876 0.070
V1406 Portuguese Company 13 3.846 1.068 0.296
Multinational Company 156 3.968 0.973 0.078
V1407 Portuguese Company 13 3.846 0.801 0.222
Multinational Company 156 3.833 1.009 0.081
V1408 Portuguese Company 13 3.385 1.121 0.311
Multinational Company 156 3.744 0.936 0.075
V1409 Portuguese Company 13 3.385 0.870 0.241
Multinational Company 156 3.474 0.967 0.077
Digital_m Portuguese Company 13 3.779 0.730 0.202
Multinational Company 156 3.884 0.753 0.060
Independent Samples T-Test 
Company type 
Independent Samples T-Test 
W p 
V1401 894.500 0.450
V1402 830.000 0.242
V1403 811.000 0.195
V1404 1151.500 0.385
V1405 1074.000 0.701
V1406 953.000 0.703
V1407 988.000 0.872
V1408 852.500 0.310
V1409 973.000 0.799
Digital_m 912.000 0.548
Note.  Mann-Whitney U test. 
Assumption Checks 
Test of Normality (Shapiro-Wilk) 
Page	198	
W p 
V1401 Portuguese Company 0.891 0.099
Multinational Company 0.845 < .001
V1402 Portuguese Company 0.820 0.012
Multinational Company 0.794 < .001
V1403 Portuguese Company 0.720 < .001
Multinational Company 0.778 < .001
V1404 Portuguese Company 0.675 < .001
Multinational Company 0.857 < .001
V1405 Portuguese Company 0.791 0.005
Multinational Company 0.832 < .001
V1406 Portuguese Company 0.791 0.005
Multinational Company 0.817 < .001
V1407 Portuguese Company 0.821 0.012
Multinational Company 0.831 < .001
V1408 Portuguese Company 0.846 0.025
Multinational Company 0.858 < .001
V1409 Portuguese Company 0.688 < .001
Multinational Company 0.868 < .001
Digital_m Portuguese Company 0.909 0.180
Multinational Company 0.919 < .001
Note.  Significant results suggest a deviation from normality. 
Test of Equality of Variances (Levene's) 
F df p 
V1401 0.003 1 0.956
V1402 1.915 1 0.168
V1403 0.467 1 0.495
V1404 6.533 1 0.011
V1405 0.101 1 0.751
V1406 0.011 1 0.916
V1407 1.117 1 0.292
V1408 1.135 1 0.288
V1409 0.046 1 0.831
Digital_m 0.048 1 0.827
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Descriptives 
Group Descriptives 
Group N Mean SD SE 
V1401 Portuguese Company 13 3.692 0.855 0.237
Multinational Company 156 3.840 0.912 0.073
V1402 Portuguese Company 13 4.000 0.707 0.196
Multinational Company 156 4.205 0.833 0.067
V1403 Portuguese Company 13 3.923 1.038 0.288
Multinational Company 156 4.256 0.857 0.069
V1404 Portuguese Company 13 4.077 0.494 0.137
Multinational Company 156 3.814 0.935 0.075
V1405 Portuguese Company 13 3.846 1.068 0.296
Multinational Company 156 3.821 0.876 0.070
V1406 Portuguese Company 13 3.846 1.068 0.296
Multinational Company 156 3.968 0.973 0.078
V1407 Portuguese Company 13 3.846 0.801 0.222
Multinational Company 156 3.833 1.009 0.081
V1408 Portuguese Company 13 3.385 1.121 0.311
Multinational Company 156 3.744 0.936 0.075
V1409 Portuguese Company 13 3.385 0.870 0.241
Multinational Company 156 3.474 0.967 0.077
Digital_m Portuguese Company 13 3.779 0.730 0.202
Multinational Company 156 3.884 0.753 0.060
ANOVA 
ANOVA - V1401 
Cases Sum of Squares df Mean Square F p 
Classes 3.788 3.000 1.263 1.552 0.203
Residual 134.236 165.000 0.814
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.808 3.000 165.000 0.491
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Descriptives 
Descriptives - V1401 
Classes Mean SD N 
<=34 3.806 0.980 31.000
35-44 3.887 0.803 71.000
45-54 3.917 0.919 48.000
>=55 3.421 1.071 19.000
ANOVA 
ANOVA - V1402 
Cases Sum of Squares df Mean Square F p 
Classes 3.016 3.000 1.005 1.495 0.218
Residual 110.925 165.000 0.672
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.690 3.000 165.000 0.171
Descriptives 
Descriptives - V1402 
Classes Mean SD N 
<=34 3.968 0.795 31.000
35-44 4.324 0.692 71.000
45-54 4.125 0.914 48.000
>=55 4.211 1.032 19.000
ANOVA 
ANOVA - V1403 
Cases Sum of Squares df Mean Square F p 
Classes 2.150 3.000 0.717 0.939 0.423
Residual 125.850 165.000 0.763
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
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Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.253 3.000 165.000 0.859
Descriptives 
Descriptives - V1403 
Classes Mean SD N 
<=34 4.129 0.806 31.000
35-44 4.338 0.774 71.000
45-54 4.229 0.905 48.000
>=55 4.000 1.202 19.000
ANOVA 
ANOVA - V1404 
Cases Sum of Squares df Mean Square F p 
Classes 3.992 3.000 1.331 1.622 0.186
Residual 135.369 165.000 0.820
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.746 3.000 165.000 0.526
Descriptives 
Descriptives - V1404 
Classes Mean SD N 
<=34 3.548 0.961 31.000
35-44 3.944 0.876 71.000
45-54 3.792 0.874 48.000
>=55 4.000 1.000 19.000
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ANOVA 
ANOVA - V1405 
Cases Sum of Squares df Mean Square F p 
Classes 1.618 3.000 0.539 0.679 0.566
Residual 131.057 165.000 0.794
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.412 3.000 165.000 0.745
Descriptives 
Descriptives - V1405 
Classes Mean SD N 
<=34 3.677 1.013 31.000
35-44 3.915 0.824 71.000
45-54 3.750 0.838 48.000
>=55 3.895 1.049 19.000
ANOVA 
ANOVA - V1406 
Cases Sum of Squares df Mean Square F p 
Classes 2.078 3.000 0.693 0.721 0.541
Residual 158.632 165.000 0.961
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.922 3.000 165.000 0.128
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Descriptives 
Descriptives - V1406 
Classes Mean SD N 
<=34 3.839 1.098 31.000
35-44 4.056 0.924 71.000
45-54 3.979 0.838 48.000
>=55 3.737 1.284 19.000
ANOVA 
ANOVA - V1407 
Cases Sum of Squares df Mean Square F p 
Classes 1.781 3.000 0.594 0.599 0.617
Residual 163.580 165.000 0.991
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
1.929 3.000 165.000 0.127
Descriptives 
Descriptives - V1407 
Classes Mean SD N 
<=34 3.710 1.071 31.000
35-44 3.944 0.969 71.000
45-54 3.813 0.842 48.000
>=55 3.684 1.293 19.000
ANOVA 
ANOVA - V1408 
Cases Sum of Squares df Mean Square F p 
Classes 1.964 3.000 0.655 0.718 0.542
Residual 150.402 165.000 0.912
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
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Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.588 3.000 165.000 0.623
Descriptives 
Descriptives - V1408 
Classes Mean SD N 
<=34 3.516 1.029 31.000
35-44 3.803 0.872 71.000
45-54 3.750 0.978 48.000
>=55 3.632 1.065 19.000
ANOVA 
ANOVA - V1409 
Cases Sum of Squares df Mean Square F p 
Classes 6.178 3.000 2.059 2.298 0.079
Residual 147.893 165.000 0.896
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
2.252 3.000 165.000 0.084
Descriptives 
Descriptives - V1409 
Classes Mean SD N 
<=34 3.065 1.181 31.000
35-44 3.549 0.824 71.000
45-54 3.563 0.873 48.000
>=55 3.579 1.121 19.000
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ANOVA 
ANOVA - Digital_m 
Cases Sum of Squares df Mean Square F p 
Classes 1.799 3.000 0.600 1.069 0.364
Residual 92.568 165.000 0.561
Note.  Type III Sum of Squares 
Assumption Checks 
Test for Equality of Variances (Levene's) 
F df1 df2 p 
0.254 3.000 165.000 0.858
Descriptives 
Descriptives - Digital_m 
Classes Mean SD N 
<=34 3.696 0.804 31.000
35-44 3.974 0.679 71.000
45-54 3.880 0.743 48.000
>=55 3.796 0.913 19.000
Page	206	
Page	207	
APPENDIX III 
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APPENDIX III – LOGISTIC REGRESSION  
123 vs 45 
Model summary 
Model Deviance AIC BIC df Χ² p McFadden R² 
H₀ 101.283 103.283 106.413 168
H₁ 25.675 83.675 174.442 140 75.608 < .001 0.747 
Coefficients 
95% Confidence 
interval 
Estimate 
Robust  
Standard 
Error 
Standardized⁺ Odds Ratio z p 
Lower 
bound 
Upper 
bound 
(Intercept) -76.125 40.020 16.331 8.694e -34 -1.902 0.057 -154.564 2.313
V101 5.536 3.316 4.763 253.718 1.669 0.095 -0.964 12.036
V102 -0.149 1.183 -0.117 0.862 -0.126 0.900 -2.468 2.170 
V103 5.292 3.579 4.214 198.711 1.478 0.139 -1.723 12.307
V104 9.432 5.652 4.948 12483.203 1.669 0.095 -1.645 20.509
V105 -6.539 4.149 -4.996 0.001 -1.576 0.115 -14.671 1.593 
V106 -1.021 0.922 -0.782 0.360 -1.108 0.268 -2.827 0.786 
V107 0.759 0.894 0.592 2.137 0.849 0.396 -0.993 2.512 
V108 4.354 3.263 3.645 77.815 1.335 0.182 -2.040 10.749
V1201 2.721 2.452 1.953 15.193 1.110 0.267 -2.085 7.527 
V1202 -3.992 2.263 -2.358 0.018 -1.764 0.078 -8.427 0.443 
V1203 1.323 0.772 0.971 3.756 1.715 0.086 -0.189 2.835 
V1204 2.848 1.683 2.086 17.246 1.692 0.091 -0.451 6.146 
V1205 -3.501 2.639 -2.581 0.030 -1.327 0.185 -8.672 1.671 
V1206 -0.362 0.844 -0.257 0.697 -0.428 0.668 -2.016 1.293 
V1207 -1.098 1.682 -0.795 0.334 -0.653 0.514 -4.394 2.198 
V1208 3.615 4.162 2.754 37.169 0.869 0.385 -4.541 11.772
V1209 1.786 0.755 1.379 5.966 2.366 0.018 0.307 3.265 
V1210 6.854 3.857 5.624 947.524 1.777 0.076 -0.706 14.414
V1211 3.438 2.267 3.083 31.130 1.516 0.129 -1.006 7.882 
V1401 7.156 2.933 6.486 1281.382 2.440 0.015 1.408 12.904
V1402 -3.546 1.520 -2.920 0.029 -2.333 0.020 -6.524 -0.567 
V1403 -3.024 1.962 -2.640 0.049 -1.542 0.123 -6.869 0.821 
V1404 -7.195 4.498 -6.553 7.501e  -4 -1.600 0.110 -16.012 1.621 
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Coefficients 
95% Confidence 
interval 
Estimate 
Robust  
Standard 
Error 
Standardized⁺ Odds Ratio z p 
Lower 
bound 
Upper 
bound 
V1405 -3.428 1.758 -3.046 0.032 -1.950 0.051 -6.873 0.018 
V1406 -1.817 3.649 -1.777 0.162 -0.498 0.618 -8.969 5.335 
V1407 4.324 3.335 4.290 75.480 1.297 0.195 -2.212 10.860
V1408 3.392 1.197 3.231 29.738 2.834 0.005 1.046 5.739 
V1409 -5.432 2.287 -5.202 0.004 -2.375 0.018 -9.915 -0.948 
⁺ Standardized estimates represent estimates where the continuous predictors are standardized (X-
standardization). 
Note.  V9a level '1' coded as class 1. 
Performance Diagnostics 
Confusion matrix 
Predicted 
Observed 0 1 
0 14.000 1.000
1 0.000 154.000
Performance metrics 
Value 
AUC 0.982 
Sensitivity 1.000 
Specificity 0.933 
Precision 0.994 
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1234 vs 5 
Model summary 
Model Deviance AIC BIC df Χ² p McFadden R² 
H₀ 231.144 233.144 236.274 168
H₁ 161.232 219.232 309.999 140 69.912 < .001 0.302 
Coefficients 
95% Confidence 
interval 
Estimate 
Robust  
Standard 
Error 
Standardized⁺ Odds Ratio z p 
Lower 
bound 
Upper 
bound 
(Intercept) -13.697 3.100 -0.535 1.126e -6 
-
4.418 < .001 -19.773 -7.621 
V101 0.431 0.302 0.371 1.539 1.428 0.153 -0.161 1.023 
V102 -0.503 0.385 -0.396 0.605 -1.305 0.192 -1.258 0.252 
V103 0.075 0.349 0.059 1.077 0.214 0.831 -0.610 0.759 
V104 0.188 0.522 0.099 1.207 0.361 0.718 -0.835 1.211 
V105 0.717 0.484 0.548 2.048 1.480 0.139 -0.232 1.666 
V106 0.254 0.367 0.195 1.289 0.692 0.489 -0.465 0.973 
V107 0.296 0.451 0.231 1.344 0.656 0.512 -0.588 1.180 
V108 1.055 0.448 0.884 2.873 2.357 0.018 0.178 1.933 
V1201 -0.001 0.415 -0.001 0.999 -0.002 0.998 -0.815 0.813 
V1202 0.831 0.562 0.491 2.297 1.480 0.139 -0.269 1.932 
V1203 -1.581 0.446 -1.160 0.206 -3.548 < .001 -2.455 -0.708 
V1204 -0.222 0.420 -0.163 0.801 -0.529 0.597 -1.044 0.601 
V1205 0.750 0.500 0.553 2.117 1.500 0.134 -0.230 1.730 
V1206 0.573 0.409 0.407 1.773 1.400 0.162 -0.229 1.375 
V1207 -0.666 0.391 -0.483 0.514 -1.704 0.088 -1.433 0.100 
V1208 0.271 0.469 0.206 1.311 0.577 0.564 -0.649 1.191 
V1209 0.661 0.393 0.510 1.937 1.685 0.092 -0.108 1.431 
V1210 -0.783 0.381 -0.642 0.457 -2.053 0.040 -1.530 -0.036 
V1211 -0.291 0.449 -0.261 0.748 -0.648 0.517 -1.171 0.589 
V1401 0.491 0.427 0.445 1.635 1.151 0.250 -0.345 1.328 
V1402 0.442 0.465 0.364 1.555 0.949 0.342 -0.470 1.353 
V1403 -0.336 0.540 -0.293 0.715 -0.623 0.533 -1.394 0.722 
V1404 -0.413 0.459 -0.376 0.662 -0.899 0.369 -1.313 0.487 
V1405 0.470 0.469 0.418 1.601 1.002 0.316 -0.449 1.390 
V1406 0.078 0.494 0.076 1.081 0.158 0.875 -0.891 1.047 
V1407 0.250 0.337 0.248 1.285 0.743 0.458 -0.410 0.911 
V1408 0.116 0.415 0.111 1.123 0.281 0.779 -0.696 0.929 
V1409 -0.119 0.403 -0.114 0.888 - 0.769 -0.909 0.672 
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Coefficients 
95% Confidence 
interval 
Estimate 
Robust  
Standard 
Error 
Standardized⁺ Odds Ratio z p 
Lower 
bound 
Upper 
bound 
0.294
⁺ Standardized estimates represent estimates where the continuous predictors are standardized (X-
standardization). 
* Vovk-Sellke Maximum p -Ratio: Based on the p -value, the maximum possible odds in favor of H₁ over H₀
equals 1/(-e p log( p )) for p ≤ .37 (Sellke, Bayarri, & Berger, 2001). 
Note.  V9b level '1' coded as class 1. 
Performance Diagnostics 
Confusion matrix 
Predicted 
Observed 0 1 
0 79.000 17.000
1 17.000 56.000
Performance metrics 
Value 
AUC 0.848 
Sensitivity 0.767 
Specificity 0.823 
Precision 0.767 
